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Abstract 
 
The mannose receptor (MR) is an important component of the immune system and understanding the 
structural and conformational characteristics of this receptor is a key aspect of targeted vaccine 
design. Improved understanding of the role of carbohydrate recognition domains (CRDs) 4-7 in 
recognising glycosylated ligands present on the surface of pathogens such as C. albicans, P. carinii, 
L. donovani, and M. tuberculosis has given new insight into MR vaccine development. Initial studies 
identified mannan and its derivatives to be important ligands in MR targeting, providing essential 
knowledge about structural properties of the MR. During the last decade many attempts have been 
made to target this receptor for applications including vaccine and drug development.  
In the present study, a library of vaccine constructs comprising fluorescently-labelled mannosylated 
lipid dendrimers that contained the ovalbumin CD4+ epitope, OVA323-339, as the model peptide 
antigen were synthesised using fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis 
(SPPS). The vaccine constructs were designed with an alanine spacer between the O-linked mannose 
moieties to investigate the impact of distance between the mannose units on receptor-mediated uptake 
and/or binding in antigen presenting cells.  
Mannosylated building blocks were prepared with a Lewis acid reaction and the reaction was 
successfully modified and monitored for a better yield. This was followed by solid phase synthesis 
of mannosylated peptides with an azide functional group and a fluorescent tag. Considering the 
presence of multi-components on the designed mannosylated peptide, different methods of 
preparation was used and a high yield of the final mannosylated peptides with an azide functional 
group and a fluorescent tag were prepared. Further, OVA323-339 lipopeptides with an alkyne functional 
group were prepared using microwave assisted peptide synthesis. Final vaccine structures were 
prepared by attaching azide and alkyne functional groups using click chemistry. The same methods 
were applied for the preparation of a library of control vaccine structures.      
In vitro uptake studies performed on macrophage (F4/80+) and dendritic (CD11c+) cells showed 
significant uptake and/or binding for vaccine constructs containing mannose and lipid, and also for 
the lipopeptide vaccine construct without mannose when compared to the controls (containing no 
lipid, no mannose and no mannose or lipid). Further, in vitro mannan competition assays 
demonstrated that uptake of the mannosylated and lipidated vaccine constructs was MR mediated. To 
address the specificity of receptor uptake, surface plasmon resonance (SPR) was performed using 
Biacore technology which confirmed a high affinity of the mannosylated and lipidated vaccine 
constructs towards the human recombinant MR in vitro when compared with vaccine constructs 
without mannose. These studies also confirmed that both mannose and lipid moieties play significant 
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roles in receptor-mediated uptake on APCs, potentially facilitating vaccine development. SPR 
methods were modified for a better quality of study.   
In vivo studies with the aim of understanding immune modulatory effects of the mannose and lipid 
moieties in relation to the structural properties were performed. There have been many studies 
indicating the ability of the MR in linking the innate immunity (short-term immune response through 
macrophages and DCs) to adaptive immunity (long-term response by T cell activation and antibody 
response). This linkage is due to the MR mediated endocytosis of macrophages and dendritic cells 
(cells of innate immunity) and then antigen presentation to the T cells which isresponsible for a long-
term adoptive response.  However, it has not been completely disclosed whether uptake by the MR 
can induce the desired pathways involved in T cell activation. In this study, OT-II T cells were 
isolated from OT-II transgenic mice (B6.Cg-Tg[TcraTcrb]425Cbn/J) and were adoptively transferred 
to C57BL/6 mice. Adoptively transferred OT-II cell proliferation was shown to be unaffected by 
mannosylated lipopetide vaccine constructs. However, antigen specific cytokine release studies done 
by cytokine bead array and intra cellular staining, showed a relationship between the structural 
properties and the selection of specific T helper pathways (Th1 and Th2). Here, presence of both 
mannose and lipid activated cytokines (IL-4, IL-5, IL-13) related to Th2 pathway. On the other hand, 
the presence of lipid alone on the vaccine structures activated inflammatory cytokines (IL-2 and IFN-
) that are related to the Th1 pathway. Here, it was also found that structural differences between the 
vaccine constructs including length of spacers between mannosyl moieties and presence of lipid could 
affect the levels of cytokine release. Structural differences were also responsible for selective action 
towards a Th pathway. For instance, two spacers on the vaccine structures with both mannose and 
lipid were more selective towards the Th2 response, while presence of lipid alone was able to act 
towards the Th1 pathway. In these studies a positive control group, ovalbumin 323-339 sequence 
mixed with cholera toxin (OVA+ CT), was used. Here, OVA+ CT, structures with mannose only and 
structures without mannose and lipid were not significant in the Th1 and Th2 cytokine activation 
pathways. Finally, antibody measurements following three time vaccinations showed a lack of 
antibody response against the vaccine constructs and their control groups. Overall, the results 
suggested activation of APCs by vaccine constructs that was not strong enough to activate a T cell or 
B cell response but could activate cytokine release. 
Mannosylation has been shown to be an effective tool for antigen delivery to the immune system. 
There are studies that have indicated that mannosylation activates pathways to which the immune 
system does not react and recognises the antigens as self-antigens. This finding could mean an 
exciting future for vaccine and drug delivery and has to be further investigated. 
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Figure 1-1. Schematic representation of immune factors involved in innate and adaptive 
immunity. (A) Innate immunity is activated hours post pathogen exposure and involves dendritic 
cells, macrophages, natural killer cells and pattern recognition receptors; cytokines released in this 
pathway are antigen independent; (B) Adaptive immunity is activated days after exposure to a 
pathogen (antigen dependant) and consists of B cells, which lead to an antibody response, and naïve 
T cells, which lead to CD4 and CD8 T cell proliferation. Naïve T cells represent a common 
intermediate between innate and adaptive immunity. Here, naïve T cells have the ability to migrate 
from where they are produced (thymus) to secondary lymphoid organs including the lymph nodes 
where they become CD4 or CD8 T cells which are the components of the adoptive immune response. 
 
Figure 1-2. Mannose Receptor classifications. Pattern recognition receptors (PRRs) promote the 
recognition, attachment, and phagocytosis of foreign pathogens via the carbohydrate recognition 
domain (CRD). CLR is a major class of PRRs which contain one or more CRDs that recognise a wide 
variety of ligands. Additionally, the entire MR family is able to distinguish self from non-self 
structures. The mannose receptor (MR) family comprises four members including the MR (CD206), 
phospholipase A2 receptor (PLA2R), Endo180 (CD280), and DEC-205 (CD205).  
 
Figure 1-3. Schematic structure showing the organisation of the Mannose Receptor. The 
Mannose Receptor Cysteine Rich (CR) domain recognises sulfated carbohydrates terminated in N-
acetyl glucosamine (15), the Fibronectin type ІІ (FNII) domain binds to collagen І, ІІ, and IV with 
high affinity and weakly to V [32, 33], and the Carbohydrate Recognition Domains (CRDs) bind 
complex carbohydrates that terminate in mannose, fucose or N-acetyl glucosamine [32, 34]. Here, 
CRD4 (*) binds mannosylated ligands found in pathogen cell walls in a calcium-dependent manner. 
CRD4-7 is essential for high affinity binding to multibranched mannosylated ligands and ligand 
internalisation. The C-terminal internalisation motif has a role in transferring ligands inside the cell.  
 
Figure 1-4. A model for the structural organisation of the Mannose Receptor and the 
attachment of glycosylated ligands. Conformational structure of the mannose receptor with mannan 
from the surface of bacteria as a model glycosylated ligand. A Compact “bent” organisational model 
proposed by Boskovic et al. where the CRD interacts with the CR domain in ligand binding [32, 40]. 
B A U-shaped model proposed by Napper et al. suggesting exposure of CRD4-5 in ligand binding 
[48]. CRD4 has high binding affinity to glycosylated ligands and CRD5-8 in addition to CRD4 is 
essential in binding multi-glycosylated ligands [32]. 
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Figure 1-5. Mannose receptor and cellular targeting pathway. 1: Attachment of glycosylated 
ligands (e.g. mannan from the surface of bacteria) to CRD4-8 of the mannose receptor, followed by 
2: internalisation and degradation of ligands by the lysosome for adaptive immune responses.  3: 
Presentation of degraded ligands to the surface of the dendritic cell through MHC I and II and co-
stimulatory receptors (e.g. CD80/CD86). 4: Naïve T cell activation through MHC I and II pathways 
where, 5: MHC II pathway activates CD4 T cells and achieves, 6: T-helper response activating 
cytokine release, or 7: MHC I pathway activates CD8+ T cells. 8: Cytotoxic T-lymphocytes response 
to eliminate infected ligands. The innate pathway activates through 9: direct release of cytokines 
through the DC. 
 
Figure 1-6. A typical N-linkage through asparagine (Asn) is highlighted with examples of mannose 
receptor binding N-linked proteins from C. albicans [97], mucin from Pichia pastoris [98] and 
Saccharomyces cerevisiae [99]. A typical serine/threonine (Ser/Thr) O-linkage is highlighted. 
Examples of mannose receptor O-linked binding proteins include mucin from Pichia pastoris, 
Saccharomyces cerevisiae and M. tuberculosis [100, 101]. 
 
Figure 1-7. Oxidised and reduced structures of mannose. Under mild oxidation conditions (e.g. 
Br2/H2O), the C-6 carbon on mannose is oxidised to a carbonyl group forming mannuronic acid; 
under reducing conditions (e.g. sodium amalgam), mannose is converted to mannitol with the 
formation of an alcohol at the C-1 carbon. Reduced and oxidised variations of mannan have been 
used to investigate mannose receptor targeting [92]. 
 
Figure 1-8. Schematic of a Manα6Man glycocluster. Frison et al. found this structure bound 
strongly to the mannose receptor resulting in endocytosis of the gycocluster [121]. 
 
Figure 1-9. Mannosylated peptides designed to investigate the relationship between the number 
of mannose groups and their receptor targeting ability. Schematic structure of the mannosylated 
peptides synthesised by Brimble et al. to investigate the relationship between linear and branched 
mannosylation and receptor targeting [130]. An investigation was carried out using A: linear 
mannosylated peptides separated by alanine spacers, and B: di-branched mannosylated peptides 
separated by alanine spacers. No difference was observed in the targeting ability of linear (A) and di-
branched (B) mannosylated constructs, however spacer length was found to play a role in receptor 
binding. A fluorescent tag (5(6)-carboxyfluorescein) was included in each glycosylated peptide for 
bioassay analysis.  
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Figure 1-10. Oligomannoside clusters synthesised by Bissen et al. The structures showing the best 
affinity for the mannose receptor are A: a cluster with five terminal mannoses, and B: a cluster with 
six terminal mannose groups.  
 
Figure 1-11. Lipid core polylysine with multiple epitopes made by Moyle et al. Structures 
contained either N-linked mannose or N-linked glucose in both acetylated and deacetylated forms. 
Both acetylated and deacetylated delivery systems that contained mannose successfully reduced 
tumour size in mice when compared to glucose delivery systems.  
 
Figure 1-12. Vaccine types. A: Subunit vaccines are prepared by use of part of the pathogen that 
provokes immune response, this can be based on biological extraction methods (recombinant) or 
synthetic methods (peptides); B: inactivated vaccines are prepared by inactivation of pathogens by 
heat or chemicals; C: live attenuated vaccines are prepared by weakening the pathogen through 
multiple passages. 
 
Figure 1-13, Schematic diagram of solid phase peptide synthesis. Solid resin support is used to build a 
peptide chain from individual amino acids where orthogonal Fmoc or Boc protecting groups are used 
depending on the synthesis conditions, such as the choice of resin. Cleavage of the poly-amino acid 
chain from the resin generates a peptide in the last step. 
 
Figure 1-14. General Structure of common lipidic adjuvants. These lipidic adjuvants are used in 
peptide conjugation to enhance immunogenicity; monophosphoryl lipid A (MPLA), di-palmitoyl-S-
glyceryl-cystein (Pam2Cys), tri-palmitoyl-S-glyceryl-cystein (Pam3Cys), LCP [159]. 
 
Figure 1-15. Toll-like receptor signalling pathway. TLRs are trans-membrane receptors from the 
family of pattern recognition receptors that exist as both extracellular (TLR-1, 2, 4, 6) and 
intracellular (TLR-3, 7, 8, 9) molecules. Signalling molecules including IRAK-1-4, TBK1, MyD88s 
activate a series of nuclear transcription factors (NF-κB, AP-1, NF-IL6 and IRF) causing the cell to 
produce inflammatory cytokines (TNF, ILs and IFN). 
 
Figure 3-1. Schematic picture of the vaccine construct library. The main library includes vaccine 
constructs where n is the number of alanine units between each mannose moiety. The sequence for 
the OVA323-339 peptide is a model antigen. Mannose is included into the structures for its mannose 
receptor targeting ability. The lipid (C12) is added to provide self adjuvanting properties. Designed 
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final vaccine structures are prepared in two sections A and B. Section A is OVA323-339 lipopetide (in 
case of controls no lipid is on the structure) with alkyne functional group able to be attached to section 
B which is the mannosylated peptide (in case of controls no mannose on the structure) with azido 
functional group. The final library is provided by an azide-alkyne reaction and formation of a triazole 
cycle (C). The vaccine control library consists of constructs without mannose (D), without lipids (E) 
and without mannose and lipid moieties (F) and these are used to compare the effect of each moiety 
on in vitro and in vivo studies. 
 
Figure 3-2. Scheme for the synthesis of Fmoc-serine mannosylated amino acid building blocks. 
1,2,3,4,6-Penta-O-acetyl-α,β-D-mannopyranosyl (1) was synthesised using D-mannose, DMAP, 
Ac2O, 46°C, 24 h, N2 gas in a 85% yield. N-Fmoc-O-(2,3,4,6-tetra-O-acetyl-α,β-D-mannopyranosyl)-
L-serine (2) was synthesised with the addition of Fmoc-serine-OH, BF3.Et2O, DCM, RT, 4 h in a 42% 
yield. 
 
Figure 3-3. Mechanism of action for the BF3.Et2O Lewis acid reaction. Conjugation of 1 
(acetylated mannosyl donor) to Fmoc-Ser-OH using BF3.Et2O in DCM at RT for 4 h generated 2 
(Fmoc-serine mannosylated amino acid building blocks) as a mixture of α and β due to attack of the 
Lewis acid from both below (β, 25.44%) and above (α, 74.55%) [230]. For synthesis details see 
Chapter 2, Section 2.1.2. 
 
Figure 3-4. Monitoring of the boron trifluoride diethyl etherate (BF3.Et2O) Lewis acid reaction 
at 1, 2, 3, 4, 6, and 8 h by analytical RP-HPLC on a C18 column (0 to 100% acetonitrile gradient over 
30 min). At 4 h, the optimum yield for the product (2, 42%) was observed with a retention time (Rt) 
of 23.6 min (peak indicated by an arrow) and this eluted at 62% solvent B (Chapter 2, Section 2.1.1). 
Rt 19.3 min is the Fmoc-serine-OH starting material and Rt: 21.5 min is the product missing one 
acetyl group. The graph was drawn using nudging (overlaying graphs with an angle) in GraphPad 
Prism. 
 
Figure 3-5. Azide functionalized mannosylated peptide 3. Peptide 3 was synthesised using Method 
1 and resulted in a low overall yield of 5%. (a) 20% Piperidine in DMF, RT; (b) Fmoc-lys(IvDde)-
OH, HATU, DIPEA; (c) 2, HATU, DIPEA, DMF; (d) Fmoc-Ala-OH, HATU, DIPEA, DMF; (d*) 
repeated a and d; (e) 5(6)-carboxyfluorscein (FAM), DIC, HOBt, DMF; (f) 5% hydrazine in DMF on 
resin (3 × 30 min), RT; (g) azidoacetic acid, HATU, DIPEA, DMF; (h) 95% TFA: 2.5% water: 2.5% 
TIS. For a detailed synthesis protocol see Chapter 2, Section 2.1.4.1. 
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Figure 3-6. HPLC traces of peptides 3 and 4. (A) 3 prepared using Method 1 and obtained in a 
yield of 5%, Rt=13.69; and (B) 4 prepared using Method 2 and obtained in a yield of 54%, Rt=20.36. 
Analytical RP-HPLC: 0-100% acetonitrile gradient over 30 min. For a detailed synthesis protocol see 
Chapter 2, Section 2.1.4.1. 
 
Figure 3-7. Reagents and conditions for the synthesis of peptides 4-7: (a) 20% Piperidine in DMF, 
RT; (a*) 2 cycles of piperidine in DMF; (b) Fmoc-lys(Mtt)-OH, HATU, DIPEA; (c) 2% TFA: 1% 
TIPS in DCM, 20 cycles; (d) azidoacetic acid, HATU, DIPEA, DMF; (e) N-Fmoc-O-(2,3,4,6-tetra-
O-acetyl-α,β-D-mannopyranosyl)-L-serine, HATU, DIPEA, DMF; (f) Fmoc-Ala-OH, HATU, 
DIPEA, DMF; (g) 5(6)-carboxyflourscein (FAM), DIC, HOBt, DMF; (h) 95% TFA: 2.5% water: 
2.5% TIS. For a detailed synthesis protocol see Chapter 2, Section 2.1.4.2. 
 
Figure 3-8. Synthesis of the Dde (9) lipid protecting group and the Dde-C12 lipid (10). 2-
Acetyldimedone (Dde, 8) was synthesised using solution synthesis, and was then used to protect the 
N-terminal of the C12 lipid (9) in a reaction with 8 generating the Dde protected C12 lipid (10, Dde-
C12). For a detailed synthesis protocol see Chapter 2, Section 2.1.5. 
Figure 3-9. Reagents and conditions for microwave-assisted synthesis of peptides 11 and 12; (a) 
20% Piperidine in DMF, 20W, 70°C for 2 min + 5 min; (b) Fmoc-Gly-OH; (c) 10, HATU, DIPEA; 
(d) 2% hydrazine in DMF (4 x 10 min); (e) Fmoc-Lys-IvDde-OH, HATU, DIPEA; (f) Fmoc-Lys-
Fmoc-OH, after deprotection of Fmoc, Ile(Boc) - Ser(tBu) – Gln(Trt) – Ala - Val – His(Trt) - Ala - 
Ala – His(Trt) - Ala – Glu(OtBu) - Ile – Asn(Trt) – Glu(OtBu) - Ala - Gly – Arg(Pbf) were coupled 
consequently (in HATU and DIPEA), all amino acids were Fmoc protected and deprotection of Fmoc 
group was performed as mentioned at (a); (g) 2% hydrazine in DMF on resin (3 × 30 min), RT; (h) 
pentynoic acid, HBTU, DIPEA, overnight, at RT; (i) 95% TFA: 2.5% water: 2.5% TIS. For a detailed 
synthesis protocol of peptides 11 and 12 see Chapter 2, Section 2.1.6. 
 
Figure 3-10. Mannosylated lipopeptide vaccine constructs 13-15, prepared from a copper-
mediated click reaction (DMSO, 5 h, RT, N2 gas) of the lipopeptide-alkyne (11) with fluorescently-
labelled mannosylated-azides (4-6). The formation of the triazole bond in this reaction is highlighted 
with a square. See Chapter 2, Section 2.1.7. 
 
Figure 3-11. Library of fluorescently-labelled mannosylated lipopeptide vaccine constructs (13-
15) and control constructs (16-18). The test constructs, containing a variable length alanine spacer 
between each mannose moiety are 13 (n=0), 14 (n=1) and 15 (n=2). Control constructs for cell-based 
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studies include 16 (no mannose moieties, n=2), 17 (no lipid moieties, n=2), and 18 (no lipid or 
mannose moieties, n=2), where n is the number of alanine amino acids. OVA323-339 epitope (model 
antigen) was included as a CD4 T cell epitope. FAM was included in each construct to enable 
detection in in vitro cell studies. The lipid is C12.   
  
Figure 3-12. RP-HPLC trace for the copper-mediated click reaction between peptides 4 and 11 
for the formation of vaccine construct 15. (A) 4, Rt 20.83 min; (B) 15 (a diastereomeric mixture), 
Rt 21.2 min, 21.6 min, 21.8 min; (C) 11 Rt 23.5 min. Click reaction was performed in DMSO at 50°C 
under an N2 atmosphere and stopped after 5 h. 
 
Figure 3-13. TEM images of vaccine constructs 13-18. (A) 13, (B) 14, (C) 15, (D) 16, (E) 17, and 
(F) 18. The scale bar is 200 nm. 
Figure 4-1. In vitro uptake/binding and mannan competition study, Vaccine constructs 13-18 (0.5 
µM) and control constructs 16-18 (0.5 µM) were assessed in (A) CD11c+ and (B) F4/80+ cells for 
uptake in the presence or absence of mannan (construct + mannan [1 mg/ml] vs construct alone). 
Dextran-FITC (1 mg/ml) was the positive control. PBS was the negative control. The study was 
performed in triplicate and the results were analysed using one-way ANOVA with mean ± SD from 
three independent experiments, p<0.0001. 
 
Figure 4-2. Confocal images, F4/80+ cells (2×105) were incubated with vaccine constructs 13, 15 
and 16 (0.5 µM) in the presence or absence of mannan, with commercially available mannan-FITC 
as the positive control. Cells were plated on culture slides. FAM-labelled vaccine constructs (green) 
were added to the cells and incubated in the presence and absence of mannan for 4 h at 37°C. Nuclei 
were stained with Hoechst stain (blue). F4/80+ cells were identified with anti-F4/80 antibody (red). 
(A) mannan-FITC; (B) vaccine construct 13; (C) cells pre-incubated with mannan followed by 
addition of 13; (D) vaccine construct 15; (E) vaccine construct 16. Analysis was performed on a GE 
DeltaVision Deconvolution confocal microscope at 60x using oil immersion, graphical scales 15µm 
and 5µm. 
 
Figure 4-3. In vitro OT-II spleen proliferation assay. Different dilutions of constructs 13-18 and 
control peptide, OVA323-339 were compared for their ability to stimulate T cell proliferation (5×10
5 
cells per well). PBS was used as the negative control. The study was performed in triplicate and the 
results were analysed with mean ± SD from three independent experiments, p < 0.0001. 
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Figure 4-4. Schematic diagram of SPR performance on a CM-5 chip. CM-5 chips have a dextran 
surface that enables ligand (the mannose receptor in this study) immobilisation on the surface. The 
analyte (vaccine constructs in this study) are allowed to pass over the ligand and the resulting 
interaction and/or binding causes a change in the reflected light from the gold layer on the chip’s 
surface (below the dextran). The optical detection unit converts changes in this reflected light to a 
readable time-response sensogram. The light source used is plain polarised light. 
 
Figure 4-5. Method development steps. Three steps were taken for method development to ensure 
accurate measurement of the vaccine constructs to the receptor. Step 1: the MR (ligand) is 
immobilised on the chip’s surface; step 2: surface performance and regeneration scouting are 
performed to investigate receptor viability and regeneration condition; and step 3: kinetics and affinity 
measurements are performed to measure binding affinity of vaccine constructs 13-18 (Chapter 3, 
Section 3.2.4, Figure 3-11) . 
 
Figure 4-6. Amine coupling of the MR onto the CM-5 chip. Free carboxylic groups on the dextran-
coated CM-5 chip are pre-activated using EDC and NHS (these two provide crosslinking ability by 
activating the carboxyl groups) to enable covalent binding of the ligand (MR) through the ligands 
free NH2 groups.  
 
Figure 4-7. Mannose receptor flow cell immobilisation trace. (A) The MR dissolved in acetate 
buffer is run over the surface of the chip without pre-activation to scout the level of binding affinity 
the receptor has for the un-activated dextran ; (B) a solution of ethanolamine is run over the chip’s 
surface to remove any unbound MR from step (A); (C) the dextran surface of the chip is activated 
with a solution of NHS:EDC; (D1-3) the MR dissolved in acetate buffer is run over the surface of the 
pre-activated chip in three pulses to reach the desired level of binding (in this instance it is 2000 RU); 
(E) ethanolamine is run over the chip to remove any excess MR that is not chemically bound from 
the previous step; and (F) the actual level of MR immobilisation is calculated and compared to the 
starting baseline level (1850 RU). Letters ‘s’ and ‘e’ signify the start and end of each injection on the 
machine, respectively. 
 
Figure 4-7. Mannose receptor flow cell immobilisation trace. (A) The MR dissolved in acetate 
buffer is run over the surface of the chip without pre-activation to scout the level of binding affinity 
the receptor has for the un-activated dextran ; (B) a solution of ethanolamine is run over the chip’s 
surface to remove any unbound MR from step (A); (C) the dextran surface of the chip is activated 
with a solution of NHS:EDC; (D1-3) the MR dissolved in acetate buffer is run over the surface of the 
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pre-activated chip in three pulses to reach the desired level of binding (in this instance it is 2000 RU); 
(E) ethanolamine is run over the chip to remove any excess MR that is not chemically bound from 
the previous step; and (F) the actual level of MR immobilisation is calculated and compared to the 
starting baseline level (1850 RU). Letters ‘s’ and ‘e’ signify the start and end of each injection on the 
machine, respectively. 
 
Figure 4-9. Schematic trace of a surface performance resonance sensogram. (A) starting baseline 
showing the flow of the running buffer; (B) binding response caused by binding of an analyte to the 
immobilised ligand (here mannose receptor); (C) dissociation of the analyte from the ligand attributed 
to a change in the running buffer; (D) regeneration of the ligands surface (removal of all the analyte) 
by changing the conditions of the buffer (acidic, basic, ionic); and (E) final baseline following 
regeneration to ensure it is the same as the starting baseline observed in step (A). 
 
Figure 4-10. Regeneration scouting using sodium dodecyl sulfate (SDS 0.05%). An ionic solution 
of SDS was used as the regeneration solution to assess the MR affinity measurements. (A) the 
sensogram baseline from the continuous flow of a buffer at 40 µl/min; (B) mannan (10 µg/ml) binding 
response showing 25 RU; (C) regeneration of the MR by 0.05% SDS solution; (D) an increase in the 
baseline level is observed following regeneration showing that this was not a successful regeneration. 
Letters ‘s’ and ‘e’ signify the start and end of each injection by the machine, respectively. 
 
Figure 4-11. Regeneration scouting using NaOH. A solution of NaOH (pH 9.5) was used as the 
regeneration solution to assess the MR affinity measurements. (A) The sensogram baseline from the 
continuous flow of a buffer at 40 µl/min; (B) mannan (10 µg/ml) binding response showing 25 RU; 
(C) regeneration of the MR using 10 mM NaOH (pH 9.5) solution; (D) a 60 RU down shift in the 
baseline was observed due to unsuccessful regeneration. Letters ‘s’ and ‘e’ signify the start and end 
of each injection by the machine, respectively. 
 
Figure 4-12. Lack of receptor activity following regeneration with NaOH. (A) No binding (an 
RU of less than 5) was observed when the MR bound to the chip was exposed to mannan (10 µg/ml). 
This correlates with previous results where the use of a high pH regeneration buffer (10 mM, NaOH, 
pH 9.5) was shown to change the baseline dramatically.  Letters ‘s’ and ‘e’ signify the start and end 
of each injection by the machine, respectively. Note, the sensogram regeneration stage is not shown. 
 
Figure 4-13. Regeneration scouting using glycine buffer. A glycine buffer (10 mM, pH 2.2) was 
used as the regeneration solution to assess the MR affinity measurements. (A) The sensogram baseline 
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from continuous flow of the buffer at 40 µl/min; (B) mannan (10 µg/ml) binding response showing 
25 RU; (C) regeneration of the MR using glycine buffer (10 mM, pH 2.2); (D) a small shift in the 
baseline (± 15 RU) was observed between the baseline at D and the baseline at A.  
 
Figure 4-14. Mass transfer study with mannan. A single concentration of mannan (500 µg/ml) at 
different flow rates (5, 15 and 75 µl/min) was exposed to the mannose receptor (MR) immobilised 
on the CM-5 chip. No change was observed in the response level (RU) between each of these runs 
indicating that mass transfer is not a limiting factor in this study. 
 
Figure 4-15. Binding affinity measurements for vaccine constructs 13-18. Surface plasmon 
resonance (SPR) analysis for the concentration-dependent binding of mannosylated constructs (13-
15) and experimental controls (16-18) with the immobilised recombinant human macrophage 
mannose receptor (MR) protein. Solutions of 13-18 (0.78-50 µM concentration range) and mannan 
(18.75–600 µg/ml) were prepared in running buffer (10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2,150 
mM  NaCl, 0.005% P20; pH 7.4) and injected over a period of 1.5 min with a dissociation interval of 
8 min. The sensogram shows the plotted level of binding in the steady state (Req) against different 
concentrations of (A) the positive control mannan, and the vaccine constructs (B) 13, (C) 14, (D) 15, 
(E) 16, (F) 17, and (G) 18. R2 indicates the fit of the results to the curve with respect to concentration. 
The affinity constant (KD) was calculated using the response level at equilibrium (Req) using Equation 
1 (Chapter 2, Section 2.2.5). 
 
Figure 5-1. Dendritic cell (DC) involved in antigen presentation and activation of CD4 and CD8 
T cells. Following antigen uptake by pattern recognition receptors (some mentioned in this thesis 
include: MR, DC-SIGN, TLRs), antigen presenting cells travel to the lymph nodes and present the 
processed antigen to CD4 and CD8 T cells by MHC II and MHC I, respectively.  CD4 or CD8 T cells 
are activated depending on the antigen type and the following pathways become activated by 
proliferation: (A) CD8 activation leading to direct antigen elimination through cytotoxic T cells or 
by inflammatory cytokines in the Th1 pathway (e.g. IL-2, IFN-γ); or (B) humoral pathway where 
CD4 activates Th2 which is followed by Th2 related interlukin (e.g. IL-6, IL-5, IL-4) production. 
Upon Th2 activation, B cells are activated and trigger antibody (IgG) production. Memory B cells 
are produced by B cells. 
 
Figure 5-2. Vaccination groups (G)1-9 used in the in vivo study. G1-3 are test compounds used to 
study immune modulatory properties affected by the differences in the number of alanine spacers 
between the mannosyl moieties. G4-8 are controls used to compare a structure-activity relationship 
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of no mannose (G4), no lipid (G5), and no mannose and no lipids (G6). A mixture of the vaccines’ 
structural components (OVA323-339, mannosyl and the lipid, G7) was used to compare with the 
chemically conjugated vaccine constructs (G1-G6). The positive control (G8) was OVA323-339 and 
CT, and the negative control was PBS (G9). All vaccine groups (G1-9) were dissolved in PBS (30 
µg/100 µl/per mouse) and injected subcutaneously (S.C.) at the tail base. Five mice were used per 
vaccine group. 
 
Figure 5-3. Schematic diagram of the in vivo study. Vaccine groups (G1-9) were introduced to 
mice following the transfer of OT-II CD45.2+ T cells isolated from transgenic mice (B6.Cg-
Tg[TcraTcrb]425Cbn/J with OVA sensitive OT-II cells) to C57BL/6 mice. Mice were vaccinated on 
days 2, 21 and 42. Blood was taken on days 10, 31 and 52 post vaccination. OT-II read outs for flow 
cytometry and ELISA were performed 10 days post each vaccination. Mice were sacrificed on day 
63. ICS and CBA studies were performed on blood samples taken 21 days post dose 3 vaccination. 
 
Figure 5-4. OT-II CD45.2+ CD4+ T cells from OT-II mice do not proliferate in C57BL/6 mice 
upon vaccination with G1-9. CD45.2+ CD4+ OT-II T cells were purified and 200 µL of suspended 
cells (0.5×106 cells) was injected intravenously at the tail base to CD45.1+ C57BL/6 mice. The 
percentage of CD45.2+ OT-II cells within the CD4+ population was measured from tail blood taken 
at days 10, 31 and 42 using flow cytometry. Mean results (±SEM) from five individual mice per time 
point are shown, (A) at day 10, (B) at day 31, and (C) day 42. Unpaired t-Test was used to show the 
significance when p <0.05. Here, G8 is the positive control group vaccinated with OVA323-339 + 
cholera toxin and G9 is the negative control group vaccinated with PBS. 
 
Figure 5-5. Percentage of CD62llow CD4+ parental T cells. Vaccine constructs G1-G9 were 
compared by percentage (%) of CD62llow CD4+ parental T cells following three vaccinations on days 
10 (A), 31 (B) and 52 (C). Mean results (±SEM) from 5 individual mice groups are shown. Unpaired 
t-test was used to show significance when p <0.05. Here, G8 is the positive control group vaccinated 
with OVA323-339 + CT and G9 is the negative control group vaccinated with PBS.  
 
Figure 5-6. Schematic process of intra cellular staining. This method is used to measure antigen-
specific cytokine release (e.g. IFN-γ, IL-2, TNF). (A) single cell suspensions from vaccination 
groups’ (G1-9) lymph nodes and spleen were stimulated by OVA323-339 peptide, PMA/ionomycin as 
experimental positive control and media only as experimental negative control, (B) cells were then 
incubated at 37°C and 5% CO2 for 3 days in the presence of protein transport inhibitor, (C) cells were 
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then permeabilised and fixed, (D) cells were stained with IFN-, IL-2 and TNF antibodies. The 
expression of IFN-, IL-2 and TNF was analysed on the CD4+T cells subset using flow cytometry. 
 
Figure 5-7. Intra cellular staining studies on INF-, IL-2 and TNF expressing T cells following 
vaccination. Percentage of CD4 (A, B, C) and CD8 (D, E, F) T cells associated with IFN-, IL-2 and 
TNF upon in situ stimulation of draining lymph nodes and spleen cells (isolated 11 days post third 
vaccination with G1-G9) with the OVA323-339 peptide and PMA/ionomycin (experimental positive 
control). Results are normalised against the media per each mouse per group. Mean results (±SEM) 
from 5 individual mice per group are shown. Unpaired t-Test was used to show the significance when 
p <0.05. Positive control is G8 vaccinated with OVA323-339 plus CT and negative control is G9 
vaccinated with PBS. 
 
Figure 5-8. Schematic of cytokine bead array measurement. (A) The fluorescent capture beads 
are conjugated with detection antibodies and are incubated with test samples containing cytokines 
and secondary antibodies to form (B) sandwich complexes. The sandwich complex is then (C) washed 
followed by acquisition of sample data using (D flow cytometry. The sample results are generated in 
graphical and tabular format using the BD CBA analysis software. 
 
Figure 5-9. Antigen specific antibody production following vaccination using ELISA assay. Sera 
were collected on days 10 (9 days post the first vaccination), 31 (10 days post the second vaccination) 
and 52 (10 days post the third vaccination). IgG UV intensity was recorded (OD 450) for a 1/200 
dilution for all mice groups (G1-G9). Mean ± SEM is shown. Unpaired t-Test was used to show 
significance when p <0.1. Positive control is G8 vaccinated with OVA323-339 plus cholera toxin and 
negative control is G9 vaccinated with PBS. There were 5 mice per group. 
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1.1 Introduction  
Vaccination has provided prevention and treatment of many infectious diseases (e.g. smallpox, polio 
and diphtheria) [1-4]. However, new vaccination strategies are required to overcome immune 
suppressive diseases, including human immunodeficiency virus (HIV) and malaria infection. The 
future of vaccine design and development depends on the advanced knowledge of immune system 
activation pathways and a better understanding of the requirements for specificity and selectivity 
towards either prophylactic or therapeutic immune pathways. Selecting antigens, inclusion of 
adjuvants (a moiety that enhances antigen immunogenicity) and addition of targeting moieties, such 
as mannose, play important roles in all aspects of vaccine  development [5].  
Vaccine development requires consideration of immunogenicity and efficacy of vaccines. Here, 
understanding the process of antigens interaction with antigen presenting cells (APCs) which is 
followed by antigen uptake and processing by these cells can be a crucial factor [6].  
Pattern recognition receptors (PRRs), are a large family of receptors that initiate recognition of any 
invasion of the body. C-type lectins are a sub-family of PRRs and within C-type lectins, the mannose 
receptor (MR) is an important component of the immune system. The MR has been subject to 
extensive studies to understand its structure and function. The MR plays an important role in linking 
both innate (nonspecific defence mechanism) and adaptive (acquired) immunities [7, 8]. Thus, 
targeting this receptor can be an important part of vaccine design and development. The MR is mainly 
found on macrophages and dendritic cells (DCs) [9]. Minimal information is available about the 
mechanisms used by DCs to recognise and internalise pathogens through the MR. However, 
understanding both the structural and conformational characteristics of this receptor are important 
aspects to be considered about interactions with this receptor. Earlier studies have found mannan, the 
primary component in the cell wall of yeast, is a MR ligand. This key finding has allowed researchers 
to better understand the role of the MR in the uptake, processing and presentation of glycosylated 
antigens [10, 11]. 
To date, many strategies have been used to develop vaccines that target the MR. These include using 
ligands that contain mannan or mannose to increase targeting specificity. However, the actual 
involvement of the MR in recognition of such mannosylated structures is less studied [9, 12, 13]. 
Vaccines that target the MR have the potential to elicit different immune responses. Through the 
analysis of ligand and antibody targeting approaches it is clear that the structural properties of the 
MR and specificity of the interaction with the MR receptor are crucial factors for determining antigen 
processing and the resultant immune response.  
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1.2 Immune system activation pathways 
The first interaction of bacteria and microorganisms with the body’s immune system is through 
receptors on the macrophages, DCs and other APCs (Langerhans cells and B lymphocytes). This 
interaction between fragments of the pathogenic cell wall and phagocytic receptors on APCs 
generates production of biologically active molecules, including cytokines and chemokines. These 
biologically active molecules are secreted proteins and are responsible for the regulation of either an 
anti-inflammatory or pro-inflammatory immune response [14]. The immune system reacts to 
pathogens in two distinct types of defence: innate and adaptive [15] Here, the innate immune system 
recognises the nature of infection by providing signals, as a first line host defence, to the adoptive 
immunity (Figure 1-1). Cells involved in the innate immune system consist of DCs, macrophages and 
natural killer cells. Each of these components of the innate immune system is able to eliminate the 
pathogen independently (Figure 1-1). Here, the DCs and macrophages first interaction with the 
pathogens is through pattern recognition receptors (PRRs), which then internalise the antigen and 
cause an immediate release of cytokines (Figure 1-1) [16]. Following cytokine release natural killer 
cells become activated and are able to digest the pathogen with interactions through their surface 
markers [17].   
Furthermore, the innate immune system plays a crucial role in the induction of an adaptive immune 
response. Unlike the innate immune system, the adaptive immune system becomes activated at a later 
period, usually 4-7 days post infection, and is associated with the adaptive immune system being 
involved with antigen recognition through antigen presentation by DCs (Figure 1-1) [18]. One of the 
important aspects of the adaptive immune system is its ability to generate a range of T and B cells 
(two types of lymphocytes or white blood cells) and antigen specific receptors including Major 
Histocompatibility Complex (MHC I and II) receptors and co-stimulatory receptors, in response to 
DC activation. Here, immature DCs recognise and internalise pathogenic antigens and play an 
important role in processing the antigenic components and presenting them to T cell receptors.  
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Figure 1-1. Schematic representation of immune factors involved in innate and adaptive 
immunity. (A) Innate immunity is activated hours post pathogen exposure and involves dendritic 
cells, macrophages, natural killer cells and pattern recognition receptors; cytokines released in this 
pathway are antigen independent; (B) Adaptive immunity is activated days after exposure to a 
pathogen (antigen dependant) and consists of B cells, which lead to an antibody response, and naïve 
T cells, which lead to CD4 and CD8 T cell proliferation. Naïve T cells represent a common 
intermediate between innate and adaptive immunity. Here, naïve T cells have the ability to migrate 
from where they are produced (thymus) to secondary lymphoid organs including the lymph nodes 
where they become CD4 or CD8 T cells which are the components of the adoptive immune response. 
Following antigen uptake, DCs travel to the lymph nodes where T cell activation occurs [15, 19]. One 
of the key roles of DCs is uptake and presentation of antigens to naïve T cells. Naïve T cells, which 
are produced in the thymus, travel to secondary lymphoid organs, including the spleen, peripheral 
lymph nodes and gut-associated lymphoid tissue. In the secondary lymphoid organs naïve T cells 
recognise CD4 and CD8 co-stimulatory receptors (CD4 and CD8 are transmembrane glycoproteins 
on the DCs that act as co-receptors for T cell receptor) on the DCs via their T cell receptor (Figure 1-
1). Upon encounter between DCs (that have internalised and presented the antigen through CD4 and 
CD8 receptors) and naïve T cells, CD4 (helper T cells) and CD8 (cytotoxic T cells) T cells are 
produced activating the B cell response [20].  
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Intracellular antigens, from tumour or viruses that develop inside body cells, are presented by MHC 
I molecules which consequently activate cytotoxic CD8 T cells [21]. CD4 T helper cells on the other 
hand are activated by extracellular antigens that are presented through MHC II molecules.  
While two distinct pathways exist for CD4 and CD8 T cell activation, cross presentation is described 
as a mechanism that allows the extracellular antigens to activate a CD8 T cell response through MHC 
I molecules (Figure 1-1). It has been suggested that CD4 co-stimulatory receptors play important 
roles in the production of memory CD8 T cell responses. Sun et al., showed that CD8 memory cells 
produced in the absence of CD4 T cells were not able to respond properly following a second 
encounter with the same antigen, and this confirmed involvement of CD4 T cells in a CD8 response 
[22]. In a review by Bourgeois and Tanchot, the importance of CD4 help for a long-term (memory) 
CD8 response was discussed. Bourgeois and Tanchot concluded that CD4 cells can affect 
complicated signalling pathways on APCs. They also confirmed the role of CD4 cells on activating 
CD8 cells causing a secondary immune response [23]. In another study by Bourgeois et al., the death 
of CD8 cells was directly related to the lack of CD4 cells in a vaccinated mouse model indicating the 
correlation between the CD4 and CD8 activation pathways[24].  
1.3 Mannose receptor and structural properties 
The MR is a carbohydrate binding receptor expressed by macrophages and DCs [25]. The MR 
[Cluster of Differentiation (CD); 206] has three other family members: phospholipase A2 receptor 
(PLA2R), Endo180 (CD280) and DEC-205 (CD205). The CD nomenclature was established in 1982 
to standardise the naming of cell surface markers to aid identification and characterisation [26]. The 
MR family are a sub-group of the C-type lectin super-family, a major class of the endocytotic PRRs 
which promote the attachment, engulfment and destruction of micro-organisms by phagocytosis 
(Figure 1-2). Unlike other C-type lectin receptors (CLR), the MR family are unique in having multiple 
carbohydrate recognition domains (CRDs) in a single polypeptide construct [27]. However, from the 
MR family only the MR and Endo180 are known to recognise and bind monosaccharides [28].  
25 
 
 
Figure 1-2. Mannose Receptor classifications. Pattern recognition receptors (PRRs) promote the 
recognition, attachment, and phagocytosis of foreign pathogens via the carbohydrate recognition 
domain (CRD). CLR is a major class of PRRs which contain one or more CRDs that recognise a wide 
variety of ligands. Additionally, the entire MR family is able to distinguish self from non-self 
structures. The mannose receptor (MR) family comprises four members including the MR (CD206), 
phospholipase A2 receptor (PLA2R), Endo180 (CD280), and DEC-205 (CD205).  
Wileman et al. originally discovered the MR in rabbit alveolar macrophages as a 175 KDa protein by 
using radio-labelled mannosylated bovine serum albumin (BSA) where it was found to recognise 
terminal glycosylated chains [29]. A further study by Ezkowits discovered that heteroantisera against 
human macrophages precipitated a 170 KDa glycoprotein from the cell surface which was confirmed 
to be the molecular weight of the human MR [30]. In 1990, Taylor et al. isolated cDNA clones that 
covered the entire coding portion of mRNA for the human MR. Sequence analysis confirmed the 
receptor to be a type І trans-membrane protein with its carboxyl terminal on the cytoplasmic side of 
the cell membrane (Figure 1-3) [31].  
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Figure 1-3. Schematic structure showing the organisation of the Mannose Receptor. The 
Mannose Receptor Cysteine Rich (CR) domain recognises sulfated carbohydrates terminated in N-
acetyl glucosamine (15), the Fibronectin type ІІ (FNII) domain binds to collagen І, ІІ, and IV with 
high affinity and weakly to V [32, 33], and the Carbohydrate Recognition Domains (CRDs) bind 
complex carbohydrates that terminate in mannose, fucose or N-acetyl glucosamine [32, 34]. Here, 
CRD4 (*) binds mannosylated ligands found in pathogen cell walls in a calcium-dependent manner. 
CRD4-7 is essential for high affinity binding to multibranched mannosylated ligands and ligand 
internalisation. The C-terminal internalisation motif has a role in transferring ligands inside the cell.  
The MR exists in both monomeric and multimeric states [31, 32, 35]. Taylor et al. expressed the 
intact receptor in rat fibroblasts and then sedimented the receptor protein confirming it to be a 
monomer in the cell membrane [36]. However, analysis by Su et al. and Boskovic et al. provided 
evidence for the receptor to exist in both states, establishing that the experimental methodology used 
to study the receptor influences the state that is recovered. Additionally, these results confirmed the 
presence of multiple carbohydrates in a single polypeptide chain (Figure 1-3) that must cooperate to 
achieve high-affinity binding of complex ligands [31, 36-39]. 
The MR is characterised by a N-terminal cysteine rich (CR) domain; a single fibronectin type II 
(FNII) domain; a carbohydrate recognition domain (CRD) ,which is also referred to as C-type lectin 
like domain (CTLD), and a C-terminal internalisation motif located at the tail (Figure 1-3). The CR 
domain acts as a second lectin domain unique to the MR and is comprised of 139 amino acids. This 
domain is capable of binding sulfated oligosaccharides and has a role in maintaining receptor stability 
of the ligand endocytosis process at acidic pH [32, 40]. The FNII domain binds collagen and the 
cytoplasmic tail contains a motif that helps transport bound antigens inside the cell [31, 41]. The CRD 
consists of eight segments (Figure 1-3) and is responsible for binding glycoconjugates on the surface 
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of bacteria, parasites, viruses, and fungi that terminate in mannose, fucose or N-acetyl glucosamine 
[31, 42]. MR family members have evolved different molecular trafficking properties with the 
receptor found to use both endocytosis and phagocytosis pathways [5]. Although the recognition of 
glycosylated ligands by MR CRDs is known, a full understanding of their function in the context of 
vaccine development requires structural knowledge of each domain and how they interact with each 
other to enable binding and specificity. Further information about the relationship between receptor 
binding and internalisation is also required. 
1.3.1 Carbohydrate recognition domains 
Understanding the mechanism of glycopeptide attachment and conformational changes associated 
with MR CRDs is essential for designing glycosylated ligands that can be used to target this receptor. 
Pathogen recognition and cellular interactions are mediated through the MR CRD in a calcium 
dependent manner [8]. An early review by Drickamer shows that the CRDs play an important role in 
innate immune responses against clinically relevant pathogens including: Leishmania donovani (L. 
donovani), Plasmodium chabaudi, and Pneumocystis carinii (P. carinii) [43, 44]. These studies 
showed that the MR participates in opsonin-mediated binding leading to opsonin-independent 
phagocytosis of pathogens by recognising glycosylated ligands capped with mannose, fucose, or N-
acetyl glucosamine, highlighting its important role in the early stages of infection [8, 45]. 
In 1992, Taylor et al. showed that the CR domain, FNІІ repeat and the first three CRDs were not 
essential for the binding and endocytosis of glycosylated ligands [11, 36]. Instead, FNІІ had collagen 
binding properties that allowed it to play a role in mediating the clearance of collagen fragments or 
in cell-matrix adhesion. Subsequently, the different types of collagen have been demonstrated to 
contain glycosylated propeptides, with the propeptide of type I collagen being highly-mannosylated. 
Here, in addition to the FNII domain, the CRDs of the MR have been shown to bind to this propeptide 
aiding its clearance from the body. This details a multi-functional role for the MR including roles in 
tissue remodelling and wound healing [33].  
Each CRD consists of approximately 120 amino acids that form eight segments designated CRD1 to 
CRD8 (Figure 1-3). Multiple CRDs are required to bind complex glycosylated ligands, supporting 
evidence that they exist as a single polypeptide chain [31, 36, 38, 39, 43]. Site directed mutagenesis, 
ligand binding and Nuclear magnetic resonance (NMR) analysis confirm that the ligation of CRDs to 
glycosylated ligands is calcium dependent. A characteristic of this family is the common folding in 
that each CRD is comprised of two alpha-helices and two small antiparallel beta-sheets held in place 
by non-covalent and covalent interactions. Four conserved cysteine residues form two disulfide bonds 
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that stabilise the structure, while contributions from hydrophobic residues make up a hydrophobic 
core. Calcium is required for carbohydrate binding and receptor activation (Figure 1-3). 
Understanding the spatial arrangement of the domains and changes induced upon ligand binding is 
essential to understanding the behaviour of the MR [8, 27, 43].  
MR proteolysis experiments showed that CDRs were resistant to degradation in the presence of 
calcium, which is consistent with a tightly folded structure [32, 36]. In vitro analysis was used to 
determine which of the extracellular domains were engaged in recognition, ligation and endocytosis 
of glycosylated ligands [11, 36, 43, 46, 47]. These studies confirmed that ligation of the CRDs to 
these ligands was dependent on the conformation of eight CRD segments and their interaction with 
the terminal glycans of the ligand [46, 47]. In 1991, Taylor et al. reported that CRD1-3 had a weak 
carbohydrate binding ability while CRD4 was found to have the highest binding affinity. This study 
concluded that at least three domains (CRD 4, 5 and 7) were required for high affinity binding and 
endocytosis of multivalent glycoconjugates [11]. It was also shown that CRD4 alone could mimic the 
saccharide binding ability of all eight CRDs. However, CRD4 binds poorly to multi-glycosylated 
ligands such as mannan, thus cannot account for the binding of the receptor to natural antigens. For 
complete affinity of the MR to glycosylated ligands, CRD4-8 must contribute to the binding of 
oligosaccharides (Figure 1-3) [32, 36].  
To determine how the CRD achieves high-affinity glycosylated ligand binding, Taylor and Drickamer 
produced internal fragments of the receptor using the baculovirus expression system and compared 
the binding affinity of natural ligands that contained high-mannose oligosaccharides (invertase and 
mannan) with that of larger protein fragments (BSA conjugated to mannan (man-BSA)). Receptor 
fragments consisting of CRDs 4-5, 4-6 and 4-7 were purified and subjected to proteolysis studies to 
determine their affinities for various ligands. It was concluded that the affinity of CRD4-5 for man-
BSA did not change after addition of CRD6-7 but when they investigated mannan’s affinity for 
CRD4-5, binding increased when CRD5 was present. This study confirmed that the affinity of the 
full MR is the same as for CRD4-8 for the studied ligands. Combined, these results indicated that 
CRD 4-8 recognised terminally mannosylated ligands [11, 36, 46]. Proteolysis experiments supported 
the idea that CRD4-5 forms a tight ligand binding core essential for high-affinity binding of 
multivalent ligands but the affinity for mannan increases as more CRDs are present indicating for 
certain ligands that CRD 6-8 is essential for binding [32].  
MR proteolysis experiments showed the resistance of CRD to degradation in the presence of calcium 
suggested a tight and folded structure. CRD4-5 did not release individual CRDs under proteolytic 
conditions, indicating that these two domains form extensive contacts implying a fixed orientation to 
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the binding sites within these two CRDs [36]. In 2006, Boskovic et al. explained the three-
dimensional (3-D) organisation of the MR showing that the CRDs are packed in pairs as CRD4-5 and 
CRD7-8 are connected by a single CRD3 and 6 respectively (Figure 1-4A). Electron microscopy 
studies coupled with 3-D reconstructions and X-ray structures modelled from the Endo180 protein (a 
member of the MR family) [42], suggested that the conformational properties of the MR were pH 
dependent, mimicking receptor recycling properties between the plasma membrane and endosome. 
The CRDs conformation potentially made some points of the receptor more accessible to glycosylated 
ligands, modelling a structure with the CRD4 domain near the FNII and CR domains in a compact 
organisation (Figure 1-4A) [32]. Here, all CRD domains have the potential to interact with the ligand 
(Figure 1-4A), however, it has been shown that only CRD4-7 actually has a role in binding and 
internalisation. This contradicts a previous model where Napper et al. performed hydrodynamic 
studies of the receptor that suggested a U-shape structural organisation (Figure 1-4B) [48]. In this 
model, only CRD4 is shown to interact with the ligand. To date, nothing further is known about the 
spatial alignment of MR CRDs and their interactions with glycosylated ligands. As no complete X-
ray structural data is available for the MR, and based on recent evidence and studies, Figure 1-4A 
represents the most up-to-date accurate structural model for the MR. Further information pertaining 
to the structural analysis of the MR can be found in published articles [32, 42]. 
Binding of the MR CRDs to saccharides was studied in the presence of mono- and oligosaccharides 
of mannose. It was shown that hydroxyl groups on the C3 and C4 position of terminal mannose ligated 
to calcium to form hydrogen bonds with glutamate and asparagine residues on the CRDs [43, 46, 47, 
49]. Drickamer et al. reported that the number of CRDs in the receptor would correlate with the ability 
of the receptor to bind different types of ligands. It was also observed that the multivalent and linear 
structures of the MRs were two essential properties that allow for recognition of a large number of 
foreign ligands [43].    
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Figure 1-4. A model for the structural organisation of the Mannose Receptor and the 
attachment of glycosylated ligands. Conformational structure of the mannose receptor with mannan 
from the surface of bacteria as a model glycosylated ligand. A Compact “bent” organisational model 
proposed by Boskovic et al. where the CRD interacts with the CR domain in ligand binding [32, 40]. 
B A U-shaped model proposed by Napper et al. suggesting exposure of CRD4-5 in ligand binding 
[48]. CRD4 has high binding affinity to glycosylated ligands and CRD5-8 in addition to CRD4 is 
essential in binding multi-glycosylated ligands [32]. 
1.4 Role of the Mannose receptor in immunity 
The MR is a PRR. Unlike single ligand receptors, PRRs are a group of receptors that recognise a 
broad spectrum of pathogens including yeasts, parasites, bacteria, and viruses [27, 50]. Pathogen 
recognition is performed by the MR CRDs bound to a variety of microorganisms including Candida 
albicans (C. albicans) [30], P. carinii [44], L. donovani [51], Mycobacterium tuberculosis (M. 
tuberculosis) [52] and influenza A virus [53]. 
The MR is an important part of innate and adaptive immunity [54]. The innate immune system is the 
body’s first non-specific defence mechanism and is responsible for the early detection and acute 
response to pathogens. Adaptive immunity is antigen specific, allowing for long-term recognition, 
and enabling the body to create immunological memory after initial exposure to a pathogen. This 
leads to an enhanced response to subsequent encounters with the same pathogen [7]. Chieppa et al. 
showed that, when exposed to anti-MR monoclonal antibodies, the MRs present on DCs caused DC 
maturation and increased the level of anti-inflammatory cytokines, which is consistent with the 
receptors’ role in adaptive immunity [55]. Additionally, the MR family (Figure 1-2) has the ability to 
recognise a diverse range of organisms without interacting with self-structures and although the 
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mechanism is not fully understood, it is thought to be associated with the CRDs recognising specific 
patterns (or ligand geometries) of terminal sugars which decorate the surface of microorganisms [27, 
56, 57]. Lorenz et al. compared the uptake of RNase versus mannosylated-RNase and reported that 
the latter increased T-lymphocyte stimulation. They proceeded to study the internalisation of soluble 
yeast mannan compared to mannosylated-RNase by APCs. This study aimed to clarify the ability of 
the immune system to recognise self from non-self proteins. The enhanced uptake of a foreign antigen 
was performed through the MR which has specific recognition ability [58]. Recent interest in the 
ability of MRs to recognise self from non-self has seen studies investigating these properties for 
potential applications in autoimmune diseases and allergies. 
In vitro studies showed that the processing and presentation of antigens was enhanced when the MR 
was targeted [59]. Research also suggested that ligand binding specificity was the main element that 
differentiated self from non-self antigens [50]. For example, hexoses (e.g. mannose and fucose) found 
on the surface of gram positive and negative bacteria have equatorially placed hydroxyl groups at 
carbons C3 and C4 organised in a branched fashion which were recognised by the receptor, while 
linear hexoses were not [50]. This indicated that ligand geometry is important in self/non-self 
recognition by the MR.  
Since 1970, mannosylated antigens have been known to effectively potentiate antigen 
immunogenicity via the MR. Receptor-mediated antigen uptake by DCs and T cell stimulation was 
shown to be 100 times higher than by pinocytosis [13, 60, 61]. Additionally, mannosylated antigens 
were also internalised and presented through MHC II, which resulted in up to 10,000 times greater 
stimulation of T cells [62]. This was supported by Levitz et al. who used mannosylated targeting 
proteins from Cryptococcus neoformans to determine the T cell response to MR activation. The 
resultant antigen-specific immune response via receptor recognition on DCs and subsequent 
internalisation and presentation through MHC I and II supported the importance of mannosylation 
for the stimulation of a targeted T cell response [61]. The response (Th1 or Th2) and the cytokine 
production profile remain largely undefined.  
DC maturation occurs after glycosylated ligands bind to the MR and stimulate the internalisation of 
the glycosylated antigens. The pathway used for antigen degradation and processing is receptor 
specific [63]. After antigen degradation, lysosomes present the degraded antigen on the surface of 
mature DCs through MHC I and II resulting in an increased expression of T cell receptor co-
stimulatory molecules CD80 and CD86 [64]. In both MHC I and II pathways, CD80/CD86 interact 
with CD28 on T cells. Activated CD4+-cells differentiate into either Th1 or Th2 cells which release 
cytokines. The MHC II pathway is responsible for the humoral immune response while the MHC I 
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pathway is responsible for cytotoxic T-lymphocyte responses (Figure 1-5) [17, 42, 65]. The important 
role of MR CRDs in promoting an immune response has prompted many clinical in vivo and in vitro 
studies [30, 44, 51, 52] and its contribution to disease through the cellular metabolic pathway was 
highlighted in a recent review [25].  
 
Figure 1-5. Mannose receptor and cellular targeting pathway. 1: Attachment of glycosylated 
ligands (e.g. mannan from the surface of bacteria) to CRD4-8 of the mannose receptor, followed by 
2: internalisation and degradation of ligands by the lysosome for adaptive immune responses.  3: 
Presentation of degraded ligands to the surface of the dendritic cell through MHC I and II and co-
stimulatory receptors (e.g. CD80/CD86). 4: Naïve T cell activation through MHC I and II pathways 
where, 5: MHC II pathway activates CD4 T cells and achieves, 6: T-helper response activating 
cytokine release, or 7: MHC I pathway activates CD8+ T cells. 8: Cytotoxic T-lymphocytes response 
to eliminate infected ligands. The innate pathway activates through 9: direct release of cytokines 
through the DC. 
1.5 Subunit vaccines for targeting the mannose receptor 
An effective MR-targeting vaccine must successfully deliver epitopes to the CRDs on the MR, 
helping to ensure optimum processing and presentation to elicit an immune response. A detailed 
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understanding of receptor-antigen interactions is critical to achieving this aim [66]. MR CRDs have 
the ability to selectively bind glycosylated ligands resulting in internalisation and processing through 
MHC I and II pathways, thus it is postulated that any procedure that triggers this cycle has the 
potential to prompt an effective immune defence. Studies that have targeted the MR have focused on 
the attachment of mannan or mannose to peptides or proteins to show receptor specificity and affinity. 
The features of the most prominent experiments have been highlighted in Table 1 and will be 
discussed throughout the remaining sections.  
Table 1-1. Mannosylated subunit vaccine development for targeting the Mannose Receptor  
Mannose Receptor 
Targeting Ligand 
Pathogen or Endogenous 
Ligand 
Immune Response References 
 
Mannan 
Lipoarabinomannan TNF, Th1 [67, 68] 
Oxidised and reduced MUCI CD8 cytotoxic lymphocyte 
reaction, Th1/Th2 
[54, 69-74] 
 
 
 
 
 
Mannose 
Bovine serum albumin MHC II presentation [60, 75] 
Pichia pastoris  MR affinity and DC 
internalisation 
[76] 
Whole OVA protein  Th1/Th2 [73] 
RNase Ligand specific uptake [58] 
Polyalanine peptides T cell response by targeting the 
MRs CRDs  
[77] 
OVA323–339  T cell response and APC 
presentation through the MR  
[78] 
PEGtide dendrons MR targeting and uptake by 
macrophages  
[79] 
Polylysine DNA  dendrimers High affinity to the MR  [80, 81] 
Polylysine dimer DC internalisation through the 
MR 
[82] 
TNF: Tumour Necrosis Factor, MHC: Major Histocompatibility Complex, Th1: T-helper cell type 1, Th2: T-helper cell 
type 2, OVA: Ovalbumin, MUCI: mucin and carbohydrate associated antigens as tumour markers 
Development of a glycosylated subunit vaccine that contained glycan moieties could potentially 
enable the targeting of a specific receptor [10]. Glycosylated proteins and peptides have been 
investigated for MR targeting for vaccine development purposes. To date, mannan and mannosylated 
antigens are one of the most effective ligands for targeting the MR and eliciting an immune response 
as a result of mannan’s strong ability to compete with other ligands for receptor binding [10, 83-87]. 
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1.6 Structural properties of mannan as a mannose receptor ligand 
Mannan, a polysaccharide of mannose [88] found in the cell wall of Sacchaomyces cerevisiae, (yeast) 
has been well characterised (Figure 1-6) [89, 90]. Mannan binds to the MR CRDs causing an immune 
response involving the up-regulation of co-stimulatory molecules (e.g. CD40, CD80 and CD86) and 
pro-inflammatory cytokines (e.g. IL-12, IL-4), required for Th1 or Th2 cell priming (Figure 1-5) [34, 
91]. Extensive studies on mannan and its derivatives have been performed to investigate the important 
structural properties of mannan that enable recognition by the MR and stimulate an immune response 
by DCs. The reduction and oxidation of mannose alters the overall structure and functional properties 
(Figure 1-7) [92]. Consequently, oxidised and reduced forms of mannan have successfully been 
shown to stimulate Th1 and Th2 responses via different cellular pathways, emphasising the 
importance of the structural interaction between mannan and the receptor [91]. Since recognising 
mannan’s ability to elicit an immune response, and later its ability to bind to the receptor, vaccine 
design attempts have investigated the yeast cell wall protein alone [93] or functionalised peptides or 
proteins with mannan or mannose to mimic the cell wall of a pathogen [71, 72, 74, 94-96].  
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Figure 1-6. A typical N-linkage through asparagine (Asn) is highlighted with examples of mannose 
receptor binding N-linked proteins from C. albicans [97], mucin from Pichia pastoris [98] and 
Saccharomyces cerevisiae [99]. A typical serine/threonine (Ser/Thr) O-linkage is highlighted. 
Examples of mannose receptor O-linked binding proteins include mucin from Pichia pastoris, 
Saccharomyces cerevisiae and M. tuberculosis [100, 101]. 
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Apostolopoulos et al. found that antigenic MUC1 peptides on the surface of tumour cells attached to 
oxidised mannan, which stimulated a cellular immune response and CD8 cytotoxic lymphocyte 
production. Earlier studies from the same group reported an unsuccessful induction of cellular 
immunity when a diphtheria toxoid carrier was used. These results indicated the importance of 
oxidised mannan in molecular design, and the effect of targeted specificity towards the MR on the 
resultant immune response [69, 74]. Oxidised mannan attached to a recombinant MUC1 fusion 
protein has undergone phase ІІІ cancer clinical trials [72, 102, 103]. The results showed that MUC1 
attached to oxidised mannan induced tumour-specific CD8 T cell responses but immunisation with 
reduced mannan-MUC1 conjugates provided poor protection [71]. Additionally, aldehyde mannan-
MUC1 elicited a stronger cellular response, inducing INF-γ production and the generation of IgG2a-
dominant antibodies [70]. The structural properties of mannan played an important role in receptor 
uptake and the immune response elicited an important consideration for targeted vaccine design. 
 
Figure 1-7. Oxidised and reduced structures of mannose. Under mild oxidation conditions (e.g. 
Br2/H2O), the C-6 carbon on mannose is oxidised to a carbonyl group forming mannuronic acid; 
under reducing conditions (e.g. sodium amalgam), mannose is converted to mannitol with the 
formation of an alcohol at the C-1 carbon. Reduced and oxidised variations of mannan have been 
used to investigate mannose receptor targeting [92]. 
Lipoarabinomannan (LAM), derived from M. tuberculosis [67, 104], contains terminal mannose 
residues that are responsible for receptor binding and eliciting secretion of tumour necrosis factor 
(TNF; a cytokine with anti-microbial activity) by macrophages. Chatterjee et al. demonstrated MR 
binding in competitive inhibition studies that used mannan, mannose-BSA, N-acetyl glucosamine-
BSA serum, and antibodies directed against the MR. LAM, derived from the M. tuberculosis H37Ra 
(avirulent) strain, which contains long mannan segments on its cell wall, caused a 100-fold greater 
secretion of TNF compared to the Erdman strain (virulent), containing shorter mannan segments. 
These studies described a receptor that was able to discriminate between mannan length isolated from 
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the virulent and avirulent strains of M. tuberculosis. Discrimination between virulent and avirulent 
strains of M. tuberculosis through the secretion of different levels and types of cytokines (e.g. TNF) 
is also noted in another study [67]. Further, Schlesinger et al. demonstrated that macrophages are 
important in mediating phagocytosis of both virulent and attenuated strains of M. tuberculosis but the 
MR plays an important role in phagocytosis of only the virulent strains [105]. These studies indicate 
that distinct domains of the MR can vary their modes of interaction with ligands, impacting cellular 
fate. Also, identification of the structural differences between virulent and attenuated strains, in 
addition to cellular differences, will enhance the understanding of MR function.  
1.7 Carbohydrate based vaccines  
In nature, glycosylated proteins occur as both O- or N-linked glycol moieties (Figure 1-6). Synthetic 
methods that model this quality are a promising way to produce vaccines with specific targeting 
ability [106, 107]. Glycosylation is used to increase peptide solubility, oral bioavailability and serum 
half-life, to gain a broader reactivity, and to provide more conformational properties to synthetic 
peptides [108]. Biologically, the structural properties of vaccine constructs are important [109]. For 
instance, the relationship between the structure of glycosylated peptides and their targeting ability 
plays an important role in an immune response [110, 111]. 
Variation of the carbohydrate epitopes that target cellular receptors is known to influence cell 
development and immune responses [112]. Sugar moieties are attached to the peptides or proteins by 
conjugation to the nitrogen of the asparagine side chain (N-linked) and O-glycosides are most 
commonly attached through the hydroxyl group of serine and threonine (Figure 1-6). Glycosylated 
peptides have roles in vaccine development due to their ability to form new ligands, thus permitting 
tailoring to meet specific receptor binding properties [112]. Recent advances in the synthesis of 
complex glycomolecules are due to an increase in experimental studies investigating the interactions 
between glycosylated ligands and a wide range of immune receptors.  
Mannosylation has proved to be an important method for vaccine targeting and design. Common 
mannosylated vaccine antigen candidates include peptides and proteins. However, other 
mannosylated systems, such as nanoparticles and liposomes, have also been extensively investigated 
as vaccine candidates. Here, mannosylation has been shown to effectively increase the uptake and 
targeting of these systems towards the MR [9, 113], [114, 115]. The primary focus of this thesis will 
be on mannosylated peptide and protein antigens for vaccine development.  
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1.7.1 Mannosylated proteins   
Initial MR studies investigated the receptors capacity to recognise and internalise various sequences 
and stimulate a T cell response. However, more recent studies have investigated the binding affinity 
of the receptor with the aim of developing targeted vaccines [116, 117]. The important role of the 
MR in the uptake and presentation of ligands to DCs results from the finding that mannosylated 
ligands are presented more efficiently than non-mannosylated ligands, subsequently generating a 
greater immune response than non-MR ligands [62, 118, 119]. The exact structural requirements for 
binding to the MR have not been determined but investigations using polymannan derivatives [91], 
mannosylated dendrimers [120] and compounds that contain a high number of mannose groups 
presented to mimic highly branched mannan [121, 122] are promising. Frison et al. attached 
Manα6Man, Manα2Man and Manα3Man to dendrimers. They found that Manα6Man was the optimal 
ligand, concluding that di-mannose clustered compounds are the best ligands for MR targeting 
(Figure 1-8) [121]. 
 
 
Figure 1-8. Schematic of a Manα6Man glycocluster. Frison et al. found this structure bound 
strongly to the mannose receptor resulting in endocytosis of the gycocluster [121]. 
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Engering et al. observed a rapid reappearance of the MR at the cell surface of immature DCs when 
exposed to mannosylated BSA, suggesting that the receptor efficiently concentrates mannosylated 
antigens for transport to compartments for processing and peptide loading and also showed that the 
receptor is recycled to the cell surface [118, 123]. In addition to chemical modification of antigens, 
natural mannosylation has been used in vaccine development for receptor targeting. A study by Liu 
et al. observed that natural protein O-mannosylation was critical to the virulence of M. tuberculosis 
(Figure 1-6) indicating the importance of natural O-mannosylation and prevalence of O-
mannosylated structures in nature  [124].  
1.7.2 Recombinant N- or O-linked mannosylation 
Glycosylation is a common post-translational modification to the surface of naturally occurring 
exposed proteins and lipids. Information derived from bacterial genome sequences combined with 
proteomic and genomic analysis has enabled identification of enzymatic glycosylation machinery. O-
mannosylated proteins are present in different groups of bacteria and fungi and play a vital role in 
stimulating an immune response through their interaction with DCs [125]. 
The affinity of the MR for N- or O-linked glycopeptides was investigated by Gustafsson et al., who 
used recombinant proteins with mannose derived from Pichia pastoris (Figure 1-6). P. pastoris 
mucin-type fusion proteins (PSGL-1/mIgG2b and AGP/mIgG2b) that predominantly contain α-
linked mannose residues in both N- and O-linked substitutions were used to target the MR. This study 
demonstrated the receptors high affinity for both N- and O-linked mannosylated proteins [76]. 
This affinity was also confirmed when yeast-derived recombinant ovalbumin (OVA) carrying 
branched N- and O-linked mannoses was more immunogenic than non-mannosylated OVA [73]. The 
mannosylation pattern in the cell wall of mutant C. albicans (Figure 1-6) was shown to be responsible 
for increased immunity. In this study, Ifrim et al. established that fungal mannan alone did not prime 
DCs from peripheral blood mononuclear cells for the production of cytokines, concluding that the 
presence of the O- and N-linked mannosylated proteins at the Candida cell surface is required for a 
strong immune response [126].  
However, effective immunogenicity by glycoprotein-based vaccines does not necessarily correlate to 
protection, and this is a challenge faced in all areas of vaccine research. Additionally, protection of 
mannosylated proteins versus un-mannosylated protein-based vaccines is also an important aspect in 
this field. An example of this is outlined in a paper by Nandakumar et al. where the protecting 
mannosylated antigenic proteins (Apa), secreted by M. tuberculosis, induced stronger CD4 T cell 
responses than un-mannosylated Apa expressed by E. coli. However, neither were successful in 
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providing protective efficacy [127]. Further, Apostolopoulos et al. showed that immunisation with 
MUC1 attached to reduced mannan provided poor protection despite induction of tumour-specific 
CD8 T cell responses [71]. Studies such as that of Napper and Taylor showed this anomaly in 
protection versus antibody titre [123], and examples of successful mannosylated versus un-
mannosyled-vaccines, whereby protection was obtained, can be found in various articles [128, 129].  
1.7.3 Mannosylated peptides  
Peptide epitopes from natural proteins have been investigated for their ability to stimulate an immune 
response [116]. O-mannosylated polyalanine peptides were synthesised by Brimble et al. in 2007 in 
an attempt to evaluate the peptides specificity of peptides for targeting MR [130]. A synthetic library 
was synthesised containing linear or branched O-mannosylated serine units, which were placed 
sequentially in the chain or separated by spacers (Figure 1-9). Binding studies showed that constructs 
that contained either mono- or branched-mannose groups had the same affinity for the receptor, while 
increasing the concentration of the mannosylated peptides increased the binding affinity [130, 131]. 
Figure 1-9. Mannosylated peptides designed to investigate the relationship between the number 
of mannose groups and their receptor targeting ability. Schematic structure of the mannosylated 
peptides synthesised by Brimble et al. to investigate the relationship between linear and branched 
mannosylation and receptor targeting. [130]. An investigation was carried out using A: linear 
mannosylated peptides separated by alanine spacers, and B: di-branched mannosylated peptides 
separated by alanine spacers. No difference was observed in the targeting ability of linear (A) and di-
branched (B) mannosylated constructs, however spacer length was found to play a role in receptor 
binding. A fluorescent tag (5(6)-carboxyfluorescein) was included in each glycosylated peptide for 
bioassay analysis.  
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Kel et al. synthesised a mannosylated OVA323–339 epitope and showed that immunisation induced 
poor T cell effector function despite enhanced antigen presentation when compared to the non-
mannosylated epitope, indicating that other pathways were being targeted [78]. To evaluate MR-
mediated macrophage targeting, Gao et al. synthesised monodispersed polyethylene glycol peptide 
(PEGtide) dendrons that contained eight mannose groups. Macrophage uptake studies confirmed high 
uptake of the mannosylated dendrons and showed that an increase in the number of mannose groups 
resulted in a better DC uptake as confirmed by confocal microscopy in the presence of competitive 
inhibitor, mannan [79]. 
Bissen et al. investigated the affinity of a library of lysine-based oligomannoside clusters that 
contained two to six mannose groups (Figure 1-10). This study demonstrated an increase in receptor 
affinity with an increase in mannose valency [80]. Kinzel et al. proposed the use of the same clustered 
structures with addition of an antigen and plasmid DNA at the C-terminus with the aim of developing 
a DNA-based vaccine, but, to date, no further information has been published [81]. O-linked 
mannosylated polylysine dendrimers, produced by Kantchev et al.,were studied by confocal 
microscopy for DC internalisation through the MR. This study demonstrated the successful 
localisation and internalisation of the dendrons, indicating mannosylated-specific targeting [82]. 
 
Figure 1-10. Oligomannoside clusters synthesised by Bissen et al. The structures showing the best 
affinity for the mannose receptor are A: a cluster with five terminal mannoses, and B: a cluster with 
six terminal mannose groups.  
Moyle et al. synthesised a vaccine candidate comprised of a human papillomavirus type-16 (E744-62) 
epitope aimed at treating established cervical cancer. Here they examined the structural placement of 
mannose groups and epitopes on the ability to target the MR (Figure 1-11). Polylysine dendrimers 
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that contained a C-terminal lipid core held four E744-62 epitopes with a mannose group attached at the 
N-terminus (Figure 1-11). This investigation confirmed that mannosylated vaccine candidates 
successfully reduced cervical cancer size while non-mannosylated candidates did not [132].  
 
Figure 1-11. Lipid core polylysine with multiple epitopes made by Moyle et al. Structures 
contained either N-linked mannose or N-linked glucose in both acetylated and deacetylated forms. 
Both acetylated and deacetylated delivery systems that contained mannose successfully reduced 
tumour size in mice when compared to glucose delivery systems.  
In 2010, Raiber et al. prepared fluorescently labelled derivatives of pepstatin (a selective inhibitor of 
aspartic proteinases that destroy lysosome antigens) attached to mannose to target DCs. Investigations 
found that mannosylated constructs selectively targeted, and were internalised by DCs and 
macrophages, stimulating activation through the MR [133].  
All studies have confirmed a requirement of terminal mannose placement in the peptidyl structures 
enabling MR binding and uptake. Further optimisation in the design of mannosylated peptidyl 
candidates for effective receptor targeting is still required. 
1.8 Peptide-based subunit vaccines 
Vaccination is an active immunisation method used to form permanent protection against infections 
(e.g. against bacteria or viruses) or used in therapies (e.g. cancer) [134]. Common vaccination 
methods are based on the use of live attenuated (Figure 1-12C), inactivated pathogens (Figure 1-12B), 
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or the use of a minimal pathogenic part of pathogens (alone or combined with immunogenic 
compounds) as subunit vaccines (Figurer 1-12A) [135]. In these latter vaccines the immunogenic 
fraction is only a minimal part of the pathogenic cell wall proteins, toxoids or globulins (Figure 1-
12A). This minimal fraction, which is usually an immunologically active peptide (epitope), has been 
the centre of growing interest due to its many advantages over whole complex pathogenic vaccination 
(Figure 1-12A) [135, 136]. Many live attenuated vaccines contain infectious material and thus, their 
preparation steps including culturing and handling may be challenging. However, using peptide-
based vaccines can be beneficial in this aspect making preparation steps easier with less risk involved 
[137].  
 
Figure 1-12. Vaccine types. A: Subunit vaccines are prepared by use of part of the pathogen that 
provokes immune response, this can be based on biological extraction methods (recombinant) or 
synthetic methods (peptides); B: inactivated vaccines are prepared by inactivation of pathogens by 
heat or chemicals; C: live attenuated vaccines are prepared by weakening the pathogen through 
multiple passages. 
Peptide epitopes can be prepared using recombinant technology (e.g. using gene delivery systems for 
large-scale production) or can be synthetically prepared [138]. Using the minimal antigenic epitope 
of a pathogenic moiety in a vaccine can provide many advantages, including the exclusion of 
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unnecessary or harmful sequences. There are some pathogenic moieties where use of the whole 
pathogen can be oncogenic (e.g. the Epstein–Barr virus) and there are pathogenic moieties where use 
of the whole pathogenic protein can cause autoimmune disease (e.g. protein from Group A 
Streptococci) [139, 140]. 
1.8.1 Solid phase peptide synthesis 
Solid phase peptide synthesis (SPPS) is a common method used to produce a well-characterised 
peptide-based subunit vaccine. This method has advantages including the production of highly pure, 
high yielding and relatively (cost) inexpensive peptide products [141]. In addition, SPPS can be 
applied for the production of both linear, branched or multi-epitope peptide dendrimers [142]. 
Peptides have a polyamide backbone where an amine from one amino acid is coupled to the carboxyl 
group from another amino acid forming a polyamino acid chain (or peptide). In 1903, Emil Fischer 
was the first to successfully attach two amino acids together using a peptide bond, however, at that 
time protecting groups were not available and elongation of a peptide chain was not possible [143, 
144]. After the development of amino acid protecting groups, including the t-benzyloxycarbonyl 
(Boc) group, and the development of deprotection methods in 1955 by du Vigneaud, the 
neurohypophyseal nonapeptide hormone, oxytocin, was the first peptide-based hormone analogue 
synthesised.. For this work, du Vigneaud received the 1955 Nobel Prize in Chemistry [145]. 
SPPS is primarily based on the use of resins as a solid support for peptide synthesis and has made 
synthesis methods easier due to an increased stability of the peptide during synthesis [146]. Here, 
resins are cross-linked polymers and when organic solvents are added to them become swollen and 
provide a solid support for peptide preparation. Resins have different sizes (80-200µm) and mesh size 
(polymer number of openings in a square inch – 70-170) and can vary in type (polystyrene, 
polyamine, tentagel and soluble) depending on the synthesis and cleavage methods chosen for peptide 
preparation [147]. There are two main types of SPPS and these are based on the N-terminal protecting 
group employed on the amino acid; Boc and 9-fluorenylmethoxycarbonyl (Fmoc) (Figure 1-13). Boc 
protection can be useful for providing stability under basic conditions since it is an acid labile 
protecting group, and can protect the peptide from hydrogenation (Figure 1-13). In this synthesis, the 
Boc group is deprotected using a strong acid such as hydrofluoric acid (HF) [148]. During the early 
stages of SPPS development, Boc-SPPS was successfully used in the preparation of many peptides, 
however, due to dangers involved in the use of HF new studies focused on the development of a 
newer technique, Fmoc-SPPS which was first introduced in 1970 [149, 150]. Fmoc-SPPS uses milder 
reaction conditions employing a basic solution to remove the Fmoc protecting group (piperidine) and 
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the peptide is cleaved from the resin using a milder acid (usually trifluoroacetic acid [TFA]) compared 
with HF used in Boc-SPPS. 
 
Figure 1-13, Schematic diagram of solid phase peptide synthesis. Solid resin support is used to build a 
peptide chain from individual amino acids where orthogonal Fmoc or Boc protecting groups are used 
depending on the synthesis conditions, such as the choice of resin. Cleavage of the poly-amino acid 
chain from the resin generates a peptide in the last step. 
Ease of preparation, drying, purification and storage are some advantages considered for synthetic 
peptide-based vaccines [136]. However, development of peptide-based vaccines requires further 
studies to overcome issues including those of optimal immunogenic sequences, choice of efficient 
delivery systems and low immunogenicity [151].  
1.8.2 Lipid incorporation into peptide-based subunit vaccine 
Although synthetic peptides have many advantages, including specificity, and ease of synthesis and 
stability, peptides themselves are poorly immunogenic [152]. Thus, engineering powerful adjuvants 
such as the inclusion of lipids in the peptide structure can improve their immunogenicity [141]. 
Therapeutic peptide-based subunit vaccines must overcome biological barriers to achieve receptor 
targeting. These barriers include chemical stability, stability against enzymatic degradation, reduced 
toxicity, and improved specificity. Thus, design and modification of peptide epitopes are essential for 
advanced vaccine development [153].  
Adjuvants are described as additions to antigenic moieties that can help increase both cell mediated 
(cytotoxic T cell) or humoral (cytokine-mediated) immune responses [152]. Commonly studied 
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adjuvants fall under the categories of recombinant cytokines, oil-emulsions, particulate delivery 
systems, polysaccharides, alum, cell-based delivery systems and chemical conjugation of lipids to 
peptides [141, 154]. Recombinant adjuvants including granulocyte macrophage colony-stimulating 
factor (GM–CSF) and IL-12 have been used in many studies for vaccine development and have 
reached human based clinical trials [1]. Oil-emulsion adjuvants such as the Montanides are primarily 
used in cancer vaccine development, however, due to their high toxicity are unlikely to be used in 
human-based vaccine trials [155]. Particulate delivery systems like liposomes, exosomes and 
virosomes have been used in combination with peptides for providing both delivery and adjuvant 
ability and have shown some success in receptor mediated uptake and cellular immune response in 
clinical/pre-clinical trials for vaccine development [1]. Inulin is a plant-derived polysaccharide that 
has been shown to produce both cellular and humoral responses [156]. Inulin has been used as an 
adjuvant in vaccine development with Th1 and Th2 activity [156]. Lastly, the most widely used 
adjuvant in the vaccine development is Alum. Alum is a well characterised adjuvant that has been 
shown to activate humoral responses; however, it lacks the ability to enhance a cellular immune 
response. Further, there are many reports of adverse effects including neurotoxicity, autoimmunity, 
and long term brain inflammation when Alum has been administered, making it unsuitable for use in 
humans [2]. Cell-based delivery (by viruses and DCs, etc.) has been extensively studied for its use as 
delivery systems for peptide-based vaccines. However, cell-based delivery systems rely on the cells 
ability for processing and presenting a peptide antigen and this has been their main limitation due to 
non-uniformity and problems with reproducibility [157]. 
There are many modification methods used to increase immunogenicity of peptides, including 
PEGylation, or the addition of lipids, phosphates or carbohydrate moieties. From these, lipidation has 
proved to be a successful method in providing lipophilicity and stability for the peptide [158]. Here, 
lipopeptide vaccines have displayed not only structurally stable and biologically active properties, 
but also have proved to have effective adjuvanting properties in a variety of vaccines, including those 
that target Group A Streptococcus and cancer [159, 160]. In another study it was shown that 
glycosylated lipopeptides were successful as peptide delivery systems with self-adjuvanting 
properties [161]. Diversity in these adjuvanting systems with variable immune responses requires the 
attention of future studies to advance the development of these adjuvanting systems, thus lipopeptide 
vaccines with the advantage of being synthetically prepared may be a path to the future in solving a 
number of debilitating diseases. 
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1.8.2.1 Peptide-lipids 
It is now well-known that in most peptide-based vaccine developments there is a need for increasing 
immunogenicity by either addition or binding of an adjuvant moiety to peptide epitopes [147, 153]. 
Lipid core peptides (LCP) are peptide antigens attached to lipid moieties (Figure 1-14). LCPs have 
been extensively used in the development of subunit vaccine [162]. The idea of using LCPs as self-
adjuvanting moieties was first established in the 1980s when it was discovered that addition of lipids 
to peptides could boost their immunogenicity [163]. Furthermore, it has been shown that different 
types of lipids influence the antigenic properties of a vaccine, but these are often antigen specific. For 
example, lipoamino acids incorporated into peptides (LCP), glycolipids (monophosphoryl lipid A 
[MPL]) and analogues of bacterial lipids inlcuding lipoproteins such as tri-palmitoyl-S-glyceryl 
cysteine (Pam3Cys) and di-palmitoyl-S-glyceryl cysteine (Pam2Cys) have been investigated as lipid 
adjuvants (Figure 1-14) [164]. Here, LCP subunit vaccines are known to have self-adjuvanting 
properties and are generally formed using a minimum of antigenic peptide epitopes necessary for 
targeting the immune system [165].  
Solid and/or solution phase peptides are commonly used to prepare LCPs which are shown to be 
stable when kept unrefrigerated [166]. To optimise the immune response, the length of the lipid 
chains, the number of lipids, and the number of spacers between each lipid can be varied. In addition, 
single or multiple peptide epitopes can be attached in a linear or branched format to the LCP system 
(Figure 1-14). The LCP system has also been shown to have the ability of targeting DCs and inducing 
cellular immune activation, including cytotoxic T cell response upon CD4 T cell activation [167]. 
Further, MPL, Pam2Cys, Pam3Cys are other lipidic structures that have been included in a peptide 
structure in different studies for their adjuvanting properties [152, 154-156, 159, 160, 162, 164, 166, 
168]. However, studies in a mouse model have shown that these lipidic structures conjugated to one 
peptide epitope (J8), showed similar immune activity when used in conjugation with a greater number 
of epitopes (J8) [169-171]. Branched lipopeptides have been shown to be resistant to lytic enzymes 
in the body and are found to give higher T cell stimulation due to their better uptake/presentation by 
DCs when compared to linear peptides [168, 172]. In a study by Daubersies et al. it was shown that 
when chimpanzees were vaccinated with lipopeptides containing palmitic acid (Figure 1-14) and the 
malaria antigen LSA-3, they were protected against a challenge with Plasmodium falciparum 
sporozoites [173]. Further, many initial clinical studies have reported success from application of 
LCP systems as subunit vaccines in the prevention and treatment of cancer, bacteria and parasites 
(e.g. hookworm) [174]. 
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Figure 1-14. General Structure of common lipidic adjuvants. These lipidic adjuvants are used in 
peptide conjugation to enhance immunogenicity; monophosphoryl lipid A (MPLA), di-palmitoyl-S-
glyceryl-cystein (Pam2Cys), tri-palmitoyl-S-glyceryl-cystein (Pam3Cys), LCP [159]. 
1.8.2.2 Lipidation and receptor binding 
Binding of a vaccine structure to a surface molecule on APCs facilitates the transport of antigenic 
moieties across the cell. Lipidation, depending on where it is located in the peptide chain (N or C 
terminus) has been shown to affect the immunogenicity of the designed constructs [158]. Here, 
studies by Lau et al. showed that addition of a lipid (cholesterol) to the N-terminus of the HA2 
influenza peptide epitope (HA2166-180) increased the cellular (Th1, cytotoxic T cell) immune response 
in a mouse model [175, 176]. Furthermore, lipid length and lipid type have also been shown to be 
important factors that affect receptor binding properties. In a study by Zhang et al., lipids with 
different lengths (C8-C18) were conjugated to galanine (neuropeptide) analogues and tested in a 
mouse model for their anticonvulsant activity through the galanine receptor. Here, it was concluded 
that shorter lipids were more successful in receptor targeting, while factors including lipophilicity 
and charge of the peptide epitope were shown to be involved in the level of anticonvulsant activity 
[177].  
Lipopeptides, lipopolysaccharides and lipoproteins derived from a pathogen’s cell wall are 
recognised by a family of transmembrane proteins called Toll like Receptors (TLRs) present on the 
surface of macrophages and DCs. TLRs are another subfamily of PRRs and play an important role in 
innate immunity by their recognition of lipidated structures and activation of inflammatory immune 
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responses (Figure 1-15) [178]. Ten TLRs (TLR 1-10) have been identified in mammalians and each 
TLR has been shown to be responsible for ligand recognition [179]. TLR stimulation by invading 
pathogens sends specific intracellular signals (through signalling molecules like IL-1 receptor 
associated kinase [IRAK-1-4], tank binding kinase 1 [TBK1], myeloid differentiation factor 88 
[MyD88s]) and activates a series of nuclear transcription factors (nuclear factor kappa B [NF-κB], 
activating protein 1 [AP-1], nuclear factor interlukin [NF-IL6] and interferon regulatory factor [IRF]) 
that ultimately cause the cell to produce inflammatory cytokines (e.g. interleukins [ILs], interferons 
[IFN] and TNF) [178]. For instance, TLR-4 was one of the first TLRs to be identified and is 
responsible for the recognition of lipopolysaccharides [18].  
 
Figure 1-15. Toll-like receptor signalling pathway. TLRs are trans-membrane receptors from the 
family of pattern recognition receptors that exist as both extracellular (TLR-1, 2, 4, 6) and 
intracellular (TLR-3, 7, 8, 9) molecules. Signalling molecules including IRAK-1-4, TBK1, MyD88s 
activate a series of nuclear transcription factors (NF-κB, AP-1, NF-IL6 and IRF) causing the cell to 
produce inflammatory cytokines (TNF, ILs and IFN). 
 
Further, TLRs-1, 2, 5 and 6 have been shown to recognise other lipidic moieties including bacterial 
lipopeptides, lipoteichoic acids, flagellin, and glycolipids [15]. Here, TLR interaction with lipidic 
ligands has been shown to result in the activation of downstream signalling pathways that cause the 
maturation of DCs (Figure 1-15) [169]. As a result, the discovery and understanding of TLR 
mechanisms are a crucial factor in the design of vaccine constructs. TLRs, like other pattern 
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recognition receptors (e.g. the MR), have been shown to be responsible for phagocytosis, activation 
of the complement system (surface proteins involved in pathogen elimination) and induction of 
inflammatory signalling pathways [18]. In addition, these TLR activities play key roles in the 
activation of both innate and adaptive immunities. Mature DCs travel to the lymphatic nodes where 
they present processed antigens with signalling molecules, through MHC and co-stimulatory 
molecules (CD80 and CD86), to naïve T cells and initiate a T cell response [18]. Inflammatory 
cytokines (e.g. IL-12) released as a result of DC maturation can further differentiate T helper (Th) 
activity into Th1. In a study by Schnare et al., MYD88 (Figure 1-15) deficient mice were immunised 
by OVA mixed with complete Freund’s adjuvant (CFA). No Th1 activity was observed while Th2 
activity was unaffected. This confirmed the important role TLRs played in the Th1 activation pathway 
[180].  
1.9 Model antigen selection 
There are many known immunogenic antigens, however, only several are used as model antigens, 
one of which is OVA [181-183]. The OVA protein and epitope OVA323-339 is one of the main proteins 
found in avian egg white [182] and is known to bind to MHC II and cause a T cell response [184]. 
The OVA protein by itself has been the centre of interest in vaccine design due to its ready 
availability, and it has been of interest for allergy model studies (asthma, food and dermal allergies) 
since it is the major protein found in egg white [182]. The OVA protein naturally exists as a 
glycoprotein, however, it was discovered that the OVA 323-339 and OVA 1-10 sequences of the OVA 
protein bore a B cell epitope that was capable of inducing a T cell response. This discovery was 
obtained by T cell mediated IgE responses that were observed against an assumed B cell epitope 
inside OVA323-339 and OVA1-10 peptides [185]. It is now well-established that the OVA323-339 peptide 
binds to MHC II molecules and appears as a CD4 T cell epitope in T cell activation [186].  
The OVA257-264 is another epitope derived from the OVA protein and is known to be a CD8 T cell 
activator through attachment to MHC I molecules, playing an important role in cytotoxic T 
lymphocyte activation [187]. However, for a successful vaccine, activation of both CD4 and CD8 T 
cells are necessary. Other structural factors including using different adjuvanting systems, application 
of multiple epitopes or glycosylation can give selectivity to a specific immune response pathway 
[188]. A study by Brooks et al. showed that application of multiple OVA257–264  epitopes in a single 
delivery system could enhance immune responses in mice by producing an antigen-specific INF- 
response [187]. In this study, multiple antigenic peptides (MAP) conjugated to the OVA257–264 (also 
known as OVA CD8) were compared to non-branched peptides for their ability to generate antigen 
specific T cells and IFN-γ. It was concluded that the use of cell penetrating delivery systems can 
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increase the level of immune response in the form of T cell activation and IFN-γ production where 
OVA323-339 was used as a negative control and lacked the ability to produce IFN-γ. Further, Sun et al. 
indicated that in allergenic mice, the OVA323-339 epitope (using 300 µg alum as adjuvant) produced a 
Th1 response but its immunogenicity was limited compared to the full native OVA protein [189]. 
This confirmed the need for an efficient adjuvant system for small proteins or peptide epitopes as 
vaccine candidates [190]. OVA was used with biopolymeric carriers to study adjuvanting ability of 
these carrier systems in C57BL/6 mice by Matzelle and Babensee [191]. Here, the OVA protein 
delivered with CFA was able to produce high antibody titres compared with OVA delivered with 
phophate buffered saline (PBS) indicating the importance of applying an adjuvant with a vaccine 
delivery. 
1.9.1 Epitope selection affects the immune pathway 
Upon pathogen entrance to the body, an immune response starts with the uptake of extracellular 
antigens by APCs using different endocytosis methods (one of which includes the MR) [192]. This 
is followed by presentation of the antigen through MHC molecules to CD4 and CD8 T cells[6]. 
However, Burgdorf et al. demonstrated that the endocytosis pathway involved in antigen uptake plays 
a crucial role in choosing presentation pathways to either CD4 or CD8 T cells [6]. In this study, the 
native OVA protein was administered to mice genetically modified to have the MR expressed on DCs 
and showed that the OVA protein could activate OVA-specific CD8 T cells (OVA257-264 sensitive T 
cells from transgenic mice, OT-I), but was not able to activate OVA-specific CD4 T cells (OVA323-
339 sensitive T cells from transgenic mice, OT-II). This highlights an important aspect of uptake 
through the MR that can affect antigen specific T cell response depending on the selection of antigens 
in a vaccine structure [6, 193]. It is known that CD4 T cells play an important role in CD8 activation. 
Here, when CD8 T cell responses were studied in the absence of CD4 T cells, CD8 T cells had little 
proliferation ability and their cytokine level, upon in vitro re-stimulation, was very low (similar to 
naïve T cells) [24]. It is now known that CD8 T cells can function in the processing of an antigen 
without the presence of CD4 T cells, however, for a memory response, the presence of CD4 T cells 
is necessary [23]. This theory was observed by Sheldock et al. when they used a recombinant vaccinia 
virus and generated normal CD8+ T cell activity within one week of vaccination, while a re-encounter 
with the same antigen caused a drastic decrease in the response group when no CD4 T cells were 
present [194]. All these studies reveal an important and complex relationship between CD4 and CD8 
T cells and this has been detailed in Figure 1-5.  
52 
 
1.10 Targeting antigens using particulate delivery 
Researchers have been investigating methods for the delivering of antigenic moieties to the immune 
system to obtain the highest possible immune response against a specific disease [195]. Considering 
the complexity of the immune system, vaccination can give an unpredicted response (e.g. allergies), 
however, synthetic design and engineering of peptide structures provides an opportunity to predict 
the outcome [3]. In the human body, DCs are responsible for constant uptake of antigenic moieties 
and this uptake is performed through different mechanisms, including phagocytosis of large particles 
(0.25-10 µm), receptor mediated endocytosis (particles smaller than 500 nm) and pinocytosis which 
is a term used for any mode of uptake that does not include a receptor [196]. Following vaccine 
injection (subcutaneously, intradermally, intramuscularly, etc), particulate size has been shown to be 
a limiting factor affecting the uptake and processing of a vaccine by the lymphatic system [134]. 
Studies have shown that larger particulates (300-500 nm) have smaller diffusion speeds and less 
ability permeate areas of the extracellular matrix, including areas less crowded by extracellular 
proteins. However, smaller molecules (less than 50 nm) can easily dissolve into the local matrix and 
be transported into the APCs or intracellular pathways [197]. When particulates arrive at the lymph 
nodes, the size effect changes and due to “lymphatic retention”, bigger sized particulates stay longer 
and can target macrophages while smaller particles have more affinity towards DCs and B cells [198]. 
Antigens designed in a particulate format are known to have the ability to activate CD4 and CD8 T 
cells through cross-presentation where these particulates can be in the form of nano- and micro-sized 
delivery systems [197, 199]. When designing particulate vaccine delivery, an important factor that 
affects the size and delivery ability is the number of antigens bound to a particle. Particles can be 
aggregations of small antigenic molecules thus the number of antigens can vary in size and 
concentration [200, 201]. The cross-presentation of antigens delivered as particulates can be size 
dependant, as suggested in a study by Kovacsovics-Bankowski and Rock, where an optimal cross-
presentation was observed by particles with a size of about 3 µm [202]. In another study, Soong et al. 
developed lipid nano-capsules with MPLA that contained a whole protein TLR-4 agonist. 
Interestingly, they found that their designed delivery system could boost antigen specific T cell 
responses [200]. All these studies suggest the importance of subunit vaccine delivery in a particulate 
form and opens future challenges in the design of delivery systems that could efficiently control a 
desired immune response.   
1.11 Conclusion 
Knowledge of vaccination has been developed throughout history however, with an ever-demanding 
need for new treatments and therapies there are still many challenges to be faced. Factors like 
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selective immune response pathways, targeting, selection of antigenic moieties, adjuvanting 
properties, and particulate delivery have to be considered for successful vaccine development. From 
the early encounter of a foreign pathogen by the immune system, the innate immune system is 
activated, which leads to a long-term memory response, also known as adaptive immunity. An 
optimum vaccination should be able to activate both these pathways to obtain a desired T cell 
response.  
Studies on the identification of the MR expressed on DCs indicated an important role for this receptor 
in immunogenicity, while its ability to recognise self from non-self has made it a useful tool in vaccine 
design and targeting. Studies to understand the targeting and processing involved in the internalisation 
of pathogenic antigens and antigen presentation through the MR are essential in order to have a better 
understanding of the function and role of this receptor in an immune response.  
A unique feature of this receptor family is the presence of multiple CRDs in a single polypeptide 
chain. Investigations have found that the CRD is important for glycosylated ligand recognition and 
internalisation. However, recent studies including computational modelling and microscopy have 
provided further evidence into the structural and binding features of this receptor. These studies have 
also confirmed that CRDs 1-3 are not essential for glycosylated ligand binding, with CRD4 having 
the same ligand biding ability as the whole MR. However, CRDs 5-7 have been shown to be essential 
for binding to highly glycosylated ligands. This has provided insights into the predicted structural 
arrangement of the MR with two contradictory models now available. Initially, a U-shaped model 
was proposed with CRDs 4-5 exposed to the glycosylated ligands, while a more recent investigation 
suggested a “bent” structure with both CRDs 4-7 and the CR domain playing an important role in the 
binding of glycosylated ligands (Figure 1-4). These model studies indicate that the structure of the 
domain is highly related to the experimental design and to date no further information about the 
structural and spatial arrangement of the CRD domains is known. 
The discovery that mannan binds strongly to the MR has enabled receptor binding studies and 
advanced targeted vaccine development. Vaccine development using mannan as a known ligand, or 
by the attachment of mannose to proteins and peptides, has been studied extensively. Vaccines 
derived from mannose exploit the targeting properties of the mannose group while avoiding the 
stimulation of a mannose-specific immune response because mannose is poorly immunogenic. 
Mannosylated proteins for vaccine design have included investigating oxidised and reduced mannan. 
Additionally, recombinant N- or O-linked mannosylated peptides and proteins have been shown to 
bind equally and be internalised by the MR receptor. In addition, attaching mannose to a peptide 
epitope is another approach to enhance receptor targeting. As a result, many strategies have been 
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employed to develop MR targeted vaccines and through the analysis of ligand and antibody targeting 
approaches it is clear that the nature and specificity of the antigen interaction with the receptor are 
critical factors in determining ligand processing and an immune response. However, further 
information about the organisation of the MR is required to advance/enhance pathogen-specific 
vaccine development. 
Among the different vaccine development methods (including attenuation and inactivation of 
pathogens or the use of purified macromolecules such as toxoids or immunoglobulins), peptide 
vaccines have offered the advantage of engineering specific qualities to vaccines, like adjuvanting 
properties such as lipidation or carbohydrates for targeting. However, peptides as epitopes require a 
proper adjuvant system that can elevate the immunogenicity of small antigenic peptides. Among the 
many suggested adjuvanting systems used today, including the most common adjuvant alum, 
lipidation has shown to be a successful method for the modification of peptide antigens to have self-
adjuvanting properties. However, adjuvanting properties caused by lipidation can vary depending on 
the number and length of the lipid moiety included in a peptide vaccine.  
TLRs are found to be a primary receptor responsible for the recognition of lipid moieties. Of the ten 
TLRs identified in humans, each has been shown to have different properties in the activation of 
downstream changes in the DCs that can cause a consequent response. Another important factor in 
vaccine development is the selection of the epitope, essential to obtain the desired cellular or humoral 
immune response. The OVA 323-339 and OVA 257-264 epitopes are two peptide epitopes from the OVA 
protein which have long been used as model antigens to study CD4 or CD8 T cell responses for 
vaccine development. Here, studies have shown a cross-presentation effect with the help of these 
antigenic moieties, with an important relationship identified between a CD4 and CD8 T cell response. 
Furthermore, delivery systems relying on particulate formation of peptide vaccines have been shown 
to enhance these immune responses. Many studies have developed delivery systems in the form of 
nano- and micro-particles and it has been found that the size of a vaccine particulate can affect the 
speed of travel to the lymph nodes and particulate stability in the lymphatic system before it can be 
processed by CD4 and CD8 T cells. Overall, size plays an important role in vaccine design and 
development. 
In general, with the current advances in the development of vaccines there are still many unknown 
aspects that need to be addressed. Further understanding of immune pathways involved in an immune 
response and a better understanding of the structural relationship in immune activation can be 
beneficial to advance future vaccine development studies.  
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1.12 Research Hypothesis 
Receptors present on the surface of APCs recognise glycoconjugates and these have been a primary 
focus of vaccine and drug-targeting research. In the generation of an immune response, receptor 
mediated antigen uptake is the first crucial step that is followed by a T cell response where subsequent 
activation of T helper pathways can be achieved. Although it has been proven that the MR can 
recognise mannosylated peptides and proteins, the structural properties needed for the design of 
mannosylated peptides with targeting ability, including the spacing or branching of the mannose units 
that are known to affect receptor targeting and binding, needs to be explored in further detail. To date, 
most MR targeting studies have focused on the number of mannose moieties. This study focuses on 
the complex synthesis and analysis of a library of O-mannosylated lipo-peptides designed to 
investigate the MR binding properties for potential use in vaccine design and targeting. Here, the 
mannosylated lipopetide containing the CD4 ovalbumin epitope (OVA323-339) is used as a model 
antigen to investigate the targeting affinity for the MR. Furthermore, structural properties in relation 
to T cell activation and cytokine release are evaluated. 
Major hypotheses: mannosylated lipopetides as model vaccines for targeting the mannose 
receptor 
It was hypothesised that vaccine constructs comprising mannosylated lipid dendrimers containing an 
ovalbumin epitope as the model peptide antigen and containing an alanine spacer between the O-
linked mannose moieties could enhance DCs receptor mediated uptake and induce an immune 
response by T cell proliferation/activation where subsequent activation of T helper pathways could 
be achieved. 
Specific hypotheses 1: Improvement to the synthesis of fluorescently tagged multicomponent 
mannosylated lipoeptides. 
Since TLRs were found to be a key element of signalling to immune pathways, lipids of different 
sources including pathogen cell walls or synthetic forms were found to be able to give adjuvanticity 
via signalling through TLRs.   O-mannosyls were also found to be a crucial part of pathogenic cell 
walls with the ability of targeting the MR. Further, mannose has been used as a tool in the 
development of structures containing O-mannosyls for better receptor targeting and consequently a 
better uptake to the APCs to achieve a vaccine delivery system. As a result, researchers have - 
included mannosyls in peptide structures in multiple vaccine development studies. However, many 
of structures used in vaccine development did not combine a targeting moiety with other components 
including a lipid adjuvant, model antigenic peptide and a fluorescent tag.  
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Here, we postulated that although synthesis of multicomponent mannosylated lipopeptides are to be 
with difficulties we could improve the yields by utilising stepwise synthetic methods. For instance 
we hypothesised that such complication could be overcome by preparation of building blocks 
containing mannose and lipid and preparation of small peptides with a final attachment. 
Specific hypotheses 2: Linear placement of mannosyl moieties in the vaccine constructs and an 
alanine spacer plays a role in antigen presenting cells uptake through enhanced receptor 
targeting. 
The MR has been shown to recognise mannosylated peptides and proteins, however, the optimal 
structural properties of these mannosylated peptides with enhanced targeting ability are unknown. 
This study proves that inclusion of a short spacing or linear placement of the mannose units affect 
receptor targeting and binding properties. 
Specific hypotheses 3: Structural properties in a vaccine construct could affect the activation 
immune pathways. 
Studies have revealed a correlation between the structural properties of antigenic peptides and their 
immunogenicity via T cell and B cell activation [203-205]. Here, T cell proliferation or activation 
and cytokine release are two of the major immune responses that have been commonly looked into 
for the determination of a vaccine construct immune activity. In this study, we designed vaccine 
structures that contained lipidic and sugar moieties and proposed that each component could 
potentially affect the immunogenicity of a vaccine construct.. In other words, we predicted a 
relationship between lipidation, glycosylation, particulate size and the immunogenicity of the 
vaccine. 
1.12.1 General Aim 
The aim of this study is to synthesise fluorescently-labelled mannosylated lipopeptides as subunit 
vaccine candidates in order to investigate the effect mannose, lipids and the distance between the 
mannose units has on immune response and receptor mediated uptake for advanced vaccine 
development. 
1.12.2 Specific Aims 
1.12.2.1 Aim 1: Vaccine Candidate Synthesis 
1. Synthesise a mannosylated amino acid for use in peptide synthesis; ser-(Ac4-man)-OH. 
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2. Synthesise a library of azido-functionalised mannosylated lipo-peptide building blocks containing 
a fluorescent tag [5(6)-carboxyfluorescein] and a different number of alanine spacers between the 
mannose moieties. 
3. Synthesise alkyne-functionalised OVA323-339 lipo-peptide building blocks. 
4. Produce solution phase copper-mediated azide-alkyne cycloaddition (CuAAC or click reaction) 
for conjugation of the mannosylated and OVA323-339 lipo-peptide building blocks to form vaccine 
candidates. 
5. Synthesise a library of control peptides, including vaccine constructs without lipid and/or 
mannose moieties. 
1.12.2.2 Aim 2: Physiochemical Evaluation and In vitro Receptor Binding Study 
1. Analyse each vaccine construct using Dynamic light Scattering (DLS) and transmission electron 
microscopy (TEM) to assess the size and shape of the particles.  
2. Investigate receptor-mediated uptake and mannan inhibition studies on splenocytes (F4/80+ and 
CD11c+ cells) using flow cytometry and confocal microscopy. 
3. Investigate receptor-mediated uptake using surface performance resonance (SPR) technology on 
the extracellular part of the MR to study receptor binding and affinity. 
4. Investigate the T cell stimulatory activity of each vaccine construct for antigen specific T cell 
proliferation. 
1.12.2.3 Aim 3: In vivo Study 
1. Isolate and purify CD45.2+OT-II cells and adoptively transfer to C57BL/6 mice to investigate T 
cell proliferation following vaccination of the vaccine candidates.  
2. Investigate the up-regulation of interferon gamma (IFN-) and antibody production using 
enzyme-linked immunoSpot (ELISPOT) and enzyme-linked immunosorbent assay (ELISA) 
techniques, respectively.  
3. Investigate immune cell cytokine production using the cytokine bead array (CBA) assay. 
4. Investigate the cytokine producing T cells using an intra cellular staining (ICS) assay. 
1.13 Thesis Outline 
 
Chapter 1. Introduction to Vaccine Development and Mannose Receptor Targeting 
This chapter provides an introduction to the immune pathways involved in antigen recognition, the 
structural properties of the MR, mannnosylation of peptides and proteins, and lipidation and selection 
of antigenic epitopes.  
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Chapter 2. Experimental Section 
This chapter includes general material and methods used for the preparation of vaccine constructs, 
and in vitro studies and in vivo studies are discussed. 
Chapter 3. Synthesis of Mannosylated Lipopeptides 
This chapter describes the synthesis of a library of mannosylated lipopeptides. The designed vaccine 
library contains the OVA323-339 epitope, lipids to increase adjuvanticity, a fluorescent tag [5(6)-
carboxyfluorescein, FAM] for visualisation in cell uptake studies, and two O-mannosyl groups for 
MR targeting. The synthesis and purification of an acetyl protected mannosylated building block [ser-
(Ac4-man)-OH] is the first step followed by inclusion of the pure compound in the mannosylated 
peptides with FAM. This is followed by synthesis of the lipidated-OVA323-339 peptide. This lipidated-
OVA323-339 peptide and the manosylated peptides are then attached using click chemistry. The final 
library of mannosylated lipopeptides (vaccine constructs) contains 0, 1 and 2 spacers of alanine 
between the mannose moieties to study the targeting of these vaccine constructs towards the MR in 
relation to the structural properties of designed vaccine constructs (Chapter 3, Figure 3-1). A library 
of control peptides is also prepared to study the effect mannose and/or lipid moieties play in vaccine 
construct targeting and immunogenicity.  
Chapter 4. In vitro Evaluation of Mannosylated Lipopeptide Vaccines 
An uptake/binding study is performed on splenocytes isolated from naïve mice (6 weeks old). Cells 
are stained with anti-CD11c and anti-F4/80 antibodies to investigate the uptake/binding by F4/80+ 
and CD11c+ subsets of cells. The uptake study is performed on all vaccine constructs. Dextran-FITC 
is the positive control and PBS is the negative control. A mannan inhibition assay is performed to 
indicate the proportion of receptor mediated uptake. Vaccine constructs are characterised for their 
size using DLS to enable size and uptake correlations. Confocal imaging supports the uptake/binding 
data observed for the vaccine constructs. Further, a SPR study is performed using Biacore technology 
where CM-5 chips are used to immobilise the human recombinant MR. Here, the affinity of the 
vaccine constructs to this human recombinant MR is measured. Lastly, the in vitro T cell stimulatory 
activity of the vaccine constructs is measured using flow cytometry in splenocytes isolated from OT-
II mice following stimulation with the vaccine constructs. 
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Chapter 5. In vivo Studies on Mannosylated Lipopeptide Vaccines 
Immune properties of the vaccine constructs are measured using purified CD45.2+OT-II cells that 
have been transferred to C57BL/6 mice. Mice are immunised with the vaccine constructs at 1, 21 and 
42 days. Blood specimens for the OT-II proliferation read out are collected and ELISA performed 10 
days post each immunisation. To measure cytokine release associated with the vaccine constructs, 
mice are sacrificed on day 63 after the last immunisation and ICS and CBA assays performed.  
Chapter 6. Conclusion and Future Directions 
This chapter contributes to the overall findings of the studies presented in this thesis and provides 
suggestions for future directions of this study. 
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Chapter 2: Experimental Section 
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2.1 Synthesis of mannosylated lipopeptides 
2.1.1 General Materials and Equipment 
All reagents used were of the highest grade available. Diethyl acetamidomalonate 1-bromodecane, 
dimedone, triethylamine, ethyl acetate (EtOAc), n-hexane, N,N'-diisopropylcarbodiimide (DIC), 
triisopropylsilane (TIS), 4-dimethylaminopyridine (DMAP), boron trifluoride diethyl etherate 
(BF3.Et2O), copper wire, FAM and diethylacetamidomalonate (DAAM) were provided from Sigma-
Aldrich (St. Louis, MO, USA). Protected amino acids were purchased from Novabiochem 
(Laufelfingen, Switzerland) and Mimotopes (Melbourne, Australia). N,N’-dimethylformamide 
(DMF), TFA, methanol (MeOH), N,N’-diisopropylethylamine (DIPEA), 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide hexafluorophosphate 
(HATU), N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), 
hydroxybenzotriazole (HOBt), piperidine, and dichloromethane (DCM) were obtained from Merck 
(Hohenbrunn, Germany). Sodium hydrogen carbonate (NaHCO3), magnesium sulfate (MgSO4) and 
acetic anhydride (Ac2O) were supplied by Chem-Supply (Gillman, South Australia, Australia). High-
pressure liquid chromatography (HPLC)-grade acetonitrile (MeCN) was purchased from RCI 
Labscan Ltd. (Bangkok, Thailand).  
Analytical reverse phase high-performance liquid chromatography (RP-HPLC) was carried out on a 
Shimadzu instrument with an LC-20AB pump, a SIL-20AHT auto-sampler and an SPD-M10A 
detector set to a wavelength of 214 nm. Preparative RP-HPLC was carried out on a Shimadzu system 
equipped with a CBM-20A controller, LC-20AT pump, SIL-10A auto-sampler and SPD-20A UV/Vis 
detector set to a wavelength of 214 nm and a FRC-10A fraction collector. Both analytical and 
preparative HPLC were performed using flows of solvent A (0.1% TFA in water) and solvent B 
(90:10:0.1% MeCN:water:TFA). 
NMR studies were performed in CDCl3 (unless otherwise specified) on a Bruker Avance 300 MHz 
instrument (Bruker Biospin, Germany). Electrospray ionisation mass spectrometry (ESI-MS) was 
performed on a PE SCIEX AP13000 triple quadrupole mass spectrometer operated with a constant 
flow of 1:1 mixture of solvent 1 (0.1% acetic acid in water) and solvent 2 (90:10:0.1% 
MeCN:water:acetic acid) at a rate of 0.5 ml/min. Synthesis of lipopeptides was carried out using a 
CEM Discovery® microwave (20 W, CEM Corporation, Matthews, NC, USA) with temperature-
resistant, open vessels from CEM Corporation (Matthews, NC, USA). In the case of manual synthesis, 
shaking was performed on a WS/180° shaker (Glas-Col, IN, United States). Size measurements were 
performed using DLS technology via a Zetasizer Nano ZP instrument (Malvern Instruments, UK). 
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TEM was performed using a JEM-1010 TEM (JEOL Ltd., Japan). TEM images were analysed using 
AnalySIS® software (Soft Imaging Systems, Megaview III, Munster, Germany). 
  
2.1.2 Synthesis of mannosylated building block 
 
2.1.5.1 Synthesis of αβ-D-mannose pentaacetate    (1) 
 
The synthesis of α-D-mannose pentaacetate (1, Chapter 3, Section 3.2.1; Figure 3-2) was carried out 
as per Kowalczyk et al. [206]. Briefly, a solution of D-mannose (6.00 g, 33.30 mmol) in Ac2O (16.00 
mL, 169.85 mmol) was refluxed (46°C) under a N2 atmosphere followed by the addition of a catalytic 
amount of DMAP (600 mg, 4.91 mmol) after 3 hours. After 24 hours, the solvent was removed in 
vacuo. The residual oil was dissolved in EtOAc (20 mL) and washed with NaHCO3 (saturated) (2 × 
10 mL), H2O (2 × 10 mL) and brine (2 × 10 mL). The organic phase was dried with anhydrous 
MgSO4, filtered and concentrated in vacuo to afford a racemic mixture (α:β) of 1 as a yellow oil (11 
mg, 85%). NMR data was as follows: 
(1): Yield = 85%. 1HNMR (500 MHz, CDCl3): δ = 2.01 (s, 3H), 2.06 (s, 3H), 2.10 (s, 3H), 2.18 (s, 
3H), 2.18 (s, 3H), 3.80-3.89 (dd, 1H), 4.061-4.11 (dd, 1H) and 4.25-4.38 (dd, 1H), 5.19 (d, 1H), 5.36-
5.37 (m, 2H), 6.09 (d, 1H). 
 
2.1.5.1 Synthesis of N-Fmoc-O-(2,3,4,6-tetra-O-acetyl-α,β-D-mannopyranosyl)-L-serine (2) 
 
The Fmoc-serine mannosylated amino acid, N-Fmoc-O-(2,3,4,6-tetra-O-acetyl-α,β-D-
mannopyranosyl)-L-serine (2, Chapter 3, Section 3.2.1; Figure 3-2) was synthesised by first 
acetylating the mannose hydroxyl groups to form α,β--D-mannose pentaacetate using a previously 
published method (1, Chapter 2, Section 2.1.2.1) [206]. This intermediate was then coupled with 
Fmoc-serine-OH in a BF3 Lewis acid catalysed reaction to generate N-Fmoc-O-(2,3,4,6-tetra-O-
acetyl-α,β-D-mannopyranosyl)-L-serine (2) [207]. Compound 2 was purified to a 28% overall yield 
using preparative RP-HPLC on a C18 column using a gradient of 20-80% over 45 min with a Rt of 
23.6 min. NMR and mass spectrometry data was consistent with previously published results :   
(2): Yield = 42%. 1HNMR (500 MHz, CDCl3): δ 7.75-7.60, 7.40–7.36, 7.32–7.28, (8H, ArH), 6.17 
(d, 1H, O-ester), 5.77 (d, 1H, NH), 5.37 (t, H4), 5.32 (bs, H2), 5.26 (dd, 1H), 4.58 (bd, 1H, CH), 4.25 
(complex, H6), 4.17 (bd, 1H, CH), 4.13 (bd, 2H, H5, H6), 3.98 (bd, 1H), 2.19, 2.10, 2.03, 2.01 (4s, 
12H, 4CH3); ESI-MS m/z: exact mass: [M+H]
+ calc. 657.62 found 658.4, [M+2H]2+ calc. 329.81 
found 331.4 
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2.1.3 General method for glycosylated solid phase peptide synthesis 
 
2.1.5.1 Resin loading 
 
Fmoc SPPS was assisted using a manual shaker on a Rink amide MBHA resin. Resin was swollen in 
DMF overnight before use. 
 
2.1.5.1 Fmoc-deprotection 
 
Each Fmoc-deprotection consisted of resin treatment with 20% piperidine in DMF followed by 
extensive DMF washing For microwave synthesis (2 x 5 min, 50°C, 20W), and for manual synthesis 
(2 × 30 min at room temperature [RT]), deprotection cycles with piperidine (20%) followed by DMF 
washing were performed. 
2.1.5.1 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)-3-methyl-butyl (IvDde) deprotection 
    
The IvDde protecting group was removed manually by treatment of the resin with a 2% hydrazine in 
DMF solution (12 × 15 min) followed by extensive washing with DMF. 
 
2.1.5.1 Amino acid coupling 
 
For manual synthesis, N-Fmoc-protected amino acids (4.2 eq.) were pre-activated with HATU (4 eq.) 
and DIPEA (5 eq.) for 5 min and coupled to the resin twice for at least 30 min. Lipoamino acids (4.2 
eq.) were prepared by dissolving them in HATU (4.0 eq.) and DMF solution followed by addition of 
DIPEA (6.2 eq.) and double coupling to the resin for 30 min.  
 
2.1.5.1 5(6)-Carboxyfluorescein (FAM) coupling 
 
FAM (1.5 eq.) was coupled to the resin manually using HOBt (2.5 eq.) and DIC (2.5 eq.) in DMF in 
the dark overnight. Removal of the unwanted FAM ester-bond was achieved by treating the resin 
with 20% piperidine (6 × 5 min or until no more yellow colour was observed in the DMF washes) 
followed by extensive washing with DMF [208].  
 
2.1.5.1 Resin Cleavage 
 
At the completion of peptide synthesis and when the terminal Fmoc group had been removed, the 
resin was washed with DMF, MeOH, and DCM, and dried in vacuo overnight. The crude peptides 
were cleaved from the resin with 95% TFA, 2.5% TIS and 2.5% water for 3 h at RT. All cleaved 
peptides were precipitated, filtered and washed thoroughly with ice-cold diethyl ether. The 
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precipitated compounds were dissolved in MeCN:water (1:1) that contained 0.1% TFA and 
lyophilised overnight to give amorphous powders. 
 
2.1.4 General methods for the synthesis and characterisation of mannosylated and un-
mannosylated azido peptides (3-7) 
 
2.1.4.1 Synthesis of mannosylated peptide 3 
 
For the synthesis of 3, manual Fmoc SPPS as described in Method 1 in Chapter 3, Section 3.2.2.1 
was employed. Briefly, Fmoc amino acids were coupled to the resin following activation with HATU 
(4.0 eq.) and DIPEA (6.2 eq.) in DMF. The Fmoc-Lys-OH side chain was protected with IvDde.  
2,3,4,6-Tetra-O-acetyl-α,β-D-mannopyranosyl (2, 1.5 eq.) building blocks were coupled manually 
using HATU (1.5 eq.) and DIPEA (4.5 eq.) in DMF for 12 h followed by washing with DMF (3 × 5 
min). A subsequent coupling was performed when the ninhydrin testing indicated it was required 
[209]. FAM (1.5 eq.) was coupled to the resin using HOBt (2.5 eq.) and DIC (2.5 eq.) in DMF 
overnight. Removal of the unwanted FAM ester-bond was achieved by treating the resin with 20% 
piperidine (6 × 5 min) followed by extensive washing with DMF [208]. The resin was then treated 
with 5% hydrazine in DMF on resin (3 × 30 min) to deprotect the lysine side chain protecting group, 
ivDde. This was followed by coupling of azidoacetic acid (4.2 eq.) which was synthesised according 
to a previously published method [210] using HATU (4.0 eq.) and DIPEA (6.2 eq.) in DMF overnight. 
Cleavage (as detailed in Chapter 2, Section 2.1.3.6) of the crude peptides was achieved by dissolving 
the crude products in solvent B that were then purified by preparative RP-HPLC on a C8 column with 
a gradient of 30% to 80% solvent B over 45 min. Due to complications as outlined in Chapter 3, 
Section 3.2.2.1, a low yield was obtained. 
 
2.1.5.1 Synthesis of mannosylated peptides 4-7 
 
For the synthesis of vaccine constructs 4-7 (Chapter 3, Section 3.2.2.2, Figure 3-7), manual Fmoc 
SPPS as described in Method 2 in Chapter 3, Section 3.2.2.2 was employed. Here, peptides were 
assembled on Rink amide MBHA resin (0.1 mmol scale) using the in situ neutralisation protocol for 
Fmoc SPPS [211]. After loading the resin with Fmoc-lys(Mtt)-OH, the 4-methyltrityl group (Mtt) 
was deprotected using TFA:TIS:DCM (1:2:97) using 20 cycles (5 min/cycle) and the resin was 
washed well with DCM after each the cycle. Following Mtt deprotection, azidoacetic acid (4.2 eq.) 
was coupled using DIPEA (6.2 eq.) in DMF overnight. 2 (1.5 eq.) was coupled (×2) to the resin using 
HATU (1.5 eq.) and DIPEA (4.5 eq.) in DMF for 12 h followed by washing with DMF (3 × 5 min). 
A subsequent coupling was performed when ninhydrin testing indicated it was required. FAM 
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coupling (Section 2.1.3.5) and resin cleavage (Section 2.1.3.6) were performed. Yield and ESI-MS 
results are described in Chapter 1, Section 3.2.2.2, Table 3-2. 
 
2.1.5 Lipopeptide Synthesis 
 
2.1.5.1 Synthesis of 2-acetyldimedone (Dde-OH) (8) 
 
Synthesis of 2-acetyldimedone (Dde-OH, 8) was carried out as per Ross et al. [212]. Briefly, 
dimedone (15 g, 107 mmol) was dissolved in DCM (100 ml). DMAP (2.61 g, 21 mmol) and 
triethylamine (30 ml, 215 mmol) were added and the mixture was stirred for 10 min at RT. Ac2O 
(9.38 ml, 1.6 mmol) was added to the mixture and the reaction was stirred for 2 days under a N2 
atmosphere. Ac2O was removed in high vacuo and the crude product was dissolved in EtOAc and 
washed with 5% HCl (3 × 300 ml). The organic phase was combined and dried over MgSO4 and the 
solvent was removed in vacuo. The resulting crude oil was purified using a silica column and n-
hexane:EtOAc (3:2) as eluent to afford the title compound (8) with the following yield and NMR: 
(8): Yield = 84%. 1H NMR (300 MHz, CDCl3): 1.08 (6H, s, C(CH3)2), 2.36 (2H, s, H-5a, H-9a), 2.54 
(2H, s, H-5b, H-9b), 2.61 (3H, s, CH3). 
 
2.1.5.2 Synthesis of [(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-D,L-dodecanoic 
Acid: (C12)   (9) 
The synthesis of 4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-D,L-dodecanoic acid (C12, 
9) was carried out as per Ross et al. [212]. Briefly, to a dry round-bottomed flask containing sodium 
ethoxide (6.8 g, 100 mmol), DAAM (21.3 g, 100 mmol) was added followed by addition of 1-
bromodecane (41.7 ml, 140 mmol). The reaction mixture was refluxed for 24 h under an atmosphere 
of N2
 gas. The reaction was stopped by removing the mixture from the reflux heat, cooling to RT and 
pouring into crushed ice to precipitate the aminodiester product (9, Chapter 3, Section 3.2.3.1, 
Figure 3-8). The product was collected using a Buchner funnel and dried in a desiccator overnight. 
DMF (14 ml) and fuming HCl (120 ml of 37%) were added to the dried product and refluxed for 3 
days. The reaction was stopped by removing the heat. The mixture was cooled to RT, then poured 
into crushed ice to precipitate the product. The product was collected using a Buchner funnel and 
dried overnight in a desiccator to yield the final product (9) with the following yield and NMR: 
(9): Yield = 42%. 1H NMR (500 MHz, CDCl3) d 13.70 (1H, d, H-bonded NH), 11.74 (1H, br s, 
COOH), 4.37 (1H, m, a-CH), 2.52 [3H, s, C(NH)CH3], 2.39 (4H, s, 2CH2CO), 2.02-1.87 (2H, m, b-
CH2), 1.43-1.23 (16H, m, 8CH2), 1.01 [6H, s, C(CH3)2], 0.85 (3H, t, CH3) 
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2.1.5.3 Synthesis of 2-(4, 4-Dimethyl-2, 6-Dioxocyclohex-1-ylidene) ethylaminododecanoic acid 
(Dde-C12-OH) (10)  
The synthesis of 2-(4, 4-dimethyl-2, 6-dioxocyclohex-1-ylidene) ethylaminododecanoic acid (Dde-
C12-OH, 10) was performed as per Ross et al. [212]. Briefly, 8 (9.76 g, 53.6 mmol) was dissolved in 
ethanol to which 9 (12.3 g, 48.7 mmol) and TEA (7.44 ml, 53.4 mmol) was added. The mixture was 
refluxed under an atmosphere of N2 for 2 days with TLC monitoring (EtOAc: n-hexane, 20:30) where 
the product had an Rf of 0.9. The solvent was removed using co-evaporation with EtOAc in vacuo. 
The resultant crude product was dissolved in EtOAc and washed with 5% HCl (3 × 200 ml). The 
combined organic phase was dried over MgSO4 and the solvent was removed in vacuo. The product 
was triturated twice with diethyl ether to afford the pure product as a white solid with the following 
yield and NMR: 
(10): Yield = 30%. 1H NMR (500 MHz, CDCl3): 0.86 (3H, t, CH3), 1.05 (6H, s, C(CH3)2), 1.43-1.23 
(16H, m, 8CH2), 2.02-1.87 (2H, m, CH2), 2.42 (4H, s, 2CH2CO), 2.55 (3H, s, C(NH)CH3), 4.38 (1H, 
m, CH). 
 
2.1.6 Synthesis and characterisation of OVA323-339 lipopeptide (11) and peptide alkynes (12) 
 
2.1.6.1 Resin loading for microwave synthesis  
 
Fmoc SPPS was assisted by a CEM Discovery microwave peptide synthesiser on Rink amide MBHA 
resin. The resin was swollen in DMF overnight before use. 
 
2.1.6.2 Fmoc-deprotection for microwave synthesis 
 
Each Fmoc-deprotection consisted of resin treatment with 20% piperidine in DMF (2 x 5 min, 50°C, 
20W) followed by extensive washing with DMF. 
 
2.1.6.3 1-(4,4-dimethyl-2,6-dioxyacyclohexylidene)ethyl (Dde) deprotection  
 
The Dde protecting group was removed manually by treatment of the resin with 2% hydrazine in 
DMF solution (12 × 15 min) followed by extensive DMF washing. 
 
2.1.6.4 Amino acid coupling for microwave synthesis  
 
N-Fmoc-protected amino acids (4.2 eq.) were pre-activated with HATU (4 eq.) and DIPEA (5 eq.) 
for 5 min and coupled to the resin (2 x 5 min, 70°C, 20W). The coupling of Fmoc-Arg(pbf)-OH was 
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carried out at 25°C for 10 min and 50°C for 10 min, respectively. For the peptide dendrimers, the 
quantities of amino acids and coupling agents were used in ratios relative to the number of branches. 
Lipopeptide 11 (Chapter 3, Section 3.2.3, Figure 3-9) was synthesised using microwave-assisted 
Fmoc SPPS on Rink Amide resin (0.2 mmol) using an in situ neutralisation protocol [211]. Synthesis 
of 8 was achieved as per Gibbons et al. [213] and 9 and 10 were synthesised as described by Ross et 
al. [212]. Branching of peptide 11 was achieved using Fmoc-lys(Fmoc)-OH followed by the 
consecutive addition of the OVA323-339 epitope by sequential coupling of Fmoc-Arg(Pbf)-OH, Fmoc-
Gly-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ile-OH, Fmoc-
Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-His(Trt)-OH, Fmoc-Ala-OH×2, Fmoc-His(Trt)-OH, Fmoc-
Val-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, and Boc-Ile-OH. Removal of 
ivDde was performed on-resin (Chapter 3, 3.2.3) followed by addition of pentynoic acid (4.2 eq.) 
which was coupled overnight to the resin using HBTU (4 eq.) and DIPEA (6.2 eq.). Following 
cleavage (detailed in Section 2.1.3.6), the crude lipopeptide was purified by preparative RP-HPLC 
with a 20% to 80% gradient of solvent B over 45 min generating 11 as a fluffy white solid. Synthesis 
of 12 (Chapter 3, Section 3.2.3.2, Figure 3-9) was achieved using a similar method to 11; however, 
lipids were omitted from the synthesis generating 12 as a fluffy white solid. Yields and ESI-MS data 
for 11 and 12 are shown in Chapter 3, Section 3.2.3, Table 3-3. 
 
2.1.8 Copper-mediated azide-alkyne cycloaddition (13-18) 
 
Fluorescently-labelled mannosylated lipopeptide vaccine constructs (13-18, Chapter 3, Section 
3.2.4, Figure 3-10) were prepared using copper-wire mediated click chemistry [214]. Briefly, purified 
fluorescently-labelled mannosylated-peptide-azides 4-6 (1.16 µmol, Section 3.2.2) were dissolved in 
separate vials that contained a solution of lipopeptide-alkyne 11 (1.1 µmol, Section 3.2.3) in DMSO 
(500 µL). Copper wires (60 mg) were added and the reaction was protected from light with aluminium 
foil and stirred under an atmosphere of N2 gas for 5 h at 45°C. The reaction was monitored by 
analytical RP-HPLC (20% to 80% gradient of solvent B over 45 min, C8 column). Upon completion 
of the reaction, copper wires were removed by filtration, washed with DMSO (1 ml), and the reaction 
was quenched by addition of Millipore water (2 ml). Crude products were purified by preparative RP-
HPLC (20% to 80% gradient over 45 min, C8 column) and lyophilised to afford pure vaccine 
constructs 13-15 as pale yellow solids. Characterisation was achieved by ESI-MS (Chapter 3, 
Section 3.2.4, Table 3-4). Vaccine constructs 16-18 were synthesised by coupling 7 to 11, 6 to 12, 
and 7 to 12, respectively using the same method as described in Chapter 3, Section 3.2.4.  
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2.1.8 Size characterisation  
 
2.1.8.1 Dynamic light scattering (DLS) 
 
The size of the particles formed by vaccine constructs 13-18 was measured in PBS (pH 7.4) using a 
non-invasive backscatter technique using a DLS instrument with DLS software. The measurement 
was performed in triplicate at 25°C in disposable cuvettes with a scattering angle of 173°. 
  
2.1.8.2 Transmission electron microscopy (TEM) 
 
TEM was operated at 100 kV. Vaccine constructs 13-18 were dissolved in PBS (0.5 µM, pH 7.4) and 
allowed to equilibrate at 25°C for at least 12 h, and used within 20 h. They were dropcast onto the 
200 mesh carbon-coated grids for 2 min, excess liquid was soaked away using filter paper and the 
dried samples were imaged within 24 h. 
 
2.2 In vitro evaluation of mannosylated lipopeptide vaccines 
 
2.2.1 General Materials and Equipment 
Phenol free IMDM Glutamax medium, 2-mercaptoethanol and streptomycin was purchased from 
Gibco® (Life Technologies, VIC, Australia). Anti-mouse CD11c Alexa Fluor® 700, FITC anti-
mouse CD4, PE anti-mouse T cell receptor Vα2 and APC/Cy7 anti-mouse F4/80 antibody were 
purchased from (Biolegend, Pacific Heights Blvd, San Diego, CA, USA). 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), ethanolamine, 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), and CaCl2, were purchased from Sigma-
Aldrich (NSW, Australia). Eri-lysis buffer and FACS buffer (PBS, 0.02% sodium azide, 0.5% BSA) 
were purchased from BD Biosciences (North Ryde, NSW, Australia). LSR II flow cytometer (BD 
Biosciences, San Jose, CA, USA) was used for in vitro uptake studies. 8-Well polylysine-treated µ-
slides (ibidi GmbH, Germany) were used for confocal microscopy (GE DeltaVision Deconvolution 
microscope). Biacore experimentation was performed using Biacore 3000 instrumentation (BIAcore, 
GE Healthcare, NSW, Australia) on a CM-5 chip provided from GE Healthcare-Australia 
(Silverwater, NSW, Australia). Glycine, MgCl2 and NaCl were obtained from Chem-Supply 
(Gillman, South Australia). Surfactant P20 was obtained from GE Healthcare-Australia (Silverwater, 
NSW, Australia). The recombinant human macrophage mannose receptor (catalogue number 2534-
MR/CF) was purchased from In Vitro Technologies Pty. Ltd. (Brisbane, QLD, Australia).  
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2.2.2 In vitro uptake 
 
Single-cell suspensions of splenocytes isolated from mice were prepared by passing the spleen 
through a 40 µm cell strainer [215]. Erythrocytes were then lysed with erylysis buffer. The remaining 
cell population was re-suspended in complete phenol free IMDM Glutamax medium, supplemented 
with 10% foetal bovine serum, 50 µM 2-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml 
streptomycin and added to sterile 12-well plates at a density of 2×105 cells per well. After 4 h 
incubation, cells were treated with vaccine constructs 13-18 at a concentration of 0.5 µM. After 24 h 
at 37°C in a humidified atmosphere of 5% CO2 and 95% air, the adherent cells were scraped from the 
plate, centrifuged and resuspended in PBS buffer that contained anti-CD11c (0.125µg/100µl) and 
anti-F4/80 (25µg/100µl) antibodies for 30 min at 4oC [215]. The cells were centrifuged and 
resuspended in FACS buffer (0.5 mL) and analysed using a LSR II flow cytometer [215]. To 
investigate receptor-mediated uptake, a mannan competition assay was performed [216]. Following 
isolation, plating and 4 h incubation of the cells (as described previously), cells were treated with 
mannan (1 mg/ml) 1 h prior to incubation with the vaccine constructs (13-18, 0.5 µM). Cell washing, 
processing and antibody staining was performed as stated previously. Data are presented as mean ± 
standard deviation for triplicate samples. Differences between vaccine groups were determined using 
a one-way analysis of variance (ANOVA) followed by a Tukey test and were considered statistically 
significant if the P value was <0.0001. 
 
2.2.3 Confocal Imaging 
 
Splenocytes were isolated as per Section 2.2.2. Cells were re-suspended in IMDM media with 5% 
foetal bovine serum in sterile plates at a density of 2×105 cells per well. Cells were treated with 
vaccine constructs 13-18 at concentrations of 0.5 µM in a humidified atmosphere of 5% CO2 and 
95% air for 4 h, at 37C. IMDM was then removed and adhered cells were stained with anti-F4/80 
antibody (25µg/100µl) and Hoechst (1 µg/100µl) stain, incubated for 30 min, and washed with IMDM 
(300 µl). Cells were observed with a GE DeltaVision Deconvolution microscope using band-pass 
filters 505 ± 36 nm, 531 ± 40 nm and 411 ± 48 nm to detect green, red and blue fluorescence, 
respectively. Receptor-mediated uptake was investigated by treating cells with mannan (1 mg/ml) at 
37°C in a humidified atmosphere of 5% CO2 and 95% air 1 h prior to incubation with vaccine 
constructs 13-18 at a concentration of 0.5 µM. Cell washing, processing, and antibody staining was 
performed as per Section 2.2.2. 
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2.2.4 In vitro OT-II Proliferation assay 
 
A single cell suspension of OT-II mice splenocytes was prepared by passing the spleen through a 40 
µm cell strainer, erythrocytes were lysed using erylysis buffer, and after centrifuging (600 g for 4 min 
at -4°C) the remaining cell populations were re-suspended in complete phenol free IMDM Glutamax 
medium containing supplements and antibiotics, as described in Section 2.2.2. Cells were plated in 
sterile 96-well plates at a density of 5×105 cells per well and incubated at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air with serial dilutions (5, 1.7, 0.5, 0.18, 0.06, and 0.02 µM) of 
vaccine constructs (13-18, dissolved in PBS) in triplicate. After 72 h, the cells were stained with anti-
mouse CD4and anti-mouse T cell receptor Vα2 antibodies. The cells were centrifuged (600 g for 4 
min at -4°C) and resuspended in FACS buffer (0.5 mL). The results were read on a LSR II flow 
cytometer.     
 
2.2.5 Real-time surface plasmon resonance (SPR) 
 
Step 1: Immobilisation: The recombinant human macrophage MR was immobilised on a CM-5 
research grade sensor chip using amine coupling chemistry according to the Biacore manufacturer’s 
instructions (Chapter 4, Section 4.5.1.1). In a typical procedure, activation of the chip’s surface was 
achieved using EDC (400 mM) and NHS (100 mM) in a 1:1 ratio at a flow rate of 20 µl/min for 8 
min. The MR was dissolved in sodium acetate buffer (10 mM sodium acetate in water, pH 4.4) at a 
concentration of 50 µg/ml and immobilised at 20 µl/min for 7 min to reach a final response unit (RU) 
of 20,000. The remaining reactive groups were blocked using ethanolamine (1 M, pH 8.5) at a flow 
rate of 20 µl/min for 7 min.  
 
Step 2: Surface performance and regeneration scouting: A surface performance test was performed 
to test the viability of the immobilised receptor using mannan (10 µg/ml) as per Chapter 4, Section 
4.5.1.2. To revive the MR from the bound mannan following regeneration buffers; sodium dodecyl 
sulphate (SDS) 0.05%, NaOH 10 mM (pH: 9.5) and glycine 10mM (pH: 2.2) were used to check their 
regeneration ability. As described in Chapter 4, Section 4.5.1.2; glycine (10 mM, pH 2.2) was chosen 
for the regeneration of MR following exposure of the chip to vaccine constructs 13-18. 
 
Step 3: Binding affinity measurement: Vaccine constructs 13-18 (50 µM to 0.78 µM) were dissolved 
in running buffer (10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 150 mM NaCl, 0.005% P20 in water, 
pH 7.4) to reach the optimum concentration. Kinetic cycle analysis was performed using mannan 
(18.75-600 µg/ml) dissolved in running buffer and was used as a positive control (Chapter 4, Section 
4.5.1.3). Each running cycle consisted of 3 steps: i) injection of the vaccine construct (or mannan) for 
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1.5 min at 40 µl/min, ii) an 8 min dissociation step at 40 µl/min with running buffer, and iii) injection 
of the regeneration buffer (10 mM glycine, pH: 2.2) for 5 min at 40 µl/min. One control flow cell, 
used as a blank sensogram for subtraction of the bulk refractive index, was also activated by EDC-
NHS and then blocked using ethanolamine (as described in Chapter 4, Section 4.2.4.1.1). All 
solutions were filtered using polytetrafluoroethylene membrane syringe filters (0.22 µm) and 
degassed prior to use. For binding studies, the temperature was kept at 25°C. The immobilised MR 
performance was analysed after each regeneration step using a surface performance test with mannan 
(30 µg/ml) to verify that the surface was still active.  
 
The KD (an affinity constant, used to measure the strength of binding of a single molecule to its ligand) 
was calculated using the binding response level at equilibrium (Req) for each vaccine construct 
(analyte) as outlined by Burkhard and Shapiro using Equation 1 (Eq. 1) [217]. Here, KA is the 
association constant, C is the analyte concentration (µM), Rmax is the response at saturation, and n is 
the number of binding sites determined by the type of fitting chosen. The steady state response level 
was chosen to show the validity of the results using BIAevaluation 4.1 software. Analysis of replicate 
experiments allowed the data to be analysed using a one-site binding model [217, 218]. 
𝑅𝑒𝑞 =
𝐾𝐴𝐶𝑅𝑚𝑎𝑥
1+𝐾𝐴𝐶𝑛
       (Eq. 1) 
 
2.3 In vivo studies on mannosylated lipopeptide vaccines 
 
2.3.1 General Materials and Equipment 
Pathogen free C57BL/6 (Animal Resources Centre, Perth, Australia) and OT-II (Walter and Eliza 
Hall Institute of Medical Research, Melbourne, Australia) mice were bred at QIMR Berghofer and 
used at 5-6 weeks of age. All animal studies were approved by the QIMR Berghofer's Animal Ethics 
Committee. All methods were followed from previously set protocols used in Professor Doolan’s 
laboratory at the QIMR Berghofer Institute [219]. Cell culture media (consisting of 10% foetal calf 
serum [FCS], 2-Mercaptoethanol, glutamin, knockout Dulbecco's-modified Eagle’s media 
[KDMEM]), magnetic cell sorting buffer (MACS; consisting of phosphate buffer saline, 2% fetal calf 
serum) and the OVA protein and OVA323-339 peptide were also provided by Professor Doolan’s 
laboratory at the QIMR Berghofer Institute.  
 
Antibodies used for in vivo OT-II cell proliferation assay: Vβ Biotin (T cell receptor, MR9-4),α-
CD4 BV510 (OT-II) and red cell lysis buffer were obtained from Biolegend (San Jose, CA, USA). 
CD45.2 PE, CD45.1 FITC (anti-mouse), α-Vα2 APC, α-CD8 APC/CY7 (anti-mouse) and Strepavidin 
PerCP/Cy5.5 were purchased from Biolegend (San Diego, CA). CD4+ (L3T4) microbeads were 
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obtained from Miltenyi Biotec (Bergisch Gladbach, Germany). FACSCalibur was used with 
CellQuest version 3.1f software (BD Biosciences, San Jose, CA, USA). Flo Jo analysis of data was 
performed post run by V9.1 (Treestar, Ashland, OR, USA). Flow Check® microbeads were purchased 
from Polysciences Inc. (Warrington, PA, USA). 
 
Intra Cellular Staining (ICS): Phorbol 12-myristate 13-acetate (PMA) and ionomycin was obtained 
from Sigma-Aldrich (NSW, Australia), GolgiplugTM and TNFα (rat α-mouse TNFα FITC) from BD 
Biosciences (NSW, Australia). IFNγ (rat α-mouse IFNγ APC), IL-2 (rat α-mouse IL-2 PE) were 
obtained from Biolegend (San Diego, CA, USA). A LSR II flow cytometer from BD Biosciences 
(NSW, Australia) was used in this study. 
 
Cytokine Bead Array (CBA): A CBA mouse Th1/Th2/Th17 cytokine kit was obtained from BD 
Biosciences (NSW, Australia). The CBA assay was performed on a FACSarray cytometer equipped 
with the CellQuest Pro and CBA software (BD Biosciences).  
 
Enzyme-Linked Immunosorbent Assay (ELISA): NUNC maxisorp 96-well plates were purchased 
from eBioscience (San Diego, CA, USA), biotinylated donkey anti-mouse IgG was purchased from 
Life Technologies (VIC, Australia), tetramethylbenzidine (TMB), stop reagent and Tween 20 were 
obtained from Sigma Aldrich (NSW, Australia), and strepavidine-peridinin chlorophyll was from BD 
Pharmingen (NSW, Australia). The VERSAmax micro plate reader was from Molecular Devices 
(CA, USA). 
 
2.3.2 OT-II cells cell preparation process, adoptive transfer 
 
Five OT-II female mice were sacrificed and CD4 splenocytes and lymphocytes were purified using 
CD4+ (L3T4) microbeads. CD4 purified cells were stained with α-CD4 (OT-II) FITC (1:200) and α-
Va2 PE (1:200) using CD4+ (L3T4) microbeads and the purity was checked using a FACSCalibur. 
The relative number of live cells was normalised by a count of Flow Check® microbeads 
(Polysciences Inc., Warrington, PA, USA) as described previously [220]. Cells were then diluted in 
PBS (9 mL) and prepared for injection. Each mouse (C57BL/6) received 200 µL of suspended cells 
(0.5×106 cells) by intravenous (I.V.) injection at the tail base. 
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2.3.3 Vaccination with vaccine constructs 
 
Vaccine groups G1-8 were dissolved in PBS (30 µg/100µl) and injected subcutaneously (S.C.) after 
the adaptive transfer of OT-II cells. Here, a control PBS group (G9) was used as the negative control. 
Immunisation was repeated 2 more times at 14 day intervals as per Chapter 5.2.1, Figure 5-3.  
 
2.3.4 OT-II proliferation activation assay 
 
Blood samples (5 µl) were taken from the tip of the tail two weeks after each immunisation. Samples 
were centrifuged and stained with a cocktail of antibodies (Table 2-1). Cells were washed and lysis 
buffer was added followed by storing for 10 min at 37°C. Cells were then washed with 2% media 
(containing 2% FCS) and then resuspended in MACS buffer (100 µl) and analysed using a flow 
cytometer (FACS BD LSRFortessa™). Single stained cells were used to set the compensation level 
for the results. Results shown in Chapter 5, Section 5.2.1, Figure 5-4. 
 
Table 2-1. Antibodies used for the CD4 proliferation assay 
Marker Fluorescent Dilution 
CD8 APC-Cy7 1:400 
CD4 BV510 1:1000 
CD45.1 FITC 1:200 
CD45.2 PE 1:200 
CD44 PE/Cy7 1:800 
CD62L BV605 1:800 
 
2.3.5 Preparing cells for intracellular staining and the cytokine bead array  
 
Vaccinated mice (G1-9, Chapter 5, Section 5.1, Figure 5-2) were sacrificed and the spleens were 
removed. Spleens were strained through a 100 µm plastic mesh and cells were suspended in 10 ml of 
2% media (contained 2% FCS) and centrifuged (600 g, 4 min at -4°C). The supernatant was removed 
and the cells were resuspended in lysis buffer (5 ml). After 5 min, 2% media was added, the cells 
were centrifuged (600 g, 4 min at -4°C) and following removal of the supernatant, 10% media (10 
mL) was added to resuspend the cells for a total count per well of 5 × 105. The cells were counted 
using FACS BD LSRFortessa™. 
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2.3.6 Intra-cellular staining (ICS)  
 
Splenocytes from a single cell preparation (5 × 105) of spleens, isolated from sacrificed mice 11 days 
post immunisation (day 63), were added to the wells of 96-well plates (5 x 105) and incubated in the 
presence of GolgiPlug (1 µl/ml), and in the presence or absence of the OVA323-339 peptide (10 µg/ml). 
Pre-mixed PMA (5 ng/ml) and ionomycin (500 ng/ml) were used as the positive control. After 3 days 
incubation (37°C and 5% CO2), cells were stained for IFN-γ (rat α-mouse IFNγ APC. 0.2 mg/ml), IL-
2 (rat α-mouse IL-2 PE, 0.2 mg/ml) and TNFα (rat α-mouse TNFα FITC, 0.5 ml/ml). The total number 
of IFN-γ, IL-2 and TNF positive CD4 and CD8 cells was determined using a LSR II flow cytometer 
and by subtracting the unstimulated controls from the peptide stimulated cells. Results are shown in 
Chapter 5, Section 5.2.2.1, Figure 5-7. 
 
2.3.7 Cytokine bead array (CBA) 
 
Cytokine measurements were performed using the supernatant of single suspensions of splenocytes 
using the Th1/Th2 kit (BD 560485) according to the manufacturer’s guidelines (BD Biosciences). 
Cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13) were measured in the supernatant of 
antigen-stimulated (OVA protein) splenocytes, unstimulated splenocytes (experimental negative 
control) and splenocytes stimulated with Con A (experimental positive control). Analysis was 
performed by a FACSarray cytometer equipped with CellQuest Pro and CBA software and the results 
are shown in Chapter 5, Section 5.2.2.2, Table 5-2.  
 
2.3.8 ELISA 
 
Blood samples (200 µl) were collected from individual mice (G1-9) 1 week post immunisation. Sera 
IgG was measured for both pooled and individual mice. 96-Well NUNC maxisorp plates were coated 
overnight at 4°C with the OVA protein (10 µg/ml, 50 µl) dissolved in bicarbonate coating buffer 
(0.05 M Na2CO3, pH 9.6). The wells were then blocked with 5% skim milk powder in PBS (100 
µl/well) for 1 h at 37°C. This step was performed to prevent non-specific binding. The plates were 
then washed with 0.05% Tween 20 in PBS (PBST) and the sera dilutions were added to the wells 
followed by 1 h incubation at 37°C. The plates were washed 3 times with 0.02% Tween in PBS. 
Biotinylated donkey anti-mouse IgG (8 µl) diluted in 100 µl PBS was added to each well and 
incubated for 1 h at 37°C. The plates were washed 4 times with PBST (0.02%). Streptavidin-
horseradish peroxidase (HRP) (160 µl) was added to each well, incubated for 1 h, and the plates were 
washed with PBST (0.02%). Plates were developed by adding RT tetramethylbenzidine (TMB, 50 
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µl/well), incubating for 10 min followed by addition of RT TMB stop reagent (50 µl/well). The optical 
density (OD) was measured at 405 nm using a micro plate reader. 
 
2.4 Data analysis and statistics 
 
Data were analysed using Prism v5.0a software (GraphPad, La Jolla, CA, USA). Statistical analysis 
was carried out using an unpaired Student’s t-test (nonparametric, Mann-Whitney), or by ANOVA 
followed by a Tukey post-test where indicated. Differences were considered to be significant when 
P<0.05 otherwise P was reported. 
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Chapter 3: Synthesis of Mannosylated Lipopeptides 
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3.1 Introduction 
Therapeutic peptides must overcome biological barriers to achieve cellular targeting. These barriers 
include chemical stability, stability against enzymatic degradation, reduced toxicity, and improved 
specificity. To achieve this, modification of peptide epitopes are inevitable procedures essential for 
vaccine development [153].  Despite the many attempts to design peptide-based vaccines for a variety 
of diseases, many of these vaccines have fallen short due to the lack of peptide stability, targeting 
ability or low immune-stimulation. However, such problems can be overcome by the addition of 
structural and immunological active components to the vaccine design. 
For instance, the lipidation of peptides is an effective method for increasing the immune-stimulatory 
properties of a peptide-based vaccine [164, 221]. Additionally, glycosylation has also been shown to 
increase the specificity of vaccine candidates towards the desired cellular target, making a 
combination of lipidation and glycosylation potentially effective vaccine attributes in a targeted 
vaccine design strategy [222]. To produce a well-characterised peptide subunit, vaccineSPPS is a 
commonly used synthesis method. Here, SPPS has advantages over solution synthesis methods, 
including the production of a highly pure, high yielding and relatively (cost) inexpensive vaccine. 
SPPS methodology can be applied for the production of both linear or branched peptide dendrimers 
[142]. In this study, lysine will serve as the branching moiety enabling incorporation of lipids, peptide 
epitopes and glycosyl moieties (mannose) into a single peptide vaccine construct [15,16]. The 
lipoamino acid attached to the OVA peptide is designed to function as the lipidic self-adjuvanting 
moiety [223].   
This chapter details the synthesis of linear O-linked mannosylated lipopeptides (Figure 3-1). Here, 
functionalisation of the serine side chain with mannose using solution synthesis enabled the step-wise 
addition of an O-mannosylated building block using SPPS techniques. Research has shown that O-
linked glycoproteins, where the glycosyl moiety is attached through a serine or threonine, are the 
most common glycoproteins found in nature [100] and are commonly isolated from the cell walls of 
yeast and bacteria [16, 224]. In this study, this O-mannosylated serine amino acid was used to target 
the C-type lectins on APCs. Here, functionalisation of the serine side chain with mannose enabled 
the step-wise addition of an O-mannosylated building block during SPPS. Fully protected mannose-
serine building blocks were used in peptide synthesis to help the stability of sugar in the process of 
peptide synthesis and also to increase sugar solubility in organic solvents which are used in SPPS 
[225]. For this purpose, hydroxyl groups on the mannose moiety were protected in a method with a 
good yield and then were coupled to serine. The mannosylated amino acid has been shown to 
successfully generate high-yielding peptides in Fmoc SPSS [207].  
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In this study, the OVA323-339 peptide epitope was included in the peptide vaccine structure as a model 
antigen with the prospect of CD4 T cell activation. Here, recombinant OVA O-mannosylation has 
been shown to be effective in MR targeting [190]. However, in a previous study, the OVA323-339 
epitope produced a Th1 response in mice but its immunogenicity was limited compared to the full 
OVA protein [189] confirming the need for an adjuvant system for small proteins or peptide epitopes 
as vaccine candidates.  
The final library of vaccine constructs (Figure 3-1) was designed to contain different length spacers 
(0, 1, 2 alanine units) between the two mannose moieties to gain information about the relative spatial 
requirements of the sugars on their uptake by APCs (Chapter 1, Section 1.4, Figure 1-5). An increase 
and/or decrease of space between each mannosyl moiety was postulated to play a role in the binding 
of these vaccine constructs to the MR, and give an increased understanding on the binding 
requirements. A fluorescent tag (FAM) was included in the vaccine structures to enable detection in 
in vitro cell studies. For more information on the selection and role of each moiety included in the 
vaccine constructs, please refer to Chapter 1, Sections 1.7-1.8. 
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Figure 3-1. Schematic picture of the vaccine construct library. The main library includes vaccine 
constructs where n is the number of alanine units between each mannose moiety. The sequence for 
the OVA323-339 peptide is a model antigen. Mannose is included into the structures for its mannose 
receptor targeting ability. The lipid (C12) is added to provide self adjuvanting properties. Designed 
final vaccine structures are prepared in two sections A and B. Section A is OVA323-339 lipopetide (in 
case of controls no lipid is on the structure) with alkyne functional group able to be attached to section 
B which is the mannosylated peptide (in case of controls no mannose on the structure) with azido 
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functional group. The final library is provided by an azide-alkyne reaction and formation of a triazole 
cycle (C). The vaccine control library consists of constructs without mannose (D), without lipids (E) 
and without mannose and lipid moieties (F) and these are used to compare the effect of each moiety 
on in vitro and in vivo studies.  
The synthesis of multi-functional glycosylated peptides that contained two mannose moieties, an 
azido functionality (to enable conjugation to the OVA antigen using azido-alkyne click chemistry), 
and a fluorescent tag (Figure 3-1A) was challenging and required selective deprotection/protection 
strategies to ensure high yields and increased stability. Microwave-assisted SPPS was utilised for the 
preparation of vaccine constructs /building blocks (Figure 3-1A). Here, microwave synthesis was 
used as it is known to generate long peptides in a faster time compared with manual synthesis [226]. 
Manual preparation of vaccine constructs (Figure 3-1B) was used to prepare the glycosylated peptides 
to achieve a good level of coupling ensuring a high yielding product. Throughout each synthesis, 
micro-cleavages were performed to confirm successful elongation of the peptide chain, ensuring a 
successful synthesis especially important with long peptide sequences. Herein, different approaches 
for the synthesis of the vaccine constructs including the main library (Figure 3-1C) and the control 
library (Figure 3-1D, E and F) are presented and discussed. 
3.2 Results and Discussion 
In nature, a large proportion of proteins are glycosylated, and the synthetic approach has provided the 
chance of preparing pathogens cell wall mimics [227, 228]. Although synthetic methods like the 
application of enzymes in carbohydrate preparation can quickly provide pure products, they are more 
efficient in the preparation of large scale glycosylated products [227].Hence, chemical synthesis, 
specially SPPS used for the preparation of glycosylated constructs with specific properties and less 
unwanted problems of natural sources, are more likely under investigation [229, 230]. In general, the 
preparation of glycoproteins is a difficult task with complications in regards to the formation of a 
reproducible glycoprotein, although the preparation of glycopeptides using SPPS gives a chance of 
designing an engineered active product [231].  
In nature, O-Linked mannose is naturally available attached to a serine or threonine amino acid [222]. 
Further studies are needed to include O-mannosyl serine/threonine building blocks in vaccine 
peptides with preservation of the mannosyl targeting properties found in nature (Chapter 1, Section 
1.6, Figure 1-6). Special arrangements of the O-mannosyl building blocks, such as the space needed 
between the glycosylic moieties in a peptide for a better receptor attachment, have rarely been 
investigated. As a result, this has prompted the exploration of the synthesis optimisation and 
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conformational properties of O-linked mannosylated peptides for use in biological and 
immunological studies with the aim of advancing vaccine development through increased targeting 
of APCs. Several studies have reported the preparation of O-mannosyl serine or threonine building 
blocks for application in peptide synthesis [208, 225]. However, these O-mannosyl serine or threonine 
building blocks have rarely been incorporated into peptides [208, 230].   
3.2.1 Design and Synthesis of Mannosylated Building Blocks 
The Fmoc-serine mannosylated amino acid 2 (N-Fmoc-O-(2,3,4,6-tetra-O-acetyl-α,β-D-
mannopyranosyl)-L-serine, Figure 3-2) was synthesised from acetylated D-mannose (1, Figure 3-2) 
as a building block for use in the synthesis of mannosylated peptides. One of the advantages of using 
this Fmoc-serine mannosylated amino acid building block is the ease of addition to a growing peptide 
chain using Fmoc SPPS.  It was previously reported that 1,2,3,4,6-penta-O-acetyl-α,β-D-
mannopyranosyl with a carboxylic pentafluorophenyl protecting group successfully generated high-
yielding peptides (63%) using Fmoc SPSS, however, the presence of the ester protecting group 
required an extra deprotection step under acidic conditions when used at the N-terminus of the peptide 
[207, 232]. Other methods for preparation of mannosyl building blocks, including application of a 
carboxylic-protected serine using t-butyl or pentaflurophenyl protecting groups also required 
additional deprotection steps. These additional deprotection steps increased the overall synthesis time 
or required the use of solution-based deprotection strategies, which could not be applied to the linear 
addition of more than one building block [207, 230]. Conjugating chlorine or bromide at the anomeric 
position of mannose before attachment to the amino acid can also add an extra step to the preparation 
of a final mannosylated building block [230]. Therefore, the two-step preparation of a Fmoc-serine 
mannosylated amino acid building block with an unprotected carboxylic acid at the C-terminus (2, 
Figure 3-2) provided an ease of application in peptide chain elongation using Fmoc SPPS. Here, the 
hydroxyl groups of D-mannose were acetylated to ensure stability of the sugar moiety during peptide 
synthesis and to avoid acylation (Figure 3-2). Without this hydroxyl protection, the glycosidic bond 
was susceptible to degradation [207]. Further, Lewis acid reaction (Figure 3-2) was chosen due to the 
ease of access to starting materials and shorter reaction times regarding the steps taken compared to 
other methods available for preparation of a mannose-serine building block.  
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Figure 3-2. Scheme for the synthesis of Fmoc-serine mannosylated amino acid building blocks. 
1,2,3,4,6-Penta-O-acetyl-α,β-D-mannopyranosyl (1) was synthesised using D-mannose, DMAP, 
Ac2O, 46°C, 24 h, N2 gas in a 85% yield. N-Fmoc-O-(2,3,4,6-tetra-O-acetyl-α,β-D-mannopyranosyl)-
L-serine (2) was synthesised with the addition of Fmoc-serine-OH, BF3.Et2O, DCM, RT, 4 h in a 42% 
yield. 
 
Figure 3-3. Mechanism of action for the BF3.Et2O Lewis acid reaction. Conjugation of 1 
(acetylated mannosyl donor) to Fmoc-Ser-OH using BF3.Et2O in DCM at RT for 4 h generated 2 
(Fmoc-serine mannosylated amino acid building blocks) as a mixture of α and β due to attack of the 
Lewis acid from both below (β, 25.44%) and above (α, 74.55%) [233]. For synthesis details see 
Chapter 2, Section 2.1.2. 
The synthesis of 1 was performed as previously described (33) and is detailed in Chapter 2, Section 
2.1.2. Here, Lewis acid (BF3) was used as a promoter for the attachment of the serine hydroxyl group 
to the anomeric carboxyl group on per O-acetylated mannose. It is postulated that an intermediate 
oxonium is formed and depending on the angle of interaction, both α or β isomers are formed (Figure 
3-3) [233].  
The synthesis of 2 was optimised by monitoring the Lewis acid reaction using analytical RP-HPLC. 
Here, a 4 h reaction was found to give a maximum yield of 42% while longer reactions resulted in 
degradation of the product (Figure 3-4). This product degradation was observed 4 h after the reaction 
was started in analytical RP-HPLC and is postulated to be associated with the rearrangement of the 
glycosyl group and formation of new subsidiary structures (Figure 3-4) [230]. Additionally, two peaks 
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were observed for the product that were attributed to α- (74.55%) and β- (25.44%) analogues of the 
sugar (Figure 3-4). Furthermore, as the Fmoc-serine amino acid was used in excess in this reaction, 
it was expected that this peak would be present at the conclusion of the reaction (Figure 3-4). At 21.5 
min (Figure 3-4) a peak was observed relating to the final product (2) without one acetyl group. This 
was also reported by Wang et al. and was explained to be related to the thermolytic condition of the 
BF3 reaction [233]. Previous studies have also reported 18 h reactions using the same reaction 
conditions described here (BF3.Et2O, DCM, RT, Fmoc-ser-OH) generating a pure yield of 5% [230]. 
Here, preparative RP-HPLC was used with a C18 column, product 2 was purified with a 30-70% 
gradient of acetonitrile over 45 min and was characterised by ESI-mass spectrometry and NMR 
(Appendix 1). 
 
Figure 3-4. Monitoring of the boron trifluoride diethyl etherate (BF3.Et2O) Lewis acid reaction 
at 1, 2, 3, 4, 6, and 8 h by analytical RP-HPLC on a C18 column (0 to 100% acetonitrile gradient over 
30 min). At 4 h, the optimum yield for the product (2, 42%) was observed with a retention time (Rt) 
of 23.6 min (peak indicated by an arrow) and this eluted at 62% solvent B (Chapter 2, Section 2.1.1). 
Rt 19.3 min is the Fmoc-serine-OH starting material and Rt: 21.5 min is the product missing one 
acetyl group. The graph was drawn using nudging (overlaying graphs with an angle) in GraphPad 
Prism. 
3.2.2 Synthesis and characterisation of fluorescently-labelled mannosylated (and un-
mannosylated) peptide azides 
Mannosylated peptides that contain more than one mannose moiety and are widely spaced have been 
shown to have increased affinity for the MR, present on APCs [234]. However, it has also been argued 
that less distance between these mannose moieties can also enhance affinity and binding towards the 
MR [131]. Further, studies have reported that a dimannoside cluster was better at recognising CRDs 
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of the MR, while single mannose-BSA was better recognised by a DC-SIGN receptor (a C-type lectin 
receptor with one CRD and with affinity towards glycosylated structures) with a single CRD, 
suggesting that linearity and spacing should be considered in the design of MR ligands [121]. Thus, 
the aim was to investigate the role of distance between the mannose units and the effect this had on 
binding and affinity towards the MR. Here, mannose units were used arranged linearly (non-
clustered) in peptide vaccine constructs. Inclusion of an alanine spacer between each mannose unit 
has also been shown to minimise unwanted steric interactions Depending on the hydrophilicity or 
lipophilicity of these spacers in the structure, different sizes and conformations can be obtained [121, 
235]. Here, two synthesis strategies (Method 1 and Method 2) were detailed for preparation of 
mannosylated peptides using Fmoc SPPS to obtain a final library of mannosylated peptides in high 
yields to be tested as potential vaccine constructs (Figure 3-1).  
3.2.2.1  Method 1:  
 
Figure 3-5. Azide functionalized mannosylated peptide 3. Peptide 3 was synthesised using Method 
1 and resulted in a low overall yield of 5%. (a) 20% Piperidine in DMF, RT; (b) Fmoc-lys(IvDde)-
OH, HATU, DIPEA; (c) 2, HATU, DIPEA, DMF; (d) Fmoc-Ala-OH, HATU, DIPEA, DMF; (d*) 
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repeated a and d; (e) 5(6)-carboxyfluorscein (FAM), DIC, HOBt, DMF; (f) 5% hydrazine in DMF on 
resin (3 × 30 min), RT; (g) azidoacetic acid, HATU, DIPEA, DMF; (h) 95% TFA: 2.5% water: 2.5% 
TIS. For a detailed synthesis protocol see Chapter 2, Section 2.1.4.1. 
Peptide 3 (Figure 3-5) was synthesised using manual Fmoc SPPS. Here, Fmoc-lys(IvDde)-OH was 
first coupled to the peptide chain.  Peptide elongation was continued by addition of 2,3,4,6-tetra-O-
acetyl-α,β-D-mannopyranosyl-serine building blocks (2, Figure 3-2) with addition of 2 alanine 
spacers between each mannose unit. Fmoc amino acids were coupled by activation with HATU and 
DIPEA in DMF. HATU has been shown to be an efficient coupling reagent for generating products 
with high reactivity and low racemisation [236]. Following addition of the last amino acid in 
sequence, FAM was coupled and excess ester-bound FAM removed by treatment with 20% 
piperidine. Addition of FAM enables visualisation in in vitro cell studies [208]. The resin was then 
treated with 5% hydrazine in DMF on resin (3 × 30 min) to remove the lysine side chain protecting 
group, IvDde, along with acetyl protecting groups on the mannosyl moieties, to enable coupling of 
an azido-functional group. This azido group enabled coupling of additional functional groups (e.g. 
peptides) using an azido-alkyne click reaction at a later stage in the project. Here, mannosylated 
peptide 3 was released from the solid support by treating the resin with a mixture of TFA, TIPS and 
water. All the acid-labile amino acid side chain protecting groups were removed concomitantly. The 
resulting crude peptide was purified by preparative RP-HPLC (0-100% solvent B) on a C8 column 
and characterised using ESI-MS (Table 3-1). For a detailed synthesis protocol see Chapter 2, Section 
2.1.4.1. 
Table 3-1. ESI-MS data, RP-HPLC Rt and yield for mannosylated peptide 3 
Peptide 
ESI-MS m/z Rt  
(min) 
Yield  
(%, column) Ionization Calculated Found 
3 [M+H]+1 1212.4 1214.1 13.69 5, C8 
 
Crude peptide 3 showed multiple peaks in the HPLC trace (Figure 3-6) and was obtained in a very 
low yield (5%). This is proposed to be due to the incomplete removal of the IvDde group and or acetyl 
protecting groups on the mannose. The multiple observed peaks in Figure 3-6 represent peptide 3 
without 2 acetyl groups, without 1 mannose unit, without the FAM moiety, and with IvDde still 
present post-cleavage. 
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The analysis of these results clarified that a couple of factors had occurred as reported in previous 
studies: 1) Hydrolysis of the fluorescent tag under basic conditions had occurred [237]; and 2) IvDde 
is a hydrophobic side chain protecting group and there have been reports on the difficulty of removing 
this protecting group and its presence in the product confirms this result [238]. Considering the low 
yield observed and also considering the amount of peptide required for the vaccine studies, a new 
method (Method 2) was proposed to overcome these problems and ultimately achieve higher product 
yields.  
 
Figure 3-6. HPLC traces of peptides 3 and 4. (A) 3 prepared using Method 1 and obtained in a 
yield of 5%, Rt=13.69; and (B) 4 prepared using Method 2 and obtained in a yield of 54%, Rt=20.36. 
Analytical RP-HPLC: 0-100% acetonitrile gradient over 30 min. For a detailed synthesis protocol see 
Chapter 2, Section 2.1.4.1. 
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3.2.2.2 Method 2: 
By changing the strategy from Method 1 (Section 3.2.2.1) to Method 2 for the preparation of azido-
functionalised mannosylated peptides, it was hoped that the complications observed with the IvDde 
removal and fluorescent tag stability observed in Method 1 (Section 3.2.2.1, Figure 3-6) were 
overcome. This was achieved by changing the lysine side chain protecting group from IvDde to Mtt 
(Figure 3-7). 
 
Figure 3-7. Reagents and conditions for the synthesis of peptides 4-7: (a) 20% Piperidine in DMF, 
RT; (a*) 2 cycles of piperidine in DMF; (b) Fmoc-lys(Mtt)-OH, HATU, DIPEA; (c) 2% TFA: 1% 
TIPS in DCM, 20 cycles; (d) azidoacetic acid, HATU, DIPEA, DMF; (e) N-Fmoc-O-(2,3,4,6-tetra-
O-acetyl-α,β-D-mannopyranosyl)-L-serine, HATU, DIPEA, DMF; (f) Fmoc-Ala-OH, HATU, 
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DIPEA, DMF; (g) 5(6)-carboxyflourscein (FAM), DIC, HOBt, DMF; (h) 95% TFA: 2.5% water: 
2.5% TIS. For a detailed synthesis protocol see Chapter 2, Section 2.1.4.2. 
Azido-functionalised mannosylated peptides 4-7 (Figure 3-7, Table 3-2) were synthesised using 
manual Fmoc SPPS. The orthogonal Mtt side chain protecting group was removed from the lysine 
using mildly acidic conditions (Figure 3-7) and azidoacetic acid was coupled to allow for 
functionalisation with the OVA323-339 lipo-peptide after cleavage. Mtt was chosen to protect the 
orthogonal lysine group because it is easily deprotected on-resin using 1% TFA and scavenger (1% 
TIS) in DCM [239]. Following this, the Fmoc group from the lysine was removed and the Fmoc-
serine-mannose amino acid (2, Figure 3-1) was coupled using standard in situ Fmoc coupling 
procedures [240]. Un-mannosylated fluorescent peptide 7 was synthesised using the same procedure 
as compounds 4-6, however, the Fmoc mannosylated serine amino acid (2) was replaced with Fmoc-
serine(tBu)-OH (Figure 3-7). Peptide 7 contains two alanine amino acids employed as a spacer 
between each mannose unit (Figure 3-7) and was used as a control for in vitro studies to investigate 
the role of mannose on receptor binding. For a detailed synthesis protocol for peptides 4-7 using 
Method 2 see Chapter 2, Section 2.1.4.2. 
Table 3-2. ESI-MS data, RP-HPLC Rt and yields for peptides 4-7 
Construct 
ESI-MS m/z C8: Rt 
(min) 
C18: Rt 
(min) 
Yield 
(%) Ionization Calculated Found 
4 [M+H]+1 1563.45 1565.0 20.83 20.64 54 
5 [M+H]+1 1634.53 1634.5 20.57 20.51 62 
6 [M+H]+1 1705.61 1706.6 20.50 20.49 68 
7 [M+H]+1 1044.39 1045.8 15.04 12.16 48 
 
 
3.2.2.3 Comparison of Method 1 with Method 2 
Method 1 gave a very low yield (5%) for the synthesis of peptide 3 and this was proposed to be due 
to the instability of FAM and acetyl groups due to a reaction to hydrazine and further difficulties in 
the removal of IvDde on the lysine side chain as explained in Section 3.2.2.1. The advantage of 
Method 2 was that FAM was added as the last functional group at the N-amino end of the peptide 
chain so it was intact and stable. It was previously shown that FAM can be unstable in the presence 
of hydrazine and it was postulated that this could be the reason for the low yield obtained in Method 
1 [208]. Further, IvDde was not completely removed which could be associated with its high 
hydrophobicity [241].  
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The revised synthesis method of first removing the Mtt protecting group on the lysine side chain, 
improved the yield by 4-5 times higher than Method 1 (Figure 3-6). As can be seen in Figure 3-6, the 
number of crude peaks observed in analytical RP-HPLC was considerably reduced in Method 2 
(Figure 3-6B) compared with Method 1 (Figure 3-6A). 
3.2.3 Synthesis and characterization of OVA323-339 lipopeptide and peptide alkynes 
Lipid moieties included in peptide (or proteins) constructs are efficient in improving their 
bioavailability by increasing the lipophilicity and have the potential to overcome enzymatic barriers 
[221]. Inclusion of lipid moieties in peptide vaccines has been shown to increase passive diffusion of 
peptides across epithelial barriers as well as increase uptake in lymphatic systems [221]. LCP 
(Chapter 1, Figure 1-13) vaccines are known to have self-adjuvanting properties and contain 
minimum epitopes necessary for targeting cells [165]. The LCP systems with 2 or 3 lipid moieties 
are known to target DCs and induce cellular activation by attachment to TLRs [167]. It has been 
shown that LCPs along with Pam3Cys and Pam2Cys are ligands for TLR2 and when incorporated 
into an antigenic moiety have been shown to elicit cellular and humoral immune responses [242]. 
Previous studies have shown that incorporation of long chain lipoamino acids into a peptide chain 
can change the size of the peptide particles and this is known to affect its immunogenic properties 
[243]. The alkyl chain in a lipoamino acid could vary in length, but the most common number of 
carbon atoms used in vaccine studies is between 12 and 16. In this study, C12 was chosen as this has 
been shown to have an adjuvanting effect when attached to the peptide epitope [244]. 
The OVA323-339 epitope of OVA is known to bind to MHC II causing a T cell response [182, 184]. 
This OVA323-339 epitope is a common antigenic peptide reported to be used in the design of peptide 
vaccines for a T cell response [245, 246]. T cells are activated when T cell receptors interact with an 
antigenic epitope and generate the release of cytokines, inducing T cell proliferation [245].  In this 
study, two copies of the OVA323-339 epitope was incorporated into the peptide vaccine constructs with 
the ultimate goal of designing a prophylactic vaccine with T helper response. Increasing the number 
of epitopes attached to a lysine core dendron can improve peptide size uniformity and has been shown 
to enhance the in vivo activity of peptides [247].     
In this project, alkyne-functionalised peptides containing two lipid moieties (C12) and two branches 
of the OVA323-339 peptide as the model antigen were synthesised using microwave-assisted Fmoc 
SPPS (Figure 3-8). The design of a branched peptide vaccine has the advantage of presenting multiple 
copies of an epitope to the immune system in one single entity. Here, the lysine amino acid, containing 
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both α and ε amino groups, provides branching points for the attachment of multiple peptide epitopes 
in one construct [248]. 
3.2.3.1 Synthesis of lipid building blocks 
It has been previously shown that the addition of lipid moieties to a peptide chain increases its stability 
and immunogenicity by increasing the lipophilicity and inducing formation of peptide particles [153]. 
Using self-adjuvanting lipopeptide vaccines has the advantage of being safe and reproducible 
(detailed in Chapter 1, Section 1.8.2) [153, 249, 250]. In this project, two lipid moieties were 
incorporated into the peptide chain. This has been shown to give the most promising antibody 
response in relation to the structural activity by improving the adjuvanting properties of the vaccine 
constructs [142].  
Synthesis of the C12 lipid (9, Figure 3-8) and subsequent protection using the Dde protecting group 
(8, Figure 3-8) was performed using previously published procedures [212, 251] and is detailed in 
Chapter 2, Section 2.1.5. Here, Dde was chosen as a protecting group for lipoaminoacids as it is 
compatible with Fmoc SPPS and can be selectively removed on resin [212, 252]. Further, the Dde-
C12 (10) was prepared by a reaction of the C12 (9) with Dde (8, Figure 3-8).  
 
 
Figure 3-8. Synthesis of the Dde (9) lipid protecting group and the Dde-C12 lipid (10). 2-
Acetyldimedone (Dde, 8) was synthesised using solution synthesis, and was then used to protect the 
N-terminal of the C12 lipid (9) in a reaction with 8 generating the Dde protected C12 lipid (10, Dde-
C12). For a detailed synthesis protocol see Chapter 2, Section 2.1.5. 
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3.2.3.2 Synthesis of OVA323-339 peptides 
Microwave-assisted Fmoc SPPS was used for synthesis of peptides 11 and 12 on Rink amide MBHA 
resin. Following coupling of the Dde-C12 (10, Figure 3-8), the Dde protecting group was manually 
removed by treating the resin with 2% hydrazine in DMF. Branching and concurrent addition of two 
OVA peptides (Figure 3-9) was achieved using Fmoc-lysine(Fmoc)-OH. Standard microwave-
assisted Fmoc SPPS protocols were used for the synthesis of peptide 11, with amino acid activation 
using HATU and DIPEA. Each amino acid (listed in Figure 3-9) coupling was followed by Fmoc 
deprotection using two cycles (5 min/cycle) of 20% piperidine in DMF. The IvDde protecting group 
on the side chain of lysine was removed manually and functionalised with an alkyne functional group. 
Peptide 12, which contained no lipid moieties, was synthesised as a control for the cell-based assays 
using a similar method to peptide 11, without inclusion of the lipids. Purification details for peptides 
11 and 12 are reported in Table 3-3. For a detailed synthesis protocol of peptides 11 and 12 see 
Chapter 2, Section 2.1.6. 
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Figure 3-9. Reagents and conditions for microwave-assisted synthesis of peptides 11 and 12; (a) 
20% Piperidine in DMF, 20W, 70°C for 2 min + 5 min; (b) Fmoc-Gly-OH; (c) 10, HATU, DIPEA; 
(d) 2% hydrazine in DMF (4 x 10 min); (e) Fmoc-Lys-IvDde-OH, HATU, DIPEA; (f) Fmoc-Lys-
Fmoc-OH, after deprotection of Fmoc, Ile(Boc) - Ser(tBu) – Gln(Trt) – Ala - Val – His(Trt) - Ala - 
Ala – His(Trt) - Ala – Glu(OtBu) - Ile – Asn(Trt) – Glu(OtBu) - Ala - Gly – Arg(Pbf) were coupled 
consequently (in HATU and DIPEA), all amino acids were Fmoc protected and deprotection of Fmoc 
group was performed as mentioned at (a); (g) 2% hydrazine in DMF on resin (3 × 30 min), RT; (h) 
pentynoic acid, HBTU, DIPEA, overnight, at RT; (i) 95% TFA: 2.5% water: 2.5% TIS. For a detailed 
synthesis protocol of peptides 11 and 12 see Chapter 2, Section 2.1.6. 
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Table 3-3. ESI-MS data, RP-HPLC Rt and yields for peptides 11-12 
Construct 
ESI-MS m/z Rt 
(min) 
Yield 
(%, Column) Ionization Calculated Found 
11 [M+3H]+3 1439.98 1440.1 17.47, 17.28, 16.96 73, C4 
12 [M+2H]+2 1962.10 1962.1 17.79 83, C18 
 
3.2.4 Conjugation of mannosylated peptide azides to lipopeptide alkynes using copper-
mediated azido-alkyne click chemistry  
Large dendritic peptides with complex branched structures can be difficult to synthesise and purify 
in a single step. However, there are a number of techniques available to assist in their synthesis [253, 
254]. In this study, copper-mediated azide-alkyne cycloaddition reaction or “click chemistry” was 
employed due to its safety, reliability, and high yielding reaction (Figure 3-10). Furthermore, cell-
based assays found that the triazole bond formed between the two products in this reaction had an 
increased stability against proteolytic degradation and was able to mimic a native peptide bond [253, 
254].  
In this study, the OVA323-339 lipopeptide-alkyne (11) was conjugated to fluorescently-labelled 
mannosylated-azides (4-6), forming a library of mannosylated vaccine constructs (13-15, Figure 3-
10) designed to test the impact of distance between the mannosyl groups on cell uptake. The click 
reaction was performed in DMSO, which easily dissolved each reaction component. The reaction was 
monitored by analytical RP-HPLC to quantify the optimal reaction duration and product identification 
was achieved using ESI-MS. Here, the reactions were found to be completed in 5 h where formation 
of the product did not proceed any further when reaction times were increased. In some cases, when 
the reaction was left longer (24 h), there was no change in the product yield and by-products had 
started to form, potentially due to the breakdown of the sugar moiety from lengthy exposure to 
elevated temperatures (50°C). In this study, copper wire was used as the source of the copper catalyst 
because of its advantages over traditional sources of copper, which require the use of use N-based 
ligands or the reduction of CuII to CuI in situ: copper wire also facilitates the easy removal of excess 
copper from the reaction [214]. At the completion of the reaction, the copper wire was removed by 
filtration, the reaction was quenched with water and lyophilised to obtain the crude test vaccine 
constructs (13-15, Figure 3-10).  
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Figure 3-10. Mannosylated lipopeptide vaccine constructs 13-15, prepared from a copper-
mediated click reaction (DMSO, 5 h, RT, N2 gas) of the lipopeptide-alkyne (11) with fluorescently-
labelled mannosylated-azides (4-6). The formation of the triazole bond in this reaction is highlighted 
with a square. See Chapter 2, Section 2.1.7. 
Vaccine constructs used as controls in in vitro and in vivo studies were also synthesised (16-18, Figure 
3-11). Here, conjugation of 7 to 11 generated 16 (Figure 3-11) which contained no mannose moieties. 
Furthermore, a mannosylated construct that contained no lipids (17, Figure 3-11) and a construct that 
contained no lipids or mannose (18, Figure 3-11) were generated by conjugation of 12 with 6, and 12 
with 7, respectively. Constructs 16-18 were designed to test the role of lipids and/or mannose in cell 
binding/uptake studies as well as immune modulation properties.  
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Figure 3-11. Library of fluorescently-labelled mannosylated lipopeptide vaccine constructs (13-
15) and control constructs (16-18). The test constructs, containing a variable length alanine spacer 
between each mannose moiety are 13 (n=0), 14 (n=1) and 15 (n=2). Control constructs for cell-based 
studies include 16 (no mannose moieties, n=2), 17 (no lipid moieties, n=2), and 18 (no lipid or 
mannose moieties, n=2), where n is the number of alanine amino acids. OVA323-339 epitope (model 
antigen) was included as a CD4 T cell epitope. FAM was included in each construct to enable 
detection in in vitro cell studies. The lipid is C12.     
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Vaccine constructs 13-18 (Figure 3-11) were purified by preparative RP-HPLC on a C8 column and 
isolated in yields of 34-51% (Table 3-4). The retention times were slightly longer than that of the 
reacting peptide building blocks due to their larger molecular size and higher hydrophobicity (Table 
3-2). Figure 3-12 shows the RP-HPLC trace for construct 15 as an example. The peak of product (15, 
Figure 3-12) and the lipopeptide starting material (11, Figure 3-12) are multivalent because the lipids 
are present as a diastereomeric mixture in accordance to previous reports [255]. Construct 15 also 
contained a mixture of both α- and β-stereochemistries for the mannose units (Figure 3-11). Here, 
broad peaks are observed for all mannosylated peptides (4-6) and lipidated peptides (10-11) due to 
the anomeric mixture of the mannose moieties and the diastereoisomeric mixture of the lipids, 
respectively (Appendices 9-12). As a result, multiple peaks were observed for the vaccine constructs 
13-16 (Appendices 9-12).  
For all constructs, the number of peaks observed in RP-HPLC is less than that expected and this can 
be attributed to each diastereoisomer having a similar retention time, and hence the broader RP-HPLC 
peaks observed. Furthermore, the mannosylated peptide azide (4), was present at the conclusion of 
the reaction (Figure 3-12A). Vaccine constructs that contained the mannose groups had been 
acetylated for peptide synthesis (13-15 and 17, Figure 3-11) and these acetyl groups were not 
removed before the cell-based assays. Previous studies have shown that acetylation of these glycosyl 
groups (including mannose) increased cell uptake and that the acetyl groups were subsequently 
removed by esterases inside the cell [231, 256]. Previous studies have also confirmed no significant 
differences in biological activity between acetylated and non-acetylated mannosylated peptides [257]. 
In addition, studies show that both acetylated and non-acetylated hexoses inhibit the binding of 
mannan to mannose binding lectins [258]. Hence, in this study, the acetyl protecting groups on 
mannose were not removed.  
Table 3-4. ESI-MS data, RP-HPLC, Rt and yields for vaccine constructs 13-18 
Vaccine 
Construct 
ESI-MS m/z 
C8: Rt (min) C4: Rt (min) 
Yield 
(%) Ionization Calculated Found 
13 [M+4H]+4 1471.09 1472.0  21.68, 21.94, 22.42 20.40, 20.65, 21.94, 21.62 33 
14 [M+4H]+4 1488.86 1489.3 21.26, 20.56, 21.97 21.24, 22.20, 23.87 35 
15 [M+4H]+4 1506.63 1506.3 19.88, 20.11, 20.47 21.31, 20.60, 20.79, 22.28 34 
16 [M+4H]+4 1341.48 1341.5 20.13, 20.41, 21.36 16.81, 17.16, 17.54, 17.85 45 
    C8: Rt (min) C18: Rt (min)  
17 [M+4H]+4 1407.97 1408.1 13.50 20.53 51 
18 [M+4H]+4 1242.82 1244.1 14.35 --- 35 
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Figure 3-12. RP-HPLC trace for the copper-mediated click reaction between peptides 4 and 11 
for the formation of vaccine construct 15. (A) 4, Rt 20.83 min; (B) 15 (a diastereomeric mixture), 
Rt 21.2 min, 21.6 min, 21.8 min; (C) 11 Rt 23.5 min. Click reaction was performed in DMSO at 50°C 
under an N2 atmosphere and stopped after 5 h. 
3.2.5 Size characterisation 
Vaccine constructs 13-18 were investigated for their self-assembly and particle formation in PBS. 
Here, the hydrophilic OVA323-339 peptide conjugated to the hydrophobic lipid created amphiphillic 
constructs that self-assembled in aqueous media to form particles, providing access to peptide 
nanoparticles with discrete sizes. Self-assembled nano-sized particulate vaccines have been shown to 
possess many advantages, including enhanced stimulation of immune responses owing to improved 
presentation of multivalent antigens on the surface of the particle and increased in vitro stability [5]. 
Furthermore, particle formation has been shown to enhance receptor accessibility to the targeting 
mannose moieties [9]. In this study, DLS measurements of vaccine constructs 13-15 showed a size 
range of 150 ± 50 nm with a polydispersity index (PDI) of 0.4-0.6 (Table 3-5).  
Particles in the vaccine formulations have size range of <5µm similar to pathogen characteristics and 
their uptake by APCs is proved to be via receptor mediated or receptor independent pathways. Self-
assembly of peptide particles is possible for a size range of nano to micron [259, 260]. Peptide 
assembly happens by presence of hydrophilic and hydrophobic amino acids in a peptide structure. 
These hydrophilic and hydrophobic forces can create a network between the peptides and form 
particulates [261]. Monomers participate in formation of a self-assembled particles and these particles 
can contain secondary structures like micelles [259]. If positive or negative charge forces are present 
between particles multilayer formations can be created and more than 50 constructs can participate 
in formation of such multilayer formations [262]. 
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Table 3-5. DLS size measurements of vaccine constructs 13-18 
Vaccine construct Size (nm) PDI SD 
13 100.2 ± 25 0.37 0.069 
14 208.3 ± 25 0.43 0.129 
15 111.6 ± 25 0.59 0.072 
16 376 ± 25 0.22 0.142 
17 376.9 ± 25 0.46 0.019 
18 216 ± 25 0.286 0.029 
TEM imaging of these constructs showed a smaller size range (80 ± 50 nm, Figure 3-13A-C) which 
has been attributed to the drying step during sample preparation [263]. TEM of 13-15 showed a size 
range of 40 ± 10 nm (Figure 3-13D-F). This smaller size can be associated with the lower molecular 
weight of control peptides and the absence of lipids. However, DLS results showed a larger size range 
for control vaccine constructs 16-18, due to aggregations forming in water. 
 
Figure 3-13. TEM images of vaccine constructs 13-18. (A) 13, (B) 14, (C) 15, (D) 16, (E) 17, and 
(F) 18. The scale bar is 200 nm. 
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3.3 Conclusion 
 
O-mannosyl-serine acetyl protected building blocks (2) were successfully synthesised and two copies 
were included linearly into azido-functionalised peptides. Alanine units (0, 1 or 2) were included 
between these two mannose moieties using Fmoc SPPS. A fluorescent tag was included in the 
designed azido-functionalised mannosylated peptides (4-7) to allow for visualisation in in vitro 
studies. Synthesis of azido-functionalised mannosylated peptides was modified by changing the 
lysine side chain protecting group from IvDde to Mtt, and as a result, a 10% improvement in the 
overall yield was achieved. Lipoamino acids containing 12 carbons in the alkyl chain were 
synthesised and two copies were incorporated into the alkyne functionalised OVA323-339 -branched 
peptide antigen 11. Click chemistry was used to join azido-functionalised (4-7) and alkyne-
functionalised peptides (11-12) to obtain a final library of vaccine constructs (13-18). The click 
reaction was monitored to the point where the final product (13-18) was achieved and no further 
progress was observed in the reaction after 5 h. The final library of vaccine constructs was 
characterised for their size properties. DLS and TEM confirmed particle formation where a smaller 
particle size was observed for the control library (16-18) due to their smaller molecular weights. 
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4.1 Introduction 
 
APCs are specialised for presentation of an antigen to T cells (Chapter 1, Section 1-2, Figure 1-1) 
[264, 265]. It is known that for T cell activation, antigenic moieties are processed into peptides for 
further presentation to MHC I and II molecules. DCs and macrophages are cell populations present 
in splenocytes that have been the centre of cell targeting studies for vaccine development. Among 
APCs, DCs have the ability to uptake and process antigens and subsequently maturate as effective 
APCs with T cell (Th1, Th2, Th17, and Treg) activating properties [63, 266]. Activation and 
processing of antigenic moieties varies depending on the properties of the antigenic moiety (e.g. 
presence of targeting moieties such as glycosyl groups) and the presence of the adjuvant in the 
vaccine. These all affect the affinity towards the APC receptors by the antigen and a consequent 
immune response [63]. Thus, targeting antigens to specific receptors on the APCs is an appropriate 
method to enhance an immune response. The MR and some of the other C-type lectins have been 
identified on the surfaces of both macrophages and DCs and have been the subject of vaccine targeting 
strategies for many decades [128]. The presence of the large numbers of the MRs on the surface of 
macrophages and DCs is known to be evidence for their significant role in antigen presentation [192, 
267].  
 
The MR contains eight extracellular CRDs and the conformation of these CRDs has been shown to 
play an important role in the recognition of glycosylated ligands [25, 31, 268]. The structural 
properties of the MR CRDs have been studied extensively, but the relationship between the antigen 
and receptor binding and recognition, and the properties that preferentially target the antigen towards 
this receptor are lesser known [12, 269, 270].  
 
Glycosylation, in particular mannosylation, has been shown to be an effective method for the 
targeting of antigenic peptides or protein vaccines to the MR, increasing the vaccines antigenic 
potential by enhancing uptake and processing by APCs [13, 25, 271]. Although the exact binding 
requirements of the MR remain to be elucidated, studies aimed at targeting this receptor have reported 
that poly-mannan derivatives, mannosylated dendrimers, and compounds that mimic a dendritic 
branched structure, known as the cluster effect, were often found to be antigenic [12, 121, 216]. 
Furthermore, it was shown that branching, multimerisation, and the number of mannose moieties all 
affect receptor binding [12, 121, 216]. In 2008, Kowalczyk et al. showed that bis-mannose 
compounds that contained a PEG spacer were taken up by human monocytes better than mono-
mannosylated compounds. However, they also identified a mono-mannosylated compound that 
showed similar binding, suggesting that the incorporation of a second mannose group in the peptide 
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chain was not essential [77, 131]. Studies by Frison et al. showed that the linear arrangement of the 
MR’s CRD (Chapter 1, Section 1-3, Figure 1-3) led to specific and high affinity binding between 
the MR and synthetic compounds that contained di-mannose clusters and/or end-standing single 
mannose units [12, 121]. The MR has been shown to bind to mannosylated ligands with different 
branching and spacing arrangements in the presence of other functional groups. Nevertheless, the 
exact binding requirements of the MR have not been clearly defined [12, 269].  
 
This chapter presents an in vitro investigation into the effect the distance between the mannose units 
has on receptor-mediated binding and uptake by APCs. Here, a library of O-mannosylated 
lipopeptides that contain a linear arrangement of mannose and the model CD4+ antigen and OVA323-
339 (Chapter 3, Figure 3-1) were synthesised as detailed in Chapter 3.  
 
In the present work, these vaccine constructs were designed to mimic the linear arrangement and O-
linked properties of glycoconjugates found in nature [272]. Studies on structural properties of such 
O-glycans was discussed in Chapter 1, Section 1.6. Here, an alanine spacer was inserted between 
the mannose units to study the structural properties of the mannosylated vaccine in relation to APC 
uptake. The alanine spacer was chosen as previous studies had reported that the distance between the 
mannose groups played an important role in the uptake of mannosylated compounds through the MR 
on monocytes [12, 131, 269]. In a study by Kowalczyk et al., the optimal uptake of mannosylated 
compounds was achieved when three alanine amino acids were inserted between the linearly attached 
O-mannose groups compared with structures with greater numbers of spacers between the mannosyl 
groups [130]. In addition, two mannose units have been included in each vaccine construct in this 
study, as previous studies have shown that synthetic constructs that contained two mannose units 
could target the MR with high affinity confirmed by a higher level of uptake [12, 77, 206, 269]. 
Additionally, shorter spacers between the mannose units have been shown to be effective at targeting 
the MR [206]. Therefore, this aspect was investigated relative to the presence of lipids and a peptide 
antigen, which are known to enhance self-adjuvanting properties and induce particulate formation [9, 
12, 206]. Amphiphillic moieties have been shown to enhance nanoparticle formation and the change 
in nanoparticle size was found to affect uptake [214].  
 
CD11c+ (a common discriminator of spleen-derived DCs from other APCs found in the spleen) and 
F4/80+ (a common discriminator of spleen-derived macrophages from other APCs found in the 
spleen) cells from splenocytes were used to study the uptake of the vaccine constructs in vitro using 
confocal microscopy and flow cytometry. Further, SPR was optimised and used to study the specific 
binding properties and in vitro T cell proliferation was studied as a preliminary indication of 
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immunomodulatory properties of vaccine constructs. The studies presented here are based on the in 
vitro targeting of the mannosylated lipopeptide vaccines 13-18 and their synthesis procedure is 
described in Chapter 3.   
 
4.2 Results and Discussion 
4.2.1 Flow cytometry cell uptake study 
 
DCs capture, process and present antigens to naive T cells. Antigen presentation by DCs develops in 
the context of MHC I and II, however, the resulting immune response, to a large extent, depends on 
the identity of the antigenic moiety [17]. Factors including the type of targeted receptor on the DCs 
and the presence of adjuvant on the delivered antigen can both affect the final immune response [273]. 
Spleen-isolated DCs are heterogeneous and two subsets of DCs are identified by their surface markers 
(subset 1: CD11c+, DEC-205+, CD24+, CD11b-, 33D1-, CD4-; and subset 2: CD11c+, DEC205-, 
CD24-, CD11b+, 33D1+, CD4-). However, both subsets are known to express CD11c [274]. CD11c+ 
DCs are commonly studied for their antigen uptake ability. In a study by Bond et al., it was shown 
that CD11c+ DCs had a higher ability of antigenic uptake compared with other dermal DCs. In their 
study, they compared fluorescently labelled OVA protein and dextran to track the ability of different 
human DCs in antigenic uptake [275]. They found that CD11c+ DCs had a significantly higher ability 
in the uptake of fluorescently labelled OVA and dextran, when compared to other subsets of DCs 
from skin [275] . In another study by Narenderan et al., it was shown that DCs were a better target 
for mannosylated-antigenic uptake than peripheral monocytes [276]. Here, they found that 
mannosylation of proinsulin antigen did not improve T cell proliferation but was able to increase the 
uptake of autoimmune antigens. F4/80 is known to be highly expressed on tissue macrophages, 
including macrophages found in cells isolated from the spleen [277]. Hu et al. chose the F4/80+ subset 
of macrophages to study the T cell activation by macrophages. They found that macrophages have 
different subsets and their T cell activation ability varies due to their different surface receptors [278]. 
Overall these studies indicate the importance of CD11c+ and F4/80+ cells and the vital role they have 
in antigen uptake for advancing vaccine development. 
 
In vitro uptake and targeting of the mannosylated vaccine constructs (13-18, Chapter 3, Figure 3-1) 
were tested using two subsets of APCs (CD11c+ DCs and F4/80+ macrophages) isolated from the 
spleens of naive C57BL/6 mice (Figure 4-1). Cells were isolated as a mixed population of APCs, 
including macrophages and DCs, using a standard protocol [215] and were used immediately. 
Fluorescently-labelled vaccine constructs (0.5 µM) dissolved in PBS were added to the isolated cells 
and allowed to incubate for 4 h before washing the cells to remove any excess or non-specifically 
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bound compound. The washing step in this procedure is known to remove unbound peptides from the 
surface of the cells [161, 279]. The vaccine constructs were labelled with a fluorescent tag (FAM) to 
facilitate cell tracking. Cells were then stained with anti-CD11c and anti-F4/80 antibodies which 
bound to cells that contained CD11c and F4/80 markers. CD11c is present in high levels on DCs and 
F4/80 on macrophages [280, 281]. Dextran has been shown to bind strongly to the MR and was used 
as a positive control for both subsets of cells [282]. The concentration of each vaccine construct was 
optimised (data shown in Appendix 15).  
 
Changing the distance between the mannose moieties from no alanine units (13, Figure 4-1) to two 
alanine units (15, Figure 4-1) resulted in a negligible difference in uptake by both CD11c+ and F4/80+ 
cells (Figures 4-1A and 4-11B, respectively). Results also confirmed a higher level of uptake by 13-
16 in CD11c+ positive cells compared to F4/80+ cells. Here, vaccine constructs 16-18 are controls 
designed with only lipids (16), only mannose moieties (17) and no mannose or lipids (18). However, 
a significantly lower binding was observed in both subsets of cells for the control peptides 16-18 that 
contained no lipid and/or no mannose moieties (Figures 4-1A and B).  
 
Mannan is a known ligand of the MR [216]. Mannan is a polycarbohydrate with the ability to block 
the uptake of the vaccine constructs by saturating the receptors involved in their uptake [283, 284]. 
A mannan inhibition study was performed to confirm receptor-mediated uptake of the constructs on 
the surface of CD11c+ and F4/80+ cells. Following pre-incubation of the cells with mannan (1 mg/ml), 
the cells were incubated for 4 h with the vaccine constructs (13-18, 0.5 µM) before separately washing 
and staining the CD11c+ or F4/80+ cells (Figure 4-1).  
 
Flow cytometry results showed a significant reduction in the uptake/binding for all constructs when 
the cells were pre-incubated with mannan (Figure 4-1), implying that mannan specifically blocked 
the receptor-mediated uptake of these compounds. A significant difference in mannan inhibition 
studies was observed in the binding and/or uptake of constructs 13-15 in both CD11c+ and F4/80+ 
cells with increased binding observed when a longer spacer was employed between the mannose 
units. However, no significant difference was observed for constructs 13-15 in the binding and uptake 
studies in the absence of mannan (Figure 4-1). From these lipidated and mannosylated constructs 
(Figure 4-1), binding inhibition in the presence of mannan was higher for construct 15 compared with 
constructs 13 and 14. It could only be concluded that 15 is the best mimic of mannan for CD11c+ and 
F4/80+ cells (15, Figures 4-1A and B). Interestingly, even the constructs that contained no mannose 
units in their structure (16 and 18) had a lower uptake in the competition assay, indicating that the 
peptide and/or lipids have non-specific binding and/or uptake into these cells (Figure 4-1), although 
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in the case of 14, this difference was not significant. It has been shown that lipids can target and bind 
the CRDs on the CLRs [285]. Unlike 15 (lipids present in the structure) whose high binding ability 
was significantly inhibited in the presence of mannan, the binding of 17 (no lipids) was not inhibited 
(Figures 4-1A and 4-1B). This indicated that lipids, and not the antigen, directed the binding and 
uptake of the tested cell lines. 
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Figure 4-1. In vitro uptake/binding and mannan competition study, Vaccine constructs 13-18 (0.5 
µM) and control constructs 16-18 (0.5 µM) were assessed in (A) CD11c+ and (B) F4/80+ cells for 
uptake in the presence or absence of mannan (construct + mannan [1 mg/ml] vs construct alone). 
Dextran-FITC (1 mg/ml) was the positive control. PBS was the negative control. The study was 
performed in triplicate and the results were analysed using one-way ANOVA with mean ± SD from 
three independent experiments, p<0.0001. 
 
The results showed that the uptake of vaccine constructs that contained both mannose and lipid 
moieties (13-15, Figure 4-1) was higher than that of constructs that contained no lipids (17) or no 
lipid and mannose moieties (18). However, 16 that did not have any mannose units in its structure 
had a higher uptake than 13 or 14. The addition of hydrophobic moieties (such as lipids) has been 
shown to increase non-specific binding to the surface of cells, which could account for the higher 
level of cell-binding observed for 16 (Figure 4-1) [255]. The non-specific binding observed for 
peptide 16 could be associated with the affinity of the vaccine candidates for non-CLRs (including 
TLRs) as previous studies on lipidated peptides have confirmed this finding [178]. The mannan 
inhibition study indicated that receptor-mediated uptake through a mannan-inhibited receptor (e.g. 
MR) is likely. However, as uptake was not completely inhibited, other receptors and mechanisms 
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contributed to the uptake [286]. Overall, results from this study suggest that both mannose and lipids 
play important roles in the uptake of vaccine constructs, with both structural features affecting 
receptor-mediated uptake.   
 
4.2.2 Confocal imaging 
 
Confocal imaging was used to confirm the uptake and/or binding of the vaccine constructs to F4/80+ 
cells. Constructs 13, 15 and 16 (0.5 µM) were incubated with cells for 4 h followed by staining with 
an anti-F4/80 antibody. The cell nucleus was stained with Hoechst stain. Mannan-FITC was used to 
show the association of mannan to the cell-surface receptors (Figure 4-2A). 
The results showed that construct 13 was localised both at the periphery of the cell and inside the cell, 
shown as punctate granules in the cytoplasm (Figure 4-2B). This was consistent for vaccine construct 
15 (Figure 4-2D). Construct 16 showed primarily peripheral localisation that confirmed non-specific 
binding to the surface of the cells hypothesised in the flow cytometry uptake results (Figure 4-2E). 
To confirm receptor-mediated uptake, cells were pre-incubated with mannan (20 times excess to 
make sure that all lectin receptors were saturated as per previous studies done on mannan inhibition) 
before incubation with 13 [283]. Pre-incubation significantly reduced the uptake with the compound 
predominantly localised on the cells’ surface (Figure 4-2C). This correlated with the mannan 
competition assay results reported in Figure 4-1. Here, differences observed in the light emission by 
15 when compared to 13 can be associated to resolution limitations in confocal microscopy [287]. 
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Figure 4-2. Confocal images, F4/80+ cells (2×105) were incubated with vaccine constructs 13, 15 
and 16 (0.5 µM) in the presence or absence of mannan, with commercially available mannan-FITC 
as the positive control. Cells were plated on culture slides. FAM-labelled vaccine constructs (green) 
were added to the cells and incubated in the presence and absence of mannan for 4 h at 37°C. Nuclei 
were stained with Hoechst stain (blue). F4/80+ cells were identified with anti-F4/80 antibody (red). 
(A) mannan-FITC; (B) vaccine construct 13; (C) cells pre-incubated with mannan followed by 
addition of 13; (D) vaccine construct 15; (E) vaccine construct 16. Analysis was performed on a GE 
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DeltaVision Deconvolution confocal microscope at 60x using oil immersion, graphical scales 15µm 
and 5µm. 
 
 
 
4.2.3 OT-II splenocyte proliferation assay 
 
OVA-specific, αβ T cell receptor (T cell receptors that have αβ domain of T cell receptor) transgenic 
mice (OT-II mice) were used to investigate whether uptake of constructs 13-18 caused in vitro T cell 
proliferation. T cells obtained from OT-II mice spleens express transgenic OVA-specific αβ T cell 
receptors and are designed to recognise the OVA323–339 peptide fragment from the OVA antigen for a 
T cell dependant B cell activation [288]. When APCs take up and process antigenic peptides they 
present the antigenic components through MHC molecules. T cell activation occurs when they 
interact with these antigenic fragments. This activation results in cytokine production and T cell 
proliferation [245]. A successfully designed immunological vaccine requires being uptaken and 
further presented to T cells by APCs. In this in vitro assay the proliferation of OT-II mice spleen T 
cells was measured in response to different dilutions of constructs 13-18 (Figure 4-3).  
 
Results showed that all constructs had higher proliferation properties compared to the OVA323-339 
peptide, with constructs 13, 15 and 16 stimulating the highest effector T cell proliferation (Figure 4-
3). This confirmed the previous results where constructs 13-16 had the highest receptor-mediated 
uptake (Figure 4-1). Here, it was further concluded that constructs 13-15 had a tendency of showing 
differences in T cell stimulation due to their structural differences. However, T cell proliferation 
seems to be independent of the presence of mannosyl moieties and probable structural conformations 
had played a more important role on the T cell activation. There have been many recent studies that 
have indicated that although the presence of mannosyl moieties could increase the uptake in APCs, 
T cell activation is mostly dependant on the antigen type and the adjuvanting moiety [9]. 
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Figure 4-3. In vitro OT-II spleen proliferation assay. Different dilutions of constructs 13-18 and 
control peptide, OVA323-339 were compared for their ability to stimulate T cell proliferation (5×10
5 
cells per well). PBS was used as the negative control. The study was performed in triplicate and the 
results were analysed with mean ± SD from three independent experiments, p < 0.0001. 
 
 
4.2.4 Real-time surface plasmon resonance (SPR) 
 
SPR is a technology developed to study molecular interactions. Measuring kinetic constants by 
optical biosensors based on molecular interactions is a common valid method applied in many studies 
[287, 289, 290]. Among these presented studies, Biacore appears to be the most widely used 
instrument to assess binding affinity of variable constructs [287]. 
The SPR method used in the Biacore machine includes immobilisation of a ligand (in this case, the 
mannose receptor) onto a chip surface, then passing an analyte (in this instance the vaccine constructs) 
over this chip in which the resulting interactions and bindings can be studied with a high level of 
detectability. SPR answers many questions, including the specificity of molecular interactions 
identified through the extent of binding, and it also provides the affinity of an interaction through 
time response curve results (Figure 4-4).  
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Figure 4-4. Schematic diagram of SPR performance on a CM-5 chip. CM-5 chips have a dextran 
surface that enables ligand (the mannose receptor in this study) immobilisation on the surface. The 
analyte (vaccine constructs in this study) are allowed to pass over the ligand and the resulting 
interaction and/or binding causes a change in the reflected light from the gold layer on the chip’s 
surface (below the dextran). The optical detection unit converts changes in this reflected light to a 
readable time-response sensogram. The light source used is plain polarised light. 
 
The advantage of SPR compared to some of the other methods available (e.g. ELISA) for ligand 
binding interactions, includes having less steps and faster results, however, experimental execution 
can sometimes be a challenge [291]. SPR is based on changes in the refractive index of a gold plate 
due to surface absorption or desorption (Figure 4-4). Here, changes in the electromagnetic properties 
of the metal surface allow evanescent wave absorption. Light wave coupling to the surface is the 
method used in a Biacore machine for measuring the angle of light that strikes the surface and 
resonance occurs. This method is called resonant wavelength SPR [292]. Here reflected light from a 
metal surface gives a graph (sensogram) that can be analysed for the binding properties of the analyte 
with ligand depending on the intensity of the reflected light. A sensogram is based on the level of 
interaction response unit (RU) against time. Analysis of this SPR sensogram provides information on 
the binding affinity (KD) of an analyte to an immobilised ligand on the surface of the chip [292]. The 
following sections describe the method development studies performed in this study to investigate 
the interaction of the vaccine constructs with the mannose receptor using Biacore SPR technology, 
and the results from this investigation. 
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4.2.4.1 Method development 
 
SPR was performed on a BIAcore 3000 system. Here, three major steps were used to measure the 
binding affinity of the vaccine constructs to the receptor bound to the chip’s surface. Step 1: 
immobilisation method used to bind the MR to the chip’s surface; step 2: surface performance was 
used to check receptor binding viability and regeneration scouting was performed to find the best 
condition for reviving the receptor after each binding; and step 3: affinity measurements were 
performed to measure binding affinity of vaccine constructs 13-18 (Figure 4-5).  
 
Figure 4-5. Method development steps. Three steps were taken for method development to ensure 
accurate measurement of the vaccine constructs to the receptor. Step 1: the MR (ligand) is 
immobilised on the chip’s surface; step 2: surface performance and regeneration scouting are 
performed to investigate receptor viability and regeneration condition; and step 3: kinetics and affinity 
measurements are performed to measure binding affinity of vaccine constructs 13-18 (Chapter 3, 
Section 3.2.4, Figure 3-11). 
 
4.2.4.1.1 Step 1: immobilisation 
 
Recombinant human macrophage mannose receptor (MMR, Catalogue number 2534-MR/CF) was 
immobilised on a CM-5 research grade sensor chip containing a carboxymethylated dextran surface 
using a standard amino-coupling method (Figure 4-6).  Running buffer used in this experiment 
consisted of HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 10 mM), CaCl2 (1 mM), 
MgCl2 (1 mM), NaCl2 (150 mM) and 0.005 % surfactant P20 all in deionized water at pH 7.5. The 
receptor was dissolved in sodium acetate buffer (20 µg/ml) and immobilised at 10 µl/min for 7 min 
on a flow cell. Gustafson et al. found acetate buffer (pH 4.5, 10mM) to be a suitable buffer for running 
the MR [293]. In general, the pH of the immobilisation buffer should be low enough to ensure 
electrostatic adsorption of the ligand (here the MR) onto the chip’s surface is achieved [294]. In this 
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reaction, the primary amino-groups on the recombinant MR protein are covalently bound to the 
carboxyl groups on the dextran-coated chip (Figure 4-6).  
 
Figure 4-6. Amine coupling of the MR onto the CM-5 chip. Free carboxylic groups on the dextran-
coated CM-5 chip are pre-activated using EDC and NHS (these two provide crosslinking ability by 
activating the carboxyl groups) to enable covalent binding of the ligand (MR) through the ligands 
free NH2 groups.  
 
The immobilisation method consisted of a binding scouting stage (Figure 4-7A) where the Biacore 
instrument measured the binding ability of the receptor to the dextran surface on the chip without 
preliminary activation (Figure 4-7A). The second stage was removal of bound receptors with a short 
injection of ethanolamine (Figure 4-7B). The third stage was surface activation with NHS:EDC at a 
1:1 ratio (Figure 4-7C) followed by the fourth stage which was a receptor injection for achieving the 
desired binding level which here is about 2000 RU. Finally, the un-functionalised active groups from 
dextran were deactivated using ethanolamine (20 µl/min) for 7 min (Figure 4-7D). The amount of 
binding of the MR to the chip was calculated by subtracting the baseline at the end of cycle (Figure4-
7F) from the starting baseline.  
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Figure 4-7. Mannose receptor flow cell immobilisation trace. (A) The MR dissolved in acetate 
buffer is run over the surface of the chip without pre-activation to scout the level of binding affinity 
the receptor has for the un-activated dextran ; (B) a solution of ethanolamine is run over the chip’s 
surface to remove any unbound MR from step (A); (C) the dextran surface of the chip is activated 
with a solution of NHS:EDC; (D1-3) the MR dissolved in acetate buffer is run over the surface of the 
pre-activated chip in three pulses to reach the desired level of binding (in this instance it is 2000 RU); 
(E) ethanolamine is run over the chip to remove any excess MR that is not chemically bound from 
the previous step; and (F) the actual level of MR immobilisation is calculated and compared to the 
starting baseline level (1850 RU). Letters ‘s’ and ‘e’ signify the start and end of each injection on the 
machine, respectively. 
 
A reference flow cell was then activated using NHS:EDC but the surface was blocked using 
ethanolamine without any receptor binding (Figure 4-8). For each SPR cycle, two flow cells 
(reference flow cell and MR flow cell) were used concurrently to ensure that during the affinity 
measurements the results were not affected by non-specifically bound analyte found in the buffers, 
and that the results could be normalised between runs. This normalisation was performed through the 
deduction of results obtained in the reference flow cell (without the MR) from the MR flow cell 
(containing the MR), which are presented as the affinity results in this study. 
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Figure 4-8. Reference flow cell immobilisation trace. (A) The dextran surface on the CM-5 chip is 
activated using a solution of NHS:EDC, and (B) a solution of ethanolamine is run over the chip’s 
surface to block the activated sites. The treated reference flow cell is used as a reference flow cell to 
normalise the results from the mannose receptor (MR) flow cell. Letters‘s’ and ‘e’ signify the start 
and end of each injection on the machine, respectively. 
 
4.2.4.1.2 Step 2: Surface performance and regeneration optimization 
 
A general SPR sensogram consists of (A) a starting baseline, (B) binding/association, (C) 
dissociation, (D) regeneration, and (E) final baseline as shown in Figure 4-9. 
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Figure 4-9. Schematic trace of a surface performance resonance sensogram. (A) starting baseline 
showing the flow of the running buffer; (B) binding response caused by binding of an analyte to the 
immobilised ligand (here mannose receptor); (C) dissociation of the analyte from the ligand attributed 
to a change in the running buffer; (D) regeneration of the ligands surface (removal of all the analyte) 
by changing the conditions of the buffer (acidic, basic, ionic); and (E) final baseline following 
regeneration to ensure it is the same as the starting baseline observed in step (A). 
 
Here, a starting baseline is identified by exposing the chip to the running buffer and ensuring no 
binding or association is observed (Figure 4-9A). The analyte dissolved in the running buffer is then 
run over the bound ligand to measure binding and affinity (Figure 4-9B). It is important to dissolve 
the analyte in running buffer that is the same as the buffer that runs over the flow cells, since 
differences in the two can result in shifts in the sensogram [294]. Choice of running buffer is also 
very important since it has a role in keeping the immobilised receptor in natural condition [295]. After 
this association step (Figure 4-9B), the machine stops the analyte injection and the bound analyte 
starts to dissociate from the ligand in the presence of running buffer. This stage is called dissociation 
(Figure 4-9C). A regeneration step is required to detach the receptor from any bound analytes to 
enable the chip to be used a number of times for the same and/or different analyte samples (Figure 4-
9D). In this case, the baseline should return to the initial level (Figure 4-9E). Optimisation of the 
regeneration conditions is discussed by applying different regeneration solutions with different pHs 
as shown in Table 4-1.  
 
Table 4-1. Regeneration scouting solutions 
Regeneration Solution pH 
Sodium dodecyl sulfate (SDS) 
0.05% 
Ionic 
NaOH 10 mM 9.5 
Glycine 10mM 2.2 
 
A surface performance test is an essential method to understand the affinity of a targeting moiety. In 
this study, a surface performance test was performed using mannan (10 µg/ml), a known MR binding 
ligand, to check the receptor activity following MR immobilisation [296]. Regeneration is an 
important step in which the receptor is revived from previous binding to be prepared for a new binding 
cycle [297]. It is essential to have a baseline at the same level of the initial baseline following each 
regeneration, otherwise, the next measurement cycle is inconsistent and the results cannot be trusted 
[294]. Here, acidic, basic and ionic regeneration solutions were used to find the optimal conditions 
for regenerating the MR following MR binding to the constructs (Table 4-1).  
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As shown in Figure 4-10, following mannan (10 µg/ml) injection (Figure 4-10B) and surface 
regeneration with a 0.05% solution of SDS (Figure 4-10C), the end baseline level (Figure 4-10D) was 
compared to the start baseline (Figure 4-10A). The results show that mannan had a binding level of 
25 RU which, at the end point of the injection of mannan injection, only 50% of the total binding was 
lost in the dissociation phase (where only running buffer passes over the MR, Figure 4-9C) while 
regeneration with SDS (0.05%) was not able to cause any further dissociation. The importance of a 
successful regeneration solution is based on the fact that a change in the level of baseline is carried 
forward into the next cycle of measurement and thus having an unstable baseline affects the results 
[294]. 
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Figure 4-10. Regeneration scouting using sodium dodecyl sulfate (SDS 0.05%). An ionic solution 
of SDS was used as the regeneration solution to assess the MR affinity measurements. (A) the 
sensogram baseline from the continuous flow of a buffer at 40 µl/min; (B) mannan (10 µg/ml) binding 
response showing 25 RU; (C) regeneration of the MR by 0.05% SDS solution; (D) an increase in the 
baseline level is observed following regeneration showing that this was not a successful regeneration. 
Letters ‘s’ and ‘e’ signify the start and end of each injection by the machine, respectively. 
 
As shown in Figure 4-10, regeneration using SDS (0.05%) was unable to remove mannan, while 
regeneration using stronger basic conditions (NaOH, pH 9.5) caused a down drift in the baseline 
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(Figure 4-11) due to potential denaturation of the MR protein and loss of receptor activity (Figure 4-
12).  
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Figure 4-11. Regeneration scouting using NaOH. A solution of NaOH (pH 9.5) was used as the 
regeneration solution to assess the MR affinity measurements. (A) The sensogram baseline from the 
continuous flow of a buffer at 40 µl/min; (B) mannan (10 µg/ml) binding response showing 25 RU; 
(C) regeneration of the MR using 10 mM NaOH (pH 9.5) solution; (D) a 60 RU down shift in the 
baseline was observed due to unsuccessful regeneration. Letters ‘s’ and ‘e’ signify the start and end 
of each injection by the machine, respectively. 
 
Another attempt at regeneration scouting was performed using NaOH (10 mM, pH 9.5). A surface 
performance test was performed using mannan as the standard ligand for the MR (Figure 4-11) to 
check the surface activity of the MR protein. The observed results showed a lack of receptor activity, 
and this was potentially due to denaturation of the receptor protein due to the high pH conditions of 
regeneration with NaOH (Figure 4-12). Olson et al. have shown that conformational changes happen 
in the MR CRDs at pHs over 7.5, and they predicted no binding would occur at that pH, however, 
they did not perform SPR studies [298].  
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Figure 4-12. Lack of receptor activity following regeneration with NaOH. (A) No binding (an 
RU of less than 5) was observed when the MR bound to the chip was exposed to mannan (10 µg/ml). 
This correlates with previous results where the use of a high pH regeneration buffer (10 mM, NaOH, 
pH 9.5) was shown to change the baseline dramatically.  Letters ‘s’ and ‘e’ signify the start and end 
of each injection by the machine, respectively. Note. the sensogram regeneration stage is not shown. 
  
As a result of a lack of receptor activity, this particular flow cell could no longer be used and a new 
flow cell was loaded with the MR. Here, glycine buffer (10 mM, pH adjusted to 2.2 using HCl) was 
used for receptor regeneration following mannan binding. As observed in Figure 4-13, using this 
glycine buffer as the regeneration solution showed little change in the end baseline when compared 
to the start baseline (Figure 4-13). This confirmed a successful MR regeneration condition and was 
used throughout the rest of the study for regeneration of the receptor between individual runs. 
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Figure 4-13. Regeneration scouting using glycine buffer. A glycine buffer (10 mM, pH 2.2) was 
used as the regeneration solution to assess the MR affinity measurements. (A) The sensogram baseline 
from continuous flow of the buffer at 40 µl/min; (B) mannan (10 µg/ml) binding response showing 
25 RU; (C) regeneration of the MR using glycine buffer (10 mM, pH 2.2); (D) a small shift in the 
baseline (± 15 RU) was observed between the baseline at D and the baseline at A.  
It was concluded that due to the properties of the MR protein (180 KD, with multiple binding sites) 
an acidic pH is the best condition for regenerating the protein binding sites. Optimisation of the 
regeneration buffer has rarely been presented in studies but there are studies that have used different 
conditions on the MR. Gustafsson et al. reported studies on human recombinant MR using glycine 
buffer (pH 2.2) for receptor regeneration following affinity measurements using O-glycan proteins 
extracted from P. pastoris (yeast) [293]. In another study, Duverger et al. used domains 1–8 of the 
human macrophage MR to study the carbohydrate-lectin interaction. Here, a 0.3 M α-methyl 
mannoside was added to the running buffer and used as the regeneration solution [294]. 
 
4.2.4.1.3 Step 3: Binding affinity measurement 
 
The recombinant MR has 8 CRDs (Chapter 1, Section 1-3, Figure 1-3) that have been proven to 
have one (or two binding motifs) involved in the binding of carbohydrates [293]. The relative distance 
between the two mannose moieties in each construct and the presence (or absence) of lipids on the 
constructs affect the binding ability to this recombinant human macrophage MR protein. This was 
investigated and affinity measurements (KD) describe the binding of a ligand (MR) to an analyte 
(vaccine constructs 13-18).  
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A concentration dependant binding affinity measurement was carried out using mannan as a positive 
control for comparing the binding affinity of vaccine constructs 13-18 (Figure 4-15). Five 
concentrations (Figure 4-15A) were chosen to run affinity measurements where Rmax was reached 
at 600 µg/ml with 47 RU (Figure 4-15A).  To plot a steady state affinity graph it is necessary to run 
affinity measurements for different concentrations of mannan (Figure 4-15A). Additionally, as 
detailed above, a glycine buffer was used between each cycle, as this buffer was optimised and shown 
to give the best results for regeneration of the MR receptor.  
 
Binding interactions between the ligand (MR) and analyte (vaccine constructs) occur in two steps. In 
the first step known as ‘mass transfer’, the analyte diffuses from the buffer to the surface of the chip 
[299]. The second step is when the actual binding occurs. Mass transfer is one of the limiting factors 
in the application of SPR when the analyte concentration is too high and is known to affect the 
accuracy of affinity calculations. Our previous studies had shown large particulate formation by 
vaccine constructs 13-18, as a result possibility of mass transfer limitation was to be addressed. 
Furthermore, the flow rate has been shown to be an essential factor for determination of mass transfer. 
An ideal binding of an analyte to a ligand occurs when the magnitude of the binding does not change 
due to changes in the flow rate (called mass transfer). Here, a mass transfer study was performed 
(Figure 4-14). One concentration of mannan (500 µg/ml) was chosen to run at three different flow 
rates (5, 15 and 75 µl/min) to check if changes in the flow rate affected the response level (RU). As 
observed in Figure 4-14, there is no difference in the RU level between the three individual runs with 
different flow rates suggesting that the surface is not mass-transport limiting in the presence of 
mannan.  
 
Figure 4-14. Mass transfer study with mannan. A single concentration of mannan (500 µg/ml) at 
different flow rates (5, 15 and 75 µl/min) was exposed to the mannose receptor (MR) immobilised 
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on the CM-5 chip. No change was observed in the response level (RU) between each of these runs 
indicating that mass transfer is not a limiting factor in this study. 
 
To achieve an accurate binding affinity calculation, an equilibrium binding coefficient was performed 
on vaccine constructs 13-18 to determine the steady state binding to the MR protein (Figure 4-16) 
[217, 300]. Results are presented of the steady state binding level (Req) as a function of analyte 
concentration (Figure 4-15) and the KD. Mannan has a reported high binding affinity to the 
macrophage MR and has also been used as an activity control for binding assays on the recombinant 
human MR protein [293, 301]. In this study, mannan was used as the positive control and, for the first 
time using Biacore technology, was shown to have a strong KD of 0.15 µm with a R
2 value of 0.9943 
(Figure 4-16A). 
 
 
Figure 4-15. Binding affinity measurements for vaccine constructs 13-18. Surface plasmon 
resonance (SPR) analysis for the concentration-dependent binding of mannosylated constructs (13-
15) and experimental controls (16-18) with the immobilised recombinant human macrophage 
mannose receptor (MR) protein. Solutions of 13-18 (0.78-50 µM concentration range) and mannan 
(18.75–600 µg/ml) were prepared in running buffer (10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2,150 
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mM  NaCl, 0.005% P20; pH 7.4) and injected over a period of 1.5 min with a dissociation interval of 
8 min. The sensogram shows the plotted level of binding in the steady state (Req) against different 
concentrations of (A) the positive control mannan, and the vaccine constructs (B) 13, (C) 14, (D) 15, 
(E) 16, (F) 17, and (G) 18. R2 indicates the fit of the results to the curve with respect to concentration. 
The affinity constant (KD) was calculated using the response level at equilibrium (Req) using Equation 
1 (Chapter 2, Section 2.2.5).  
 
The results indicated that vaccine construct 14 (KD = 0.83, R
2 = 0.9950, Figure 4-16C) had the highest 
level of binding (Rmax value) and affinity (KD value) when compared with vaccine constructs 13-16 
which had binding affinities between 2.9 and 22.8 (Figures 4-15B, D-E). Here, the lower the KD
 the 
better the affinity of the construct to the receptor. Furthermore, the consistency of the results at 
varying concentrations was indicated by the R2 values with a good value being close to 1.00. These 
results suggest that the optimal affinity and binding was dependent upon the compounds’ structural 
properties. Here, construct 14, containing only one alanine spacer between the mannose moieties, was 
shown to have a similar range of particle size as constructs 13 and 15, 14 (Chapter 3, Section 3.2.4, 
Figure 3-11). Therefore, this increase in binding level can be associated with other factors, including 
conformation and structural properties (length of spacer, particle size, etc). 
 
Furthermore, construct 16 (control) containing only lipids in the structure (no mannose) also showed 
a very high KD
 of 128 (R2 = 0.9744, Figure 4-15G) (low affinity) when compared to constructs 13-
15. It is well known that the MR binds to the lipoarabinomannan structures, exogenous glycolipid 
antigen moieties found on the cell walls of mycobacteria [302]. The MR has also been shown to play 
an important role in the uptake of lipidic structures [303]   
 
Interestingly, these results indicate that even with an absence of mannose in the vaccine constructs, 
control compound 17, which contains two mannose moieties in close proximity and no lipids, had a 
strong affinity to the recombinant MR protein (Figure 4-15F). However, it can be observed from the 
Rmax that the level of binding is low (Figure 4-15F). Additionally, construct 18 containing no mannose 
and no lipids also showed a very low affinity (KD
 of 128 µM, R2 = 0.9744, Figure 4-15G). Overall, 
the poor level of binding obtained for constructs 16-18 suggests that for a better interaction with the 
MR, OVA-based vaccine constructs need to contain both mannosyl and lipidic moieties.  
 
Overall, interesting findings were obtained from this SPR study supporting observations made in the 
uptake and binding studies performed using flow cytometry and confocal microscopy experiments 
on DCs and macrophage isolated from the spleens of mice (Figures 4-1 and 4-2, respectively). A 
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tabulation of in vitro OT-II proliferation, KD and Rmax is presented in Appendix 17 showing the 
correlation between MR binding affinity, binding level and OT-II proliferation. 
 
 Both mannose and lipidic moieties appear to be necessary for the enhanced uptake and binding of 
these vaccine constructs to the MR. It was also confirmed that structural properties, such as the 
distance between the mannose units, play an important role in binding.  
 
4.3 Conclusion 
 
The presence of both mannose and lipids in the vaccine constructs was shown to increase their uptake 
in both DCs and macrophages. Furthermore, a receptor competition study by mannan confirmed that 
the uptake of vaccine constructs 13-16 was receptor mediated. Investigation into the ability of these 
vaccine constructs in T cell proliferation indicated that the presence of lipids in vaccine construct 16 
significantly increased T cell proliferation, while constructs 13 and 15 showed similar potency as 16 
in T cell activity. This indicated that the presence of a mannosyl moiety did not affect T cell 
proliferation properties. Further investigations were developed by SPR to assess the binding ability 
of vaccine constructs to the MR. Glycine buffer with pH 2.2 was chosen as the effective receptor 
regenerator. The SPR results indicated that all vaccine constructs had affinity for the MR while the 
highest affinity for the MR was observed for constructs 14 and 17. Overall, the results indicate that a 
higher affinity for the MR is correlated with lower T cell proliferation ability. 
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Chapter 5: In vivo Studies on Mannosylated Lipopeptide Vaccines 
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5.1 Introduction 
 
This chapter aims to investigate synthetic peptide-based subunit vaccines and the impact lipids and 
glycosylic (mannose) moieties have on T cell orientation (Figure 5-2). More specifically, the purpose 
of this study is to design vaccine constructs that bear lipidic and mannose moieties in a linear 
arrangement and investigate their impact on the immune response in a murine model. Particularly, 
the structural properties (effect of distance between each mannose unit, and the presence or absence 
of lipids and mannose) that affect the activation of different Th pathways through the study of T cell 
expansion and cytokine release are investigated.     
 
The OVA323-339 peptide epitope has long been studied for its immune activating properties [189, 304]. 
In this study, the vaccine constructs contained a double branched OVA323-339 epitope conjugated to 
mannose (for MR targeting) and lipids moieties (for self-adjuvanting properties) and the design, 
synthesis and in vitro analysis of these was outlined in Chapters 3-4. There have been some studies 
that have included a glycosylic or lipidic moiety on the OVA323-339 epitope, however, co-presence of 
both the targeting and adjuvanting moieties on a single peptide epitope has rarely been studied for 
their immune stimulating properties [93, 288, 305]. 
 
The innate immune system recognises pathogen cell walls through PRRs and responds through APCs. 
Activation of APCs causes the adaptive immune system to respond according to the type of threat by 
producing cytokines or cytotoxic T cells, as detailed in Chapter 1, Section 1-2. Here, development 
of constructs that could activate these responses can be valuable for a better understanding of immune 
pathways.  
 
Prophylactic and therapeutic vaccinations are successful methods for the elimination of infectious 
and cancerous cells with the ability to produce cellular or humoral responses [4, 188].  PRRs are the 
front line receptors activated during these infections and are primarily involved in the innate immune 
response (Chapter 1, Section 1-4, Figure 1-5). 
 
An innate immune response is activated through antigen uptake by DCs at the site of infection, 
including the epithelial layer, non-lymphoid tissues, etc [306]. DCs deliver the processed antigen to 
the lymph nodes where the antigen is then presented to naïve T cells. Here, T cell activation (called 
an adaptive immune response) involves both cellular and humoral responses (B cell activation) [306]. 
The T cell receptor (located on lymphocyte T cells) is recognised as a key receptor in T cell activation 
and immune responses produced by vaccine constructs. First line T cell activation is based on the 
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antigen presentation by APCs to MHC molecules. Thus, peptides and proteins with different targeting 
properties (glycosyl or lipidic moieties, or specific antigens) are uptaken by APCs and this can lead 
to MHC I or II activation and a consequent difference in the resulting T cell response (Figure 5-1) 
[307]. T cell activation is further recognised by Th polarisation into Th1 and Th2 T cells, and this 
polarisation is determined by cytokine secretion assays (Figure 5-1) [308]. Lectins with the ability to 
recognise carbohydrates moieties are important surface receptors on APCs [305]. Lectins play an 
important role in the selective recognition of carbohydrates and are essential in pathogen 
neutralisation [309].  
 
The MR, an important member of the lectin family, is known to recognise mannosylated components 
of pathogenic antigens and process these antigens into the lysosomal compartments in APCs. Here, 
the antigen is processed and can be presented through MHC I and MHC II molecules to CD8+ and 
CD4+ T cells for cellular or humoral responses (Figure 5-1) [9]. It is known that mannosylation of 
different epitopes, for the purpose of MR-targeted vaccine design and development, have been shown 
to be an effective method for studying both innate and adaptive immune responses [310, 311]. The 
MR on APCs is known to be involved in antigen uptake that is followed by antigen presentation 
through MHC molecules (Chapter 1, Section 1.4, Figure 1-5). In a study performed by Turner et al. 
it was shown that defects in the levels of MR in serum caused recurrent infections in children showing 
the important role of the MR in the control of infection.  [312]. Although there have been many 
studies indicating the link between the MR and innate immunity to adaptive immunity, it is not yet 
completely elucidated whether uptake by the MR can induce the desired pathways involved in T cell 
activation. For instance, antigen mannosylation has shown variable immune responses due to the 
cross-reaction with other PRRs, including TLRs and DC-SIGN [313]. Studies by Apostopolus et al. 
have indicated that mannan-bound peptides are internalised and presented by both MHC I and II 
molecules [314]. However, vaccines that are designed to target the MR can also overlap with these 
other lectin receptors (e.g. DC-SIGN). Also, TLRs can also be targeted due to presence of lipids on 
the vaccine structures (Figure 5-1) [315].  
 
The MR is also reported to have an important role in the elimination of endogenous (produced in the 
body) mannosylated peptides, causing a downstream increase of pro-inflammatory cytokines that are 
produced by Th1 (a subset of CD4+ T cells) activation [316]. In general, adding mannose moieties to 
a vaccine structure can be a selective tool to enhance the targeting of specific pathways in the immune 
system, and more studies on this combination can benefit future vaccine design and development.  
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Figure 5-1. Dendritic cell (DC) involved in antigen presentation and activation of CD4 and CD8 
T cells. Following antigen uptake by pattern recognition receptors (some mentioned in this thesis 
include: MR, DC-SIGN, TLRs), antigen presenting cells travel to the lymph nodes and present the 
processed antigen to CD4 and CD8 T cells by MHC II and MHC I, respectively.  CD4 or CD8 T cells 
are activated depending on the antigen type and the following pathways become activated by 
proliferation: (A) CD8 activation leading to direct antigen elimination through cytotoxic T cells or 
by inflammatory cytokines in the Th1 pathway (e.g. IL-2, IFN-γ); or (B) humoral pathway where 
CD4 activates Th2 which is followed by Th2 related interlukin (e.g. IL-6, IL-5, IL-4) production. 
Upon Th2 activation, B cells are activated and trigger antibody (IgG) production.  
 
Recent studies have shown lipidic moieties have lectin receptor targeting properties that aidg the 
immunogenicity of peptide antigens through the activation of TLRs [317]. TLRs have been widely 
studied for their ability to modulate immunestimulatory (adjuvanting) responses [318, 319]. Vaccine 
constructs that target TLRs have been shown to generate the desired Th1 response. A Th1 response 
is measured by the production of IL-2, INF-γ, macrophage activation and elimination of antigens 
[320]. On the other hand, a Th2 response is characterised by cytokine release and B cell activation 
(IL-4, 5, 13) (Figure 5-1) [320].  
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Addition of lipids to vaccines has been shown to induce self-adjuvanting properties through TLR 
recognition and/or activation [153, 162, 223]. Here, peptidoglycans attached to the synthetic lipid 
(Pam3/2Cys) have been shown to stimulate a Th2 response via TLR-2 activation [321]. 
Lipopolysaccharides extracted from the bacterial cell wall were able to stimulate TLR-4 and activate 
both Th1 and Th2 pathways [322]. Furthermore, lipid moieties incorporated into peptide-based 
vaccines have been shown to enhance the hydrophobic properties of the peptide epitope, aiding the 
epitopes stability and delivery to the site of action [158].  
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Figure 5-2. Vaccination groups (G)1-9 used in the in vivo study. G1-3 are test compounds used to 
study immune modulatory properties affected by the differences in the number of alanine spacers 
between the mannosyl moieties. G4-8 are controls used to compare a structure-activity relationship 
of no mannose (G4), no lipid (G5), and no mannose and no lipids (G6). A mixture of the vaccines’ 
structural components (OVA323-339, mannosyl and the lipid, G7) was used to compare with the 
chemically conjugated vaccine constructs (G1-G6). The positive control (G8) was OVA323-339 and 
CT, and the negative control was PBS (G9). All vaccine groups (G1-9) were dissolved in PBS (30 
µg/100 µl/per mouse) and injected subcutaneously (S.C.) at the tail base. Five mice were used per 
vaccine group. 
 
 
Vaccine constructs 13-18 used for the vaccination of mice (now called G1-6 where G stands for 
groups, Figure 5-2) were prepared as per Chapter 3. Here, G1-3 contained two C12 lipid moieties 
and two mannose units separated by 0 (G1), 1 (G2) or 2 (G3) alanine units between each mannose 
moiety (Figure 5-2). Experimental controls to check the structure-activity relationship included G4 
(no mannose), G5 (no lipid) and G6 (no mannose and lipid). In addition, a physical mixture of the 
OVA323-339 peptide with the mannose and lipid moieties (1:1:1) in PBS (G7) was used to study the 
relationship between a physical mixture of the vaccine components and the chemically-bound 
constructs (G1-G6). OVA323-339 pre-mixed with CT in PBS (G8) was used as the positive control, and 
PBS (G9) was used as a negative control (Figure 5-2). This mannosylated lipopeptide vaccine library 
is examined in in vivo immune pathways for T cell activation (OT-II study) and cytokine release 
(ICS/CBA studies) (Figure 5-3).  
 
5.2 Results and Discussion 
5.2.1 In vivo CD4 T-cell proliferation/activation 
 
Overall, there are two different pathways involved in CD4+ T cell activation, i) an antigen dependant 
pathway (Figure 5-1), and ii) an antigen independent pathway (Chapter 1, Section 1.2, Figure 1-1). 
The antigen dependant pathway occurs when the T cell receptor binds to antigens presented by MHC 
molecules [323]. The antigen-independent pathway, however, is a cytokine dependant pathway 
characterised by T cell activation through cytokine release and occurs in the early stages of an immune 
response when DCs encounter an antigenic moiety (Chapter 1, Section 1.2, Figure 1-1) [323]. It has 
been shown that only a negligible percentage of T cell activation occurs along the antigen-
independent pathway. A huge advantage of infections and vaccines successful in targeting the antigen 
through the antigen dependant pathway is the production of very specific antigen-related immune 
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responses [324, 325]. Antigen dependant CD4 T cell activation primarily occurs in secondary 
lymphoid organs (lymph nodes, spleen and skin). Within the lymph nodes, activation of CD4 occurs 
through antigen recognition presented on MHC II molecules. There are three professional APCs with 
the ability of MHC II presentation and subsequently CD4 activation: macrophages, DCs and B cells. 
Since macrophages are mostly located in non-lymphoid tissues that do not include the areas in which 
T cells exist, activation of APCs and MHC II presentation is unlikely to happen through this cell 
subset. Furthermore, studies with macrophage knock-out mice have shown a normal T cell activation 
[265, 323]. B cells on the other hand, have been shown to contribute to MHC II presentation. Early 
studies demonstrated that B cells lacking antigen-specific surface immunoglobulin were inefficient 
at taking up the antigen and presenting the subsequent antibody response. It was concluded that B 
cells required help from T cells to be efficient in antigen elimination [326].  
 
In this study, T cell proliferation was assessed in order to understand the T cell activation ability of 
vaccine constructs (G1-6) along with experimental controls (G7-9) upon APC presentation. In 
Chapter 4, Section 4.2.1, Figure 4-1 it was shown that the vaccine constructs 13-16 were 
successfully taken up through DCs and macrophages in a receptor mediated pathway in vitro meaning 
the designed vaccine constructs could potentially initiate an adoptive long-term immune response. 
Thus, further investigate was needed to determine whether these vaccines were able to activate T cells 
(OT-II T cells specific for OVA323-339
 epitope) in an in vivo murine model. Hence, OT-II (CD4, 
CD45.2+) cells were separated from transgenic mice (B6.Cg-Tg[TcraTcrb]425Cbn/J) to be adoptively 
transferred to C57BL/6 mice. OT-II cells are T cells with the ability to recognise and activate 
constructs containing the OVA323-339
 epitope. Upon adoptive transfer of OT-II cells to C57BL/6 mice, 
vaccination with vaccine constructs (Figure 5-2) was performed on C57BL/6 mice using S.C. 
injection on days 2, 21 and 42  (Figure 5-3). OT-II proliferation results and ELISA was performed on 
days 10, 31 and 52. Ten days post vaccination of G1-9, mice were sacrificed (day 63) and cytokine 
measurement assays including ICS and CBA, were performed ex vivo (Figure 5-3). Figure 5-3 shows 
the schematic in vivo study that is presented in this chapter. 
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Figure 5-3. Schematic diagram of the in vivo study. Vaccine groups (G1-9) were introduced to 
mice following the transfer of OT-II CD45.2+ T cells isolated from transgenic mice (B6.Cg-
Tg[TcraTcrb]425Cbn/J with OVA sensitive OT-II cells) to C57BL/6 mice. Mice were vaccinated on 
days 2, 21 and 42. Blood was taken on days 10, 31 and 52 post vaccination. OT-II read outs for flow 
cytometry and ELISA were performed 10 days post each vaccination. Mice were sacrificed on day 
63. ICS and CBA studies were performed on blood samples taken 21 days post dose 3 vaccination.  
 
5.2.1.1 Immunisation by mannosylated peptides resulted in an impaired T cell response 
 
OVA323-339 epitope is known to activate OVA specific T cells through MHC II molecules. It is also 
argued that this epitope also bears at least one B cell epitope (323-339), however, there is only one 
study that has mentioned the presence of the B cell epitope [327]. In a study by Sun et al., it was 
shown that 50% of the B cell response generated by the OVA protein was antibody specific to the 
OVA323-339 epitope [327]. It is well-established that upon antigen activation CD4
+ T cells differentiate 
into Th1 or Th2 T cells (Figure 5-1) [328]. This differentiation is mainly characterised by the type of 
cytokine produced. Th1 activation is known by the production of IFN-γ and IL-2, while Th2 
activation can be characterised by IL-4, 5 and 13 cytokines (Figure 5-1). Th2 is also involved in B 
cell activation (Figure 5-1). APCs activate a CD4 response that consequently activates a Th2 response 
which in turn activates a B-cell response, detected by IgG antibody production (Figure 5-1). 
 
As the vaccine structures (G1-6) contain the CD4 epitope (OVA 323-339), the in vivo ability of vaccine 
structures (G1-9) for a T cell activation proliferation was assessed. Here, OT-II proliferating cells are 
considered to be activated when T cells expressing CD45.2 increase in percentage over the total 
parental CD4+ T cells [329]. For this purpose, OT-II cells (CD45.2 CD4+ T cells) were purified and 
injected (I.V.) into C57BL/6 mice to study the T cell population. Vaccine constructs G1-6 were 
prepared by mixing 30 µg of each construct with 100 µl of PBS.  One day post OT-II T cell adoptive 
transfer, mice were immunised with the vaccine constructs (G1-9) (Figure 5-3). Vaccination was 
132 
 
performed 3 times at 21 days intervals. On days 10 (Figure 5-4A), 31 (Figure 5-4B) and 52 (Figure 
5-4C), blood was collected from the mouse tail and the proliferation of CD45.2+ OT-II cells was 
quantified using flow cytometry (Figure 5-4). Here, CD45.2+T cells (OT-II) were identified and their 
percentage over the total parental T cells was measured.  
 
 
 
Figure 5-4. OT-II CD45.2+ CD4+ T cells from OT-II mice do not proliferate in C57BL/6 mice 
upon vaccination with G1-9. CD45.2+ CD4+ OT-II T cells were purified and 200 µL of suspended 
cells (0.5×106 cells) was injected intravenously at the tail base to CD45.1+ C57BL/6 mice. The 
percentage of CD45.2+ OT-II cells within the CD4+ population was measured from tail blood taken 
at days 10, 31 and 42 using flow cytometry. Mean results (±SEM) from five individual mice per time 
point are shown, (A) at day 10, (B) at day 31, and (C) day 42. Unpaired t-Test was used to show the 
significance when p <0.05. Here, G8 is the positive control group vaccinated with OVA323-339 + 
cholera toxin and G9 is the negative control group vaccinated with PBS.  
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In the immune system CD4+ T cells have the role of maturation and also providing B cell activation. 
As a result, it is important for a successful vaccine to have the ability of CD4+ T cell activation to 
generate a subsequent antibody response [330]. Figure 5-4 shows the percentage of CD4+ CD45.2+ 
OT-II for each group of mice immunised with the vaccine constructs (G1-9). Here, an impaired T 
cell response was observed for vaccine groups G1-7 and no OT-II expansion was observed. As can 
be seen in Figure 5-4, the percentage of OT-II cells was significantly higher after the first vaccination 
dose (day 10) for G1 and G8 (positive control) when compared to the PBS group (Figure 5-4A), 
however, following the second (Figure 5-4B) and third (Figure 5-4C) vaccinations, no significant 
difference was observed between mice groups (G1-G7) and the PBS control group (G9). Here, a low 
percentage of CD4+ CD45.2+ OT-II cells (less than 1%) indicates a lack of antigen presentation and 
a consequent decrease in the number of CD4+ CD45.2+ OT-II cells. For a T cell proliferation and B 
cell activation, CD4 cells should recognise the CD4 epitope in the immunogen, however, sometimes 
epitope suppression occurs and can cause a non-detectable T cell proliferation due to tolerance to the 
epitope [330, 331].  
 
Further, the observed reduction of the proliferation responses, associated with a diminishing 
percentage of CD4+ CD45.2+ OT-II cells post vaccination, could be caused by a lack of antigen 
recognition or presentation in an in vivo model as was reported by Trépanier et al. [332]. Other factors 
also play a role in this observed decline of the CD4+ CD45.2+ OT-II cell population. One possible 
explanation for a lack of OT-II proliferation might be that significant proliferations might have had 
happened at earlier time points than a week, for example, at days 3 or 4 post vaccination [246]. 
Simerska et al. reported OT-II proliferation 4-7 days after vaccination by LCPs containing the 
OVA323-339 epitope [246]. These results could have been better observed at an earlier time point after 
vaccination, due to possible proliferation that might have occurred at earlier time points rather than 
10 days after vaccination. 
 
Another explanation for the diminishing percentage of CD4+ CD45.2+ OT-II cells is associated with 
a lack of migratory properties of APCs to the lymph nodes (where the antigen is presented to the T 
cells), which caused a reduction in the number of OT-II cells and subsequently lack of T cell 
activation. This has been reported by Mirenda et al. [333]. They reported that partial T cell activation 
can cause T cell unresponsiveness (anergic T cells) due to the defects caused on the T cells migratory 
ability [333, 334].  
 
Further, OT-II proliferation has been shown to affect Th1 polarisation, and only a completely 
polarised Th1 can affect inflammation [335]. The results presented in Figure 5-4 show that 
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vaccination with the vaccine constructs (G1-G6) stops the proliferation and differentiation stage in 
OT-II cells. This lack of OT-II activation was previously reported to be a result of mannosylation, 
where mannosylation has been shown to inhibit T cells from recognising antigenic moieties [335]. 
However, the irresponsiveness of the T cells was not observed in in vitro studies performed on 
splenocytes for the CD4+OT-II T cell activation proliferation (detailed in Chapter 4, Section 4.2.3). 
This in vitro proliferation study showed a significant increase in effective CD4 proliferation response 
for constructs G1-G4 when compared with the OVA3232-339 peptide alone. These observations are in 
line with previous reports on the decreased in vivo T cell response despite increased in vitro T cell 
proliferation by mannosylated antigenic peptides [311, 335].  
 
 
5.2.1.2 CD62L precursor of memory T cell 
 
CD 62L is from the family of L selectin proteins expressed on the surface of memory T cells [336]. 
Previous studies have demonstrated that memory T cells express low amounts of CD62L (CD62Llow)  
on their surface. CD62Lhi T cells are referred to as “central memory” T cells, while CD62Llow T cells 
are referred to as “effector” memory T cells [337]. CD62L positive T cells are activated in the lymph 
node by APCs. In this process, CD62L is cleaved by enzymes including disintegrin and 
metalloprotease [338]. Studies have shown that CD62L shedding plays an important role in T cell 
activation in the lymph nodes. Further, it is confirmed that although CD62L is present on memory T 
cells its shedding is not essential for the production of memory T cells or T cell immigration to the 
infection site, thus, the lack of shedding can affect the viral elimination effect [339]. 
 
In this study, measurement of the percentage of CD4+CD62Llow T cells was performed with OT-II 
readout flow cytometry study at time points mentioned in Figure 5-4 (days 10, 31 and 52). As can be 
seen in Figure 5-5, the results only showed a significant increase (** , p <0.008) in the percentage of 
CD4+CD62Llow cells (of total CD4+ T cells) for G8 (positive control) when compared to G9 (negative 
control) that was consistent after the second (Figure 5-5B, day 31) and third vaccinations (Figure 5-
5C, day 52). It can be observed that following the final vaccination the OT-II readout from day 52, 
G7 had the highest percentage of CD4+CD62Llow proliferation (**, p <0.008) compared with the 
vaccination groups G1-6 which did not show significance when compared to the PBS control group 
(G9). This indicated that G7 contained unattached moieties of mannose, lipid and OVA323-339. This 
is consistent with a previous study by Sun et al. where it was demonstrated that OVA protein 
conjugated to CT had failed to induce a T cell proliferation/activation; they showed that the results 
were weaker when OVA323-339+ CT was injected [340]. 
135 
 
 
 
Figure 5-5. Percentage of CD62llow CD4+ parental T cells. Vaccine constructs G1-G9 were 
compared by percentage (%) of CD62llow CD4+ parental T cells following three vaccinations on days 
10 (A), 31 (B) and 52 (C). Mean results (±SEM) from 5 individual mice groups are shown. Unpaired 
t-test was used to show significance when p <0.05. Here, G8 is the positive control group vaccinated 
with OVA323-339 + CT and G9 is the negative control group vaccinated with PBS.  
 
 
All vaccinated groups (G1-G6, Figure 5-5) showed no increase in the percentage of CD62LlowCD4+ 
following the second (Figure 5-5B) and third (Figure 5-5C) vaccinations, and the results were not 
significant. Following the third vaccination, all groups except G7 failed to increase the percentage of 
CD62LlowCD4+ when compared to the PBS group (G9). Overall, these results suggest that lipidic and 
mannosyl moieties may perform better for a memory T cell response only when are physically mixed 
together (G7) (Figure 5-5). Overall, the mannosylated lipopetide vaccines were not able to change 
their percentage of CD62llow CD4+ parental T cells. A lack OT-II in vivo proliferation/activation by 
mannosylated peptides (PLP139-151)  was also observed in a study by Kel et al.[341]. 
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5.2.2 Th activation pathway and cytokine release 
 
Vaccine constructs G1-G9 were screened for their ability to induce cytokine production by CD4+ 
cells in vaccinated C57BL/6 mice 11 days after the final vaccination (day 63). The study of cytokines 
released was performed to help clarify the Th pathway(s) involved in an immune response by these 
vaccine constructs. Both subsets of CD4+ cells, Th1 and Th2, are necessary components of a 
successful long-term immune response, and hence study of the relation between structural properties 
of vaccine constructs and the consequent activated immune pathway are important aspects of vaccine 
development [342]. To enable this part of the study, ICS (Chapter 2, Section 2.3.6) and CBA 
(Chapter 2, Section 2.3.7) assays were used to measure post vaccination cytokine production. 
Development of techniques including ICS and CBA has provided an ability to investigate the specific 
pathways that vaccines activate. It has been established that upon activation of CD4+ T cells, Th1 and 
Th2 cells are differentiated (Figure 5-1). Here, Th1 is responsible for the production of IFN-γ, TNF 
and IL-2, while Th2 is responsible for the production of IL-4, IL-5, IL6, IL-10 and IL-13 (Table 5-1) 
[343, 344].  
 
Table 5-1. Essential cytokines of Th1 and Th2 [345] 
Th1 
IFN- Activates cytotoxic T cells 
IL-2 Promotes T cell development  
TNF Involved in protection and cure 
Th2 
IL-4 
Promotes T cell differentiation into Th2, regulates 
antibody production  
IL-5 Involved in humoral immunity against parasites 
IL-6 T cell and B cell activation and differentiation 
IL-10 Inhibits inflammatory cytokines (TNF) production 
IL-13 
Inhibits inflammatory cytokines (IFN- and IL-2) 
production 
 
 
T helpers (Th1 and Th2) are the most important cells in an adaptive immune response (Table 5-1) 
[307]. T helpers have been shown to activate B cells and enable production of antibodies or activation 
of cytotoxic T cells. T cells are activated by the markers on the surface of APCs which present 
antigens (Figure 5-1). Upon APCs’ antigen presentation to the T cells, T cell activation occurs through 
two separate recognition pathways, recognition of antigens presented by the MHC molecule and 
recognition of antigens along the APCs’ intracellular pathway. If a T cell receives only one of these 
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two signals it will progress along the apoptosis pathway and cannot be activated [307, 346]. Upon 
activation effector T cells then produce IL-2. IL-2 is a cytokine that after attaching to its receptor and 
activating intracellular signalling can cause further T cell proliferation (Figure 1-5).  
 
5.2.2.1 Cytokine release study by intra cellular staining 
 
Antigen-specific T cell responses and recognition of activated pathways (Th1, Th2) depends on the 
type of cytokines released. The ICS assay has been applied in immunological studies for the purposes 
of specifying the type of cytokines produced (Figure 5-6) [347]. 
 
 
Figure 5-6. Schematic process of intra cellular staining. This method is used to measure antigen-
specific cytokine release (e.g. IFN-γ, IL-2, TNF). (A) single cell suspensions from vaccination 
groups’ (G1-9) lymph nodes and spleen were stimulated by OVA323-339 peptide, PMA/ionomycin as 
experimental positive control and media only as experimental negative control, (B) cells were then 
incubated at 37°C and 5% CO2 for 3 days in the presence of protein transport inhibitor, (C) cells were 
then permeabilised and fixed, (D) cells were stained with IFN-, IL-2 and TNF antibodies. The 
expression of IFN-, IL-2 and TNF was analysed on the CD4+T cells subset using flow cytometry. 
 
The ICS (Figure 5-6) assay was performed (as detailed in Chapter 2, Section 2.3.6) to characterise 
antigen specific T cells immune-cytokine responses induced by vaccination groups G1-9. At day 63 
G1-9 mice were sacrificed (Figure 5-3) and two tests were performed. Lymph nodes and spleens were 
collected and in situ recall response was performed on the T cells in the presence of OVA323-339 
peptide. Also cells from lymph nodes and spleens were used to prepare single cell suspensions for 
cytokine release measurement. This was followed with excitation of splenic and lymphatic cells by 
the OVA323-339 peptide. A positive experimental control (PMA/ionomycin) and a negative 
experimental control (media only) were used to validate the experiment. Cells were then cultured for 
3 days in the presence of protein transport inhibitor, which results in accumulation of cytokine 
(detailed in Chapter 2, Section 2.3.6). Following this cells were permeabilised and fixed and anti-
cytokine antibodies added before flow cytometry analysis was performed (Figure 5-6). 
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The desired aim of preparing the vaccine constructs (G1-6) was an immune activity either through a 
T cell activation or cytokine release. Here, cytokines indicative of a CD4 Th1 response include IL-2, 
IFN-γ and TNF. Th1 cells are known to secrete IL-2, IFN-γ and TNF which have been shown to 
eliminate intra-cellular pathogens that have entered macrophage lysosomes by activating macrophage 
lysosomal killing [307]. IFN-γ is also known to prohibit IL-4 production by blocking the activation 
of Th2 [343]. IL-4 is a cytokine involved in the up-regulation of the MR. This argument has already 
been proven by studies showing that IFN-γ affects MR mediated uptake of antigens [348]. 
 
 
Figure 5-7. Intra cellular staining studies on INF-, IL-2 and TNF expressing T cells following 
vaccination. Percentage of CD4 (A, B, C) and CD8 (D, E, F) T cells associated with IFN-, IL-2 and 
TNF upon in situ stimulation of draining lymph nodes and spleen cells (isolated 11 days post third 
vaccination with G1-G9) with the OVA323-339 peptide and PMA/ionomycin (experimental positive 
control). Results are normalised against the media per each mouse per group. Mean results (±SEM) 
from 5 individual mice per group are shown. Unpaired t-Test was used to show the significance when 
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p <0.05. Positive control is G8 vaccinated with OVA323-339 plus CT and negative control is G9 
vaccinated with PBS. 
 
The ICS assay (Figure 5-7) indicated CD4 and CD8 T cells were expressing antigen specific cytokines 
including INF-, IL-2 and TNF(Figure 5-7). Here, G4 had a significantly (*) higher CD4/IL-2 
production than G9 (negative PBS vaccinated group), while differences between G1-G3 were not 
significant for IL-2 production (Figure 5-7B).  In an study by Zhu et al., palmitoyl attached 
lipopeptides (herpes simplex virus type 1 peptide was used as the model antigen) could induce higher 
T cell related IL-2 production when compared with their control glycopeptide [175]. G1-G2 indicated 
significantly higher (*p <0.05) CD4/IFN-γ production than G9 which is an indicator of activation of 
the Th1 pathway as detailed by Bettahi et al. (Figure 5-7A) [349]. Bettahi et al. used glycol 
lipopeptides to vaccinate C57BL/6 mice and the results showed a significant antigen specific IFN- 
production in comparison with the negative PBS vaccinated mouse group [349]. G1 CD4 associated 
TNF production (Figure 5-7C) was also significantly higher than G9 (negative PBS group). G1’s 
ability to induce pathways involved in CD4/TNF and CD4/IFN- links this vaccination group to the 
Th1 activation pathway. A previous study by Braumuller et al. showed that combining TNF and IFN-
 permanently stopped cancer cells from growing [350]. By comparing the CD4 associated cytokine 
release (Figure 5-7) with T cell proliferation results, the significance in the OT-II cells proliferation 
by G1 when compared to the negative control, G9 (Figure 5-4A), was observed indicating activation 
of the pathway that results in production of IFNγ cytokine, which was consistent with the OT-II 
proliferation results (day 10, Figure 5-4A). An overview of the results (Figure 5-7) indicated a 
significant production of CD4 linked IL-2 and IFN-γ by G1 when compared to the negative control 
group (Figure 5-7A and B). G2, on the other hand, activated CD8+ linked INF- and TNF (Figure 5-
7D and F). Here, the difference between G1 (vaccinated with 13, 0 space between mannosyl groups 
in the structure) and G2 (vaccinated with 14, 1 space between mannosyl groups in the structure) is 
the number of alanine spacers. IL-2 and IFN-γ are mediators of CD8 activation and cellular response, 
where activation of CD8 (cellular response) may occur by the cross-presentation of antigens to MHC 
I molecules upon uptake by the MR [330]. G2’s level of CD8/IL-2 (Figure 5-7D) was significantly 
(*) higher than the control G9 group, indicating a cross-presentation of this vaccine group upon its 
high affinity to the MR as was indicated before in Chapter 4, Section 4.2.4. Here, G8 failed to show 
CD4 or CD8 linked IL-2, IFN- and TNF activation. In general, there are different observations for 
OVA+ CT; while some studies have shown a lack of T cell proliferation, others have indicated Th1 
and Th2 activated cytokine release following vaccination [327, 340, 351].  
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5.2.2.2 Inflammatory cytokine measurement 
 
It has been established that antigen mannosylation can enhance the pathways involved in antigen 
presentation to MHC II molecules [352]. Many studies have sought an antibody response through B 
cell activation with the help of CD4 that provides activation of Th2 cells. Upon T cell antigen specific 
activation, Th1 or Th2 pathways get activated (Figure 5-1) [344]. The advantage of Th2 activation is 
that it generates long-term memory immunity, compared with Th1 which gives an immediate cellular 
response [330]. However, an advantage of Th1 activation is its involvement in cytotoxicity enabling 
the elimination of a specific pathogen [307]. Thus, studies of cytokines involved in Th1 and Th2 
pathways requires detection of cytokines released by splenic and lymphatic cells following 
vaccination with, in this case, G1-9. In this study, the designed vaccine structures were assessed for 
their ability to produce a Th response and consequent cytokine production.  
 
The OVA3233-339 peptide has been previously studied and is known to have the ability of both Th1 and 
Th2 related cytokine release (IL-2, IL-4, IL-5 and IFN-) through OVA-specific CD4+ T cells 
extracted from BALB/c mice [353]. Here, the structural differences affecting cytokine secretion 
pertaining to both Th1 and Th2 pathways using CBA methodology were studied. CBA methodology 
is a useful technique to analyse small volumes of samples for several cytokines in a single well [354]. 
  
In this experiment, the supernatant (collected from the spleen and lymph node of a mouse) was 
combined with antibody-labelled microspheres (Figure 5-8A) that were designed to bind specifically 
to certain cytokines (listed in Table 5-2). Streptavidin–phycoerythrin bound to secondary antibodies 
was used for detection of the cytokines (Figure 5-8B). This was followed with washing to remove 
unwanted molecules (Figure 5-8C) (including non-specifically bound antibodies). Cytokine 
production was identified by fluorescence intensity on a flow cytometer (Figure 5-8D).  
 
 
Figure 5-8. Schematic of cytokine bead array measurement. (A) The fluorescent capture beads 
are conjugated with detection antibodies and are incubated with test samples containing cytokines 
and secondary antibodies to form (B) sandwich complexes. The sandwich complex is then (C) washed 
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followed by acquisition of sample data using (D flow cytometry. The sample results are generated in 
graphical and tabular format using the BD CBA analysis software. 
 
 
Results from this CBA study showed that application of vaccine structures bearing the OVA323-339 
epitope along with both mannose and lipidic moieties (G1-G2) activated pathways involved in the 
activation of Th1 (IL-2) and Th2 (IL-4, IL-5, IL-6, IL-10, IL-13) immune responses. G3 (which also 
contained the OVA323-339 epitope, mannose and lipids but had the longest distance between each 
mannose moiety) showed increased selectivity towards the Th2 pathway through the generation of 
cytokines, however, no IL-2 response was observed. Here, IL-2, as a pro-inflammatory cytokine, has 
been shown to play a role in the suppression of the MR whereas IL-4, an anti-inflammatory cytokine, 
has a role in the up-regulation of the MR [348]. Further, additional cytokines released through Th2 
activation (e.g. IL-13 and IL-10) were shown to up-regulate the MR [355]. This could increase uptake 
through the MR on APCs. It was previously shown (Chapter 4, section 4.2.4.1.3, Figure 4-16) that 
G2 had a high binding and affinity to the MR. 
 
Table 5-2. Cytokine bead array results presented as a heat map. Red cells indicate the strongest 
results while the green cells indicate the weakest results per cytokine for each vaccination group (G1-
G9).   
G IL2 IL4 IL5 IL6 IL10 IL12p70 IL13 TNF 
1 15.65 1.78 34.49 10.21 0.00 0.00 48.50 0.00 
2 8.87 2.89 15.44 14.98 21.71 0.00 6.36 0.00 
3 0.00 0.00 2.35 0.00 17.53 2.08 33.58 11.20 
4 6.28 0.00 5.88 20.68 12.76 9.85 0.00 0.00 
5 3.37 1.45 0.00 17.95 0.00 0.00 0.00 11.67 
6 4.28 0.00 1.36 0.00 17.04 0.00 0.00 0.00 
7 20.93 0.00 4.95 41.93 6.83 15.97 18.17 12.87 
8 2.28 0.00 0.00 0.00 0.00 20.00 0.00 0.00 
9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
 
By comparing the mannosylated (G1, G2 and G3) and non-mannosylated (G4 and G6) vaccine 
constructs, G1-G2 which were involved in the uptake by MR (indicated in Chapter 4, Section 4.2), 
activated production of IL-4, 5 and 13 (Table5-2). These three cytokines have been shown to be 
involved in a Th2 type immune response. Interestingly, G3 was the strongest in the level of Th2 
antigen specific cytokines measured in this study (highest level of IL-5 and 13, Table 5-2). However, 
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G1 and G2 were also able to activate Th1 due to IL-2 production (Table 5-2). Further, it can be 
postulated that factors affecting conformational properties of a vaccine structure (e.g. the number of 
alanine spacers between mannosyl moieties) could affect the Th actvation pathway. As can be seen, 
G1-G3 only varied by their number of alanine spacers but had different levels of cytokine production. 
The CBA results further showed that G4 with no mannose on the structure showed no IL-4 production 
but showed comparatively higher levels of IL-2, showing a tendency to activate the Th1 pathway 
(Table 5-2). The positive control G8 showed a high level of IL-2 and TNF (Table 5-2). Another study 
by Fabienne et al. showed that when OVA protein was injected subcutaneously it could generated 
cytokines related to the Th1 pathway [356]. In general, all vaccine constructs G1 and G2 and G4-8 
were able to induce cytokines related to Th1 pathway, however, G3 was more selective towards the 
Th2 pathway with no IL-2 production.   
 
TLRs 2 and 4 have been shown to be involved in binding to lipopolysaccharides on bacterial cell 
walls and consequently activating Th1 cytokines (including TNF and IL-12) resulting in varying 
levels of cytokines depending on the structural properties of the selected lipopolysaccharides [357]. 
Further, it has been shown that TLR activation can consequently activate Th1 while a lack of TLR 
activation can result in the production of cytokines responsible for Th2 [357]. 
 
These results are exciting due to the fact that differences in the structure, including presence or 
absence of lipid has been able to affect the cytokine production pathway and this could enlighten the 
future of targeting specific immune pathway. There has been a growing interest in the application of 
cytokines and vaccine constructs that activate specific cytokine pathways for cancer therapy [358-
360].  
 
Comparing the results from ICS and CBA shows that G1 and G2, which had shown significance in 
the level of IFN- produced, had a relatively high IL-2 response in the CBA assay confirming 
activation of Th1. 
 
5.2.3 Antibody production  
 
Antibody measurements are generally performed to estimate the level of humoral response resulting 
from B cell activation through a Th2 pathway (Figure 5-1) [361]. Antibody production is essential to 
the immune system for pathogen deactivation. In this study, sera from vaccinated mice were collected 
at days 10, 31 and 52 following 1, 2 and 3 vaccinations, respectively. An ELISA was performed 
whereby ELISA plates were coated in OVA protein (dissolved in PBS) to capture the IgG specific 
143 
 
antibody response found in the vaccinated mice sera (Figure 5-8). Experimental details are described 
in Chapter 2, Section 2.3.8.  
 
The ELISA results (Figure 5-9) indicated that the B cell epitope in the OVA323-339 epitope that is 
hypothesised to activate a B cell response through polarisation of CD4 to Th2 did not give strong 
activation for a B cell response to produce antibodies. Antibody production for the vaccine constructs 
(G1-G9) was analysed by ELISA (Figure 5-9). Results were significant (p<0.1) for an IgG response 
of G4 (no mannose, Figure 5-9) when compared to G1 and G2 and G5-G7, G8 and G9 following 
the first, second and third vaccination. Antibody production by OVA protein injected with CT is 
previously reported to be very low [356]. 
 
Comparing G1 ELISA results with the cytokine production study in Section 5.2.2 implies that G1 
has a tendency to activate the Th1 pathway and is further confirmed by a lack of antibody response.  
    
 
Figure 5-9. Antigen specific antibody production following vaccination using ELISA assay. Sera 
were collected on days 10 (9 days post the first vaccination), 31 (10 days post the second vaccination) 
and 52 (10 days post the third vaccination). IgG UV intensity was recorded (OD 450) for a 1/200 
dilution for all mice groups (G1-G9). Mean ± SEM is shown. Unpaired t-Test was used to show 
significance when p <0.1. Positive control is G8 vaccinated with OVA323-339 plus cholera toxin and 
negative control is G9 vaccinated with PBS. There were 5 mice per group. 
 
An antibody response is known to be correlated to the Th2 activation pathway which is followed by 
B cell activation (Figure 1-5) [341]. Although Section 5.2.2 results indicated that addition of mannose 
to these constructs caused selectivity towards a Th2 pathway activation, this activation was not 
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confirmed with antibody production after each vaccination dose.  This was also observed by Junda et 
al., who reported that mannosylated OVA323-339 administered with CFA impaired antibody response 
[341]. In a study done by Anjuere et al. it was observed that cholera toxin B transdermal injection 
could activate Th1 cytokines while supressing antibody production [356]. 
 
Further, in this study, lipids alone on a vaccine construct (G4) caused a B cell response which was 
confirmed with antibody production (Figure 5-9). Thus, lipidic and mannosyl moieties present with 
the OVA323-339 on the vaccine structures (G1-3) have failed to help in IgG production.   
 
In addition, G2 and G3 showed a relatively higher antibody titre following the third vaccination ( 
Figure 5-9), however, when the vaccinated groups (G1-9) were tested for the amount of antibody 
production per mouse per group (Figure 5-9), only one mouse per group gave a high antibody 
response showing immune variations in the inbred mouse [362].  
 
In general, antibody production by the vaccination groups G1-8 was considered to be not significant 
in comparison with the negative control (vaccinated with PBS). Previous studies on OT-II transgenic 
or wild-type C57BL/6 mice immunised with OVA323-339 had reported failure of IgG production in the 
vaccinated mice sera when compared to negative control (saline) [363]. In another study by Kel et 
al., it was reported that vaccination with mannosylated OVA323-339 resulted in significantly lower 
levels of IgG antibody compared to the negative control group (PBS) [335]. This reduction in the IgG 
level was used as a positive aspect for control of hypersensitivity [335].  Future studies with more 
numbers of mice may produce more reliable results which may indicate a better understanding of 
structural variations on antibody response. In general, the results showed a lack of an antibody 
response following vaccination with G1-9 as well as a lack of T cell proliferation (Section 5.2.1). 
 
5.3 Conclusion 
 
This chapter presented in vivo results to determine the structural relation of G1-6 to immunity 
pathways activated following vaccination. This was assessed through T cell proliferation studies on 
adoptively transferred OT-II T cells in C57BL/6 mice, following vaccination by G1-G9. G7-9 were 
the control vaccination groups where G7 was a non-conformed vaccination group containing a 
mixture of OVA323-339, mannose and lipid. G8 was OVA323-339 plus CT as a positive control and G9 
was a negative control (PBS). 
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Mannosylated OVA peptides have long been investigated for their cellular and immunological 
properties [120]. OVA323-339 is known to be presented through MHC II molecules on DCs. Here, the 
structural relationship of O-mannosylated OVA323-339 lipopeptides was investigated by observing the 
immune response in the mice. Interestingly, the in vivo OT-II proliferation ability remained 
unchanged following vaccination by mannosylated lipopeptides, due to possible partial activation, 
however, the same vaccine constructs 13-16 were able to activate OT-II cells proliferation in vitro 
(Chapter 4, Section 4.2.3). This contrast shows the need of better mouse models for the study of 
CD4 T cell activation where adopted T cells do not diminish in a short period of time. Along with a 
lack of OT-II production ability, vaccine groups 1-6 failed to show significance of CD62LlowCD4+ 
cells responsible for recall.  
 
ICS and CBA assay results showed antigen specific cytokine release linked to CD4+ T cells. G1 and 
G2 (mannosylated lipopeptides with 1 and 2 alanine spaces between mannosyl moieties) had the 
ability to activate the pro-inflammatory cytokines involved in Th1 and Th2 pathways (Figure 5-7, 
Tables 5-1, 5-2).  Among all the studied vaccination groups (G1-9), G4 was the most selective 
towards the release of cytokines involved in the Th1 pathway, however, the level of cytokine for G4 
was not significantly high. G3 showed no Th1 activation but showed Th2 activation. The overall 
results showed that cytokine release indicated that presence of mannosyl moiety on the vaccine 
structure, which in turn shows a tendency towards cytokine production along the Th2 pathway. 
Lipidation, on the other hand, showed cytokine production related to the Th1 pathway. Further, it was 
found that structural differences including the number of spacers between mannosyl moieties could 
affect specificity towards different Th pathways. 
 
Selectivity towards the activation of T helpers is an important aspect of vaccine designs. G3 showed 
selectivity towards Th2 pathway to release cytokines but showed no Th1 activation. This finding is 
interesting since the difference between G1, G2 and G3 was the space between the mannosyl 
moieties, indicating that a bigger space between the mannosyls produces selectivity towards Th2 
activation pathway. This change in the number of spaces was shown in Chapter 4 to affect the in 
vitro results. A possible conformational change could be responsible in the antigen position in the 
formed particles. 
 
IgG production was studied by ELISA assay (Figure 5-9). Here, lipid moiety alone on the vaccine 
structures was relatively helpful in antibody production by activating B cell antigen recognition while 
it was concluded that addition of mannosyl and lipid moiety (G1-5) to the OVA323-339 peptide failed 
to increase IgG to a significant level when compared to the negative control. Positive control group 
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G8 showed no success in activating an antibody response which was in line with its Th1 activated 
cytokines (results from ICS and CBA assays). This lack of antibody response and activation of Th1 
pathway was previously reported [356]. 
 
In general, the designed structures showed selectivity towards different Th response pathways, which 
provides progress towards the future design of peptide-based subunit vaccines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
Chapter 6: Conclusion and future prospects 
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In the area of vaccine development for immune modulation, targeting specific receptors on cells 
involved in the immune system’s front line of defence has been shown to enhance an immune 
response. Here, within the family of C-type lectins, the MR is a key front line receptor in the body’s 
defence against pathogens [270]. This receptor is located on DCs and macrophages which form the 
first barrier when foreign pathogens enter the body. APCs have been well-documented in the removal 
of pathogens from the body and their role in the immune response. Targeting these specific cells and 
their surface receptors is seen as a promising way of advancing vaccine design. 
Many studies have investigated the enhanced development of vaccines (and delivery systems) 
through the targeting of the MR. The most common approach has been achieved through 
glycosylation of antigens to mimic the pathogen’s cell surface, for a better recognition and a 
consequent internalisation. However, there are many unknown aspects of targeted vaccine design, 
including the structure of the receptor, the required arrangement of targeting moieties and spatial 
arrangement of CRDs, making this receptor an important focus for researchers investigating advanced 
vaccine design. It is known that glycosylated antigens, in particular mannosylated, have enhanced 
binding and targeting of the MR and research has recently focused on this approach for enhancing 
vaccine development. This stems from glycosylation being present on the surface of pathogens that 
researchers want to mimic this in their research. This approach has been common for the targeting of 
peptide and protein-based vaccines for a number of diseases. However, due to the unknown 
conformation of the MR, there are many questions surrounding the conformational properties and 
structure of a glycosylated vaccine required for effective receptor targeting, and these are yet to be 
addressed [268].  
Synthetic peptide vaccines, due to their stability and their easily modifiable structure, are found to be 
an important part of vaccine development studies. Tailoring of these peptide vaccines through the 
inclusion of antigenic moieties, addition of lipids and/or glycosyl units, and addition of one or more 
epitopes enables researchers to develop a vaccine for a particular disease with defined structural 
properties, potentially enhancing the desired immune response. This synthetic approach also offers 
the ability to target specific cell surface receptors, such as the MR, through inclusion of mannose 
units, potentially advancing vaccine development.    
This thesis aimed to develop mannosylated lipopeptides that could target the MR and activate the 
immune system.  
A library of mannosylated lipopeptides was designed that included an OVA323-339 epitope as a model 
epitope, two lipid moieties to give adjuvanting properties, and two mannose moieties. The constructed 
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library was designed to investigate the effect the distance between the two mannose units had on MR 
affinity (in vitro and in vivo) and to achieve this an alanine spacer (0, 1, or 2 alanine amino acids in 
length) was inserted between each mannose moiety. A fluorescent tag was also included in each 
construct to enable tracking in in vitro cell studies. A library of control vaccine constructs was also 
prepared to study the role of lipid and/or sugar moieties on the targeting of this receptor (in vitro) and 
immune response (in vivo). This thesis aimed to test three hypothesis; hypotheses 1: Improvement of 
the synthesis of fluorescently tagged multicomponent mannosylated lipoeptides; hypotheses 2: Linear 
placement of mannosyl moieties in the vaccine constructs and an alanine spacer plays a role in antigen 
presenting cells uptake through enhanced receptor targeting, and hypotheses 3: structural properties 
in a vaccine construct could affect the activation immune pathways. 
To answer hypotheses 1: Synthesis of this multi-component vaccine construct library (containing 
mannose, lipids, OVA epitope, and a fluorescent tag) and the control library (containing either/or 
mannose, either/or lipids, OVA epitope, and a fluorescent tag) was carried out using a combination 
of manual methods and microwave assisted solid phase peptide synthesis. To enable successful 
synthesis of a complex library, the constructs were prepared as two building blocks which were then 
conjugated. This has been shown to give higher yields and purity when compared with a linear 
synthesis of such large and multi-complex molecules. In this study, the peptides were prepared as two 
sections; 1) azido-functionalised mannosylated peptides with a fluorescent tag, and 2) alkyne OVA323-
339 lipopeptides. In addition to this, the synthesis of O-mannosylated serine building blocks was 
prepared using a Lewis acid reaction to enable the easy addition of the mannose moieties into each 
construct using the peptide synthesis methodology. This Lewis acid reaction was successfully 
monitored and optimised to obtain a better yield than that reported in the literature (42% compared 
with 5%, respectively).  
The method for the synthesis of the azido-functionalized mannosylated peptides was also optimised 
to ensure high yields although it was complicated by the presence of many different functional groups 
in a single moiety (azide moiety [for conjugation and formation of the final vaccine constructs at a 
later stage in the project], mannose units, fluorescent tag). Here, the order of functional group addition 
and type of side chain protecting groups present on the lysine amino acid (which enables the addition 
of multiple functional groups) was optimised and overall, high yielding peptides were achieved (4-6, 
54-68%). 
The alkyne OVA323-339 lipopeptides were prepared using microwave assisted SPPS which enabled a 
faster synthesis compared with manual synthesis without compromising yield or purity (11-12, 73-
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83%). In these constructs, the alkyne moiety was added to enable conjugation and formation of the 
final vaccine constructs at a later stage in the project. 
Following successful synthesis of the building blocks, alkyne OVA323-339 lipopeptides and azido-
functionalised mannosylated peptides, the final vaccine constructs were prepared using azido-alkyne 
copper mediated ‘click’ chemistry. In this reaction, formation of a triazole bond was generated which 
has been shown to be stable chemically and metabolically. This ‘click’ reaction was performed using 
copper wire and monitored using RP-HPLC. Overall, the reaction was completed in about 5 hours 
with the final library of vaccines (13-15, Figure 3-11) and control constructs (16-18, Figure 3-11) 
successfully synthesised. 
To answer hypotheses 2: In vitro analysis of this construct library revealed their specificity towards 
the MR. The analysis involved (1) uptake/binding studies on macrophages and dendritic cells which 
are two important types of APCs; (2) a mannan competition assay (where mannan is a known ligand 
for the MR) investigating receptor-mediated uptake; (3) a SPR assay investigating the binding of 
these constructs to a recombinant human macrophage MR using Biacore technology; and (4) a T cell 
activation proliferation assay investigating potential T cell activation upon uptake. These in vitro 
assays were performed to show how the designed construct library specifically interacted with the 
MR and how the alanine spacers (or distance between each mannose unit) affected their binding 
and/or uptake affinity. Further, the in vitro T cell activation was specifically investigated following 
uptake of these constructs which are all important factors for any vaccine development. 
Uptake studies performed on macrophages and dendritic cells showed a significantly higher uptake 
for the constructs containing both mannose and lipid (13-15) and the control peptide with only a lipid 
(no mannose, 16) when compared to other vaccine constructs and the negative control group (PBS). 
The mannan inhibition assay showed that a significant amount of uptake of the mannosylated 
constructs (13-16, 60-70%) was mediated through the lectin receptors. Interestingly, uptake for the 
control lipopeptide that contained no mannose was also shown to be lectin-receptor mediated (16, 
60%). It was concluded that although mannan had blocked the CLRs, other receptors present on these 
cell (e.g. TLRs) were still capable of processing the vaccine constructs.  
The in vitro OT-II cell proliferation assay on the OVA sensitive T cells isolated from OT-II transgenic 
mice showed that the vaccine constructs affected proliferation of the OT-II cells when compared with 
the PBS negative control. This observed proliferation confirmed that vaccine constructs which 
contained both mannose and lipids, and the control vaccine with only lipids present could 
significantly increase the number of OT-II cells in vitro. 
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SPR studies (using Biacore technology) were developed and successfully optimised using the 
recombinant human MR to study the specific affinity/binding of vaccine constructs and the role of 
spacer length on receptor binding ability. Here, mannan was used as the positive control and had a 
strong binding affinity towards the MR (KD: 0.15 µM, Rmax: 47). Mannosylated vaccine constructs 
with a single alanine spacer between the mannose groups (14) had a high affinity and level of binding 
to the MR (KD: 0.83 µM, Rmax: 425), while the vaccine construct with only a lipid (no mannose, 
16) showed a high affinity to the MR, but the level of binding was very low (KD: 2.91 µM, Rmax: 
5). Additionally, the vaccine construct with mannose but no lipids (17) also showed a high affinity 
for the MR but again the binding level was low (KD: 0.12 µM, Rmax: 8). It can be concluded that 
the presence of both mannose and lipids enhance binding and affinity for this receptor.   
Interestingly, the overall in vitro findings suggest that vaccine constructs that contain both mannose 
and lipids have increased APC uptake, affinity and binding for the MR but were equally successful 
in regulatory T cell activation with vaccine constructs containing only lipid. This is supported by a 
study by Rauen et al. They confirmed that the capacity of OT-II cells proliferation was unchanged in 
the presence of mannose, but the presence of lipids was found to be the key factor in T cell 
proliferation [188].  
To answer hypotheses 3: In vivo studies were designed to assess the ability of the vaccine constructs 
in T cell proliferation, cytokine release and antibody response in a mouse model. Here, OT-II cells 
from transgenic mice were purified and injected into C57BL/6 mice. These mice were then 
vaccination three times (days 2, 21 and 42) with the vaccine constructs. Ten days post each 
immunisation, blood was collected and analysed using both ELISA and T cell proliferation assays; 
ICS and CBS assays were used to measure cytokine release and Th pathway activation.  
In the T cell activation/proliferation assay, the OT-II cells transferred to C57BL/6 mice diminished 
and their proliferation ability was not affected by vaccination. It was also observed that mannosylation 
enhanced cytokine production related to the Th2 pathway, while lipidation of the constructs (no 
mannose) enhanced cytokine production indicative of a Th1 pathway. In line with the lack of OT-II 
cell proliferation, the ELISA results were poor and only the vaccine construct with a lipid (no 
mannose) was able to induce an antibody response (although small, OD < 1), where further 
assessment on sera from each mouse per group showed a huge variation in antibody levels between 
the individual mice. This lack of in vivo OT-II proliferation, despite being proved in in vitro 
proliferation by mannosylated peptides, was reported previously by Kel et al. [335]. In addition, 
impaired antibody production with the OVA323-339 epitope has also been reported by Leung et al. who 
concluded that OVA323-339 did not potentiate an antibody response and did not activate OT-II T cells 
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[288]. Despite these results, one interesting finding was the relationship between the structural 
properties and cytokine release pathway as shown in the CBA assay. Here, the vaccine construct with 
two alanine spacers (15) induced specificity towards the Th2 pathway as confirmed by IL-5 and IL-
10 production.  
The trivial task of purifying carbohydrate moieties from pathogenic cell walls can be overcome by 
the synthesis of mannosylated peptides that bear effective moieties for vaccine development [364]. 
Recent advances in adjuvant development have proved that the addition of lipid(s) to an antigenic 
structure can improve antigen delivery, and in some cases, enhance an immune response. Further, 
addition of carbohydrates and lipid moieties to an antigenic peptide epitope can be easily achieved 
with the use of organic chemistry resulting in pure, high yields [365]. Additionally, mannosylation 
can be a helpful method to increase specific uptake by the immune system’s responsible cells such as 
macrophages and DCs through lectin receptors. Recent advances in the development of methods to 
enhance and characterise the binding affinity of peptides or proteins to specific receptors have 
changed the understanding of the requirements for successful targeting of vaccines and drugs. Among 
these methods, SPR has proved to be a recent methodology used in this type of study, enhancing drug 
and vaccine screening through in vitro binding and affinity measurements. 
Many studies have reported failure in in vivo T cell activation by mannosylated peptides however, 
there are studies that have shown success in the development of therapies against delayed type 
hypersensitivity reactions (which are a type of an autoimmune disease caused by T cell malfunction).  
Studies have reported success in destroying T cells involved in this disease [335]. In the case of 
preparing protein and peptides with targeting ability, an understanding of methods that use this 
specific ability of mannosylation in T cell destruction as well as further progress in application of 
such qualities in autoimmune diseases would be valuable. 
Vaccine development is composed of many aspects and has many hurdles to overcome. These hurdles 
pertain to the selection of an appropriate antigen and the design of vaccines that can effectively induce 
the desired therapeutic response. In many cases, vaccines struggle to thrive/advance where mouse 
models fail to accurately represent the disease and/or immune response when replicated in humans. 
As a result, more intensive studies are required to solve these variabilities.  
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Appendices: RP-HPLC Trace, NMR and Mass spectrometry Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix 1a  
 
 
Appendix 1. N-Fmoc-O-(2,3,4,6-tetra-O-acetyl-α,β-D-mannopyranosyl)-L-serine 
(2) 
 
 
Appendix 1a. Yield = 42%, 1HNMR (500 MHz, CDCl3): δ 7.75-7.60, 7.40–7.36, 7.32–7.28, (8H, 
ArH), 6.17 (d, 1H, O-ester), 5.77 (d, 1H, NH), 5.37 (t, H4), 5.32 (bs, H2), 5.26 (dd, 1H), 4.58 (bd, 
1H, CH), 4.25 (complex, H6), 4.17 (bd, 1H, CH), 4.13 (bd, 2H, H5, H6), 3.98 (bd, 1H), 2.19, 2.10, 
2.03, 2.01 (4s, 12H, 4CH3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix 1b 
 
 
 
 
Appendix 1b. Exact mass, [M+1H]+1  calculated: 657.63 and found 658.4; calculated [M+2H]+2 
329.81 and found 331.4. Found 675.7 referring to calculated mass+Na 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
Appendix 2. Mannosylated peptide 4 
 
  
 
Appendix 2. RP-HPLC trace and mass spectra for Peptide 4 (54 % yield). Rt=20.835 min (C8 
column, 0-100% solvent B, 30 min). A solvent peak was observed between 4-10 min. Exact mass of 
Peptide 4 [M+1H]+1 calculated: 1562.51 and found 1564.3; calculated [M+2H]+2 782.255 and found 
783.0. Purity ≥ 95%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Appendix 3  
 
Appendix 3. Mannosylated peptide 5 
 
 
 
Appendix 3. RP-HPLC trace and mass spectra for Peptide 5 (62 % yield). Rt=20.576 min (C8 
column, 0-100% solvent B, 30 min). A solvent peak was observed at 8 min. Exact mass of 
Peptide 5 [M+1H]+1 calculated: 1633.55 and found 1634.5; calculated [M+2H]+2 8173.77 and 
found 818.3. Purity ≥ 95%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4 
Appendix 4. Mannosylated peptide 6 
 
 
 
Appendix 4. RP-HPLC trace and mass spectra for Peptide 6 (68 % yield). Rt=20.50 min (C8 
column, 0-100% solvent B, 30 min). Exact mass of Peptide 6 [M+1H]+1 calculated: 1704.58 
and found 1706.6; calculated [M+2H]+2 853.29 and found 853.8. Purity ≥ 95%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5 
Appendix 5. Mannosylated peptide 7 
 
 
 
Appendix 5. RP-HPLC trace and mass spectra for Peptide 7 (48 % yield). Rt=15.042 min (C8 
column, 0-100% solvent B, 30 min). Exact mass of Peptide 7 [M+1H]+1 calculated: 1044.39 and found 
1045.6; calculated [M+2H]+2523.195 and found 528.7. Purity ≥ 95%. 
  
 Appendix 6 
Appendix 6. 2-(4, 4-Dimethyl-2, 6-Dioxocyclohex-1-ylidene) 
ethylaminododecanoic acid (Dde-C12-OH) (10) 
 
Appendix 6. Yield = 30%, 1H NMR (500 MHz, CDCl3): 0.86 (3H, t, CH3), 1.05 (6H, s, C(CH3)2), 
1.12-1.26 (16H, m, 8CH2), 2.01-1.87 (2H, m, CH2), 2.42 (4H, s, 2CH2CO), 2.55 (3H, s, C(NH)CH3), 
4.38 (1H, m, CH). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix 7a 
Appendix 7. Peptide 11 
 
 
 +Q1: 6.848 to 7.149 min from Sample 1 (TuneSampleID) of MT20140424132856.wiff (Ion Spr... Max. 1.1e6 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
1.00e5
2.00e5
3.00e5
4.00e5
5.00e5
6.00e5
7.00e5
8.00e5
9.00e5
1.00e6
1.08e6
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)
865.1
720.7
1080.9
617.9
1440.4
541.0 879.1
732.5 1439.51097.9
1728.61384.3 2160.1 2793.61824.9 2662.8
 Appendix 7b 
 
 
Appendix 7. RP-HPLC trace and mass spectra for Peptide 11 (73 % yield). Rt=16.96, 17.28 and 17. 
75 min (C4 column, 0-100% solvent B, 30 min). Exact mass of Peptide 11 [M+1H]+1 calculated: 
4316.39; calculated [M+2H]+2 2159.195 and found 2159.7, 2160.1 and 2160.7; calculated [M+3H]+3 
1439.8 and found 1440.1, 1440.1, 1440.6; calculated [M+4H]+4 1080.09 and found 1081.0, 1080.9, 
1080.0; calculated [M+5H]+5 864.38 and found 865.6, 865.1, 865.2. Purity ≥ 95%. 
 
 
 
 
 
 
  
 +Q1: 4.390 to 4.791 min from Sample 1 (TuneSampleID) of MT20140424132856.wiff (Ion Spr... Max. 6.5e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.5e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)
865.1
720.7
1081.0
617.9
1440.1
541.1
879.2739.4
1097.9
528.8 1230.9 1465.2 1728.6 2159.71852.1 2742.8 2817.1
 +Q1: 4.390 to 4.791 min from Sample 1 (TuneSampleID) of MT20140424132856.wiff (Ion Spr... Max. 6.5e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.5e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)
865.1
720.7
1081.0
617.9
1440.1
541.1
879.2739.4
1097.9
528.8 1230.9 1465.2 1728.6 2159.71852.1 2742.8 2817.1
Appendix 8 
Appendix 8. Peptide 12 
 
 
 
Appendix 8. RP-HPLC trace and mass spectra for Peptide 12 (83 % yield). Rt=17.79 min (C18 
column, 0-100% solvent B, 30 min). Exact mass of Peptide 12 [M+1H]+1 calculated: 3922.03; 
calculated [M+2H]+2 1962.01 and found 1962.1; calculated [M+3H]+3 1308.34 and found 1308.8; 
calculated [M+4H]+4 981.50 and found 981.7; calculated [M+5H]+5 785.40 and found 785.6. Purity ≥ 
95%. 
 
 
 
 
  
Appendix 9a 
Appendix 9. Vaccine construct 13 
 
 
 
 +Q1: 0.753 to 1.079 min from Sample 1 (TuneSampleID) of MT20140328145524.wiff (Ion Spray) Max. 3.4e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.4e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
841.5
981.5
736.3
1177.4
794.1
1471.8
851.7
794.8 984.1654.5 1179.9
859.6516.8
1028.0776.6656.0 1486.6 1536.1 2766.21961.3
 Appendix 9b 
 
 
 
 
Appendix 9. RP-HPLC trace and mass spectra for Peptide 13 (33 % yield). Rt=21.67, 21.94 and 
22.42 min (C8 column, 0-100% solvent B, 30 min). Exact mass of Peptide 13 [M+1H]+1 calculated: 
5876.89; calculated [M+2H]+2 2939.45; calculated [M+3H]+3 1959.96 and found 1961.3 and 1961.4; 
calculated [M+4H]+4 1470.22 and found 1471.8 and 1472; calculated [M+5H]+5 1176.37 and found 
1177.3 and 1177.4. Purity ≥ 90%. 
 
 
 
 
 
 
 
 
  
 +Q1: 4.114 to 4.390 min from Sample 1 (TuneSampleID) of MT20140328144644.wiff (Ion Spray) Max. 4.2e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
841.5
981.3
1177.3
736.4
1471.8
794.0
851.7
427.6 654.8 1191.6
874.9 1475.3938.7974.3 1525.7 2909.21961.41715.8 2828.7
 +Q1: 3.462 to 3.838 min from Sample 1 (TuneSampleID) of MT20140328145524.wiff (Ion Spray) Max. 3.4e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.4e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
841.3
981.3
736.2
1177.3
794.3 1472.0
427.4 654.5 852.0
694.9 1191.9419.6 735.5 971.6923.6 1489.6 1687.6 1831.0 1999.8 2076.4 2754.0 2918.0
Appendix 10a 
Appendix 10. Vaccine construct 14 
 
 
 
 +Q1: 14.298 to 14.499 min from Sample 1 (TuneSampleID) of MT20140401160318.wiff (Ion Spra... Max. 9.6e4 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
9.6e4
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
1191.5
993.1
1488.9
1102.2
1168.7
851.9
1059.7 1985.3
1205.8 1497.2
449.5 1010.8803.7 1244.4585.5
1151.1
1432.1
 Appendix 10b 
 
 
 
Appendix 10. RP-HPLC trace and mass spectra for Peptide 14 (35 % yield). Rt=21.26, 21.97 and 
21.56 min (C8 column, 0-100% solvent B, 30 min). Exact mass of Peptide 14 [M+1H]+1 calculated: 
5947.93; calculated [M+2H]+2 2974.965 and found 2971.9; calculated [M+3H]+3 1983.64 and found 
1985.4, 1985.3 and 1990.1; calculated [M+4H]+4 1487.98 and found 1489.8, 1488.9 and 1489.2; 
calculated [M+5H]+5 1190.58 and found 1192.1 and 1191.5. Purity ≥ 90%. 
 
 
 
 
 
  
 +Q1: 9.607 to 9.808 min from Sample 1 (TuneSampleID) of MT20140401160318.wiff (Ion Spray) Max. 2.9e4 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
2.6e4
2.8e4
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
1192.1
1489.8
1168.7
865.6 993.2 1985.4
1497.6
1125.5 1206.3
637.7 938.3 1460.81280.3597.8 1214.9721.4
1506.6 1819.3
 +Q1: 4.691 to 4.992 min from Sample 1 (TuneSampleID) of MT20140401162240.wiff (Ion Spray) Max. 8.8e4 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
8.8e4
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
658.5
675.8 1191.5
696.3 992.8
1489.21125.4
938.2 1194.7 1333.4974.7
851.9 1005.1 1243.7712.8 1460.5 1521.9444.8 1990.11065.4 1658.4 2649.1 2971.9836.9
Appendix 11a 
Appendix 11. Vaccine construct 15 
 
 
 
 +Q1: 1.405 to 1.605 min from Sample 1 (TuneSampleID) of MT20140328122624.wiff (Ion Spray) Max. 4.3e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.3e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(3)(4)(5)(6)(7)(8)
1005.2
861.5
1205.9
754.2
1506.9
814.6
670.3 1016.7957.3427.6 1219.9
1539.71257.8 2009.2575.0 1180.3 2705.2 2750.11914.5 2158.0 2306.3 2491.2
 Appendix 11b 
 
 
Appendix 11. RP-HPLC trace and mass spectra for Peptide 15 (34 % yield). Rt=19.88, 20.11 and 
20.47 min (C8 column, 0-100% solvent B, 30 min). Exact mass of Peptide 15 [M+1H]+1 calculated: 
6018.97; calculated [M+2H]+2 3009.98; calculated [M+3H]+3 2007.32 and found 2009.2 and 2011.9; 
calculated [M+4H]+4 1505.74 and found 1511, 1506.9 and 1506.4; calculated [M+5H]+5 1204.79 and 
found 1206, 1205.9 and 1205.6. Purity ≥ 90%. 
 
 
 
 
 
 
  
 +Q1: 7.400 to 7.651 min from Sample 1 (TuneSampleID) of MT20131211140525.wiff (Ion Spray) Max. 1.2e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
1.00e4
2.00e4
3.00e4
4.00e4
5.00e4
6.00e4
7.00e4
8.00e4
9.00e4
1.00e5
1.10e5
1.20e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(3)(4)(5)(6)(7)(8)(9)
1005.2
1206.0
862.0
1209.4
754.0 1511.0
814.7 1220.2950.2 1017.0609.8 1512.5
854.0517.6 879.9 1258.0986.3
712.6 1528.7 2021.9 2539.5477.0 915.8 2815.41478.71348.0 1591.51705.9
 +Q1: 1.555 to 1.806 min from Sample 1 (TuneSampleID) of MT20140328123238.wiff (Ion Spray) Max. 1.4e5 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
I
n
t
e
n
s
it
y
,
 
c
p
s
(3)(4)(5)(6)(7)(8)
861.7
1005.5
1205.6
753.7
670.5
950.5455.8
814.4
1016.6867.8773.0427.1 820.7
1223.91204.9 1506.4 2481.8580.8 1620.8 2011.9
Appendix 12a 
Appendix 12. Vaccine construct 16 
 
 
 
 +Q1: 0.878 to 1.104 min from Sample 1 (TuneSampleID) of MT20140221142144.wiff (Ion Spr... Max. 2.9e4 cps.
400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000
m/z, amu
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
2.6e4
2.8e4
2.9e4
I
n
t
e
n
s
it
y
,
 
c
p
s
(2)(3)(4)(5)(6)(7)(8)
1076.8
1083.6897.7
1341.7
427.5 1091.5
1354.61057.4
516.7 671.3 902.7
1374.71117.5 1789.0
866.0818.4678.0 1431.9456.4 2983.9
1191.0 1239.0939.7 1629.41876.8 2428.1
 Appendix 12b 
 
Appendix 12. RP-HPLC trace and mass spectra for Peptide 16 (45 % yield). Rt=20.13, 20.41 and 
21.36 min (C8 column, 0-100% solvent B, 30 min). Exact mass of Peptide 16 [M+1H]+1 calculated: 
5358.78; calculated [M+3H]+3 1787.26 and found 1789 and 1788.1; calculated [M+4H]+4 1340.69 
and found 1341.7 and 1345.8; calculated [M+5H]+5 1072.75 and found 1076.7, 1076.8 and 1074. 
Purity ≥ 90%. 
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 +Q1: 3.186 to 3.562 min from Sample 1 (TuneSampleID) of MT20140221142144.wiff (Ion Spr... Max. 8.5e4 cps.
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Appendix 13 
Appendix 13. Vaccine construct 17 
 
 
 
Appendix 13. RP-HPLC trace and mass spectra for Peptide 17 (51 % yield). Rt=13.501 min (C8 
column, 0-100% solvent B, 30 min). Exact mass of Peptide 17 [M+1H]+1 calculated: 5624.61; 
calculated [M+3H]+3 1875.78 and found 1877.1; calculated [M+4H]+4 1407.15 and found 1408.1; 
calculated [M+5H]+5 1125.92 and found 1126.9. Purity ≥ 92%. 
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Appendix 14. Vaccine construct 18 
 
 
 
 
Appendix 14. RP-HPLC trace and mass spectra for Peptide 18 (35 % yield). Rt=13.501 min (C8 
column, 0-100% solvent B, 30 min). Exact mass of Peptide 18 [M+1H]+1 calculated: 4964.42; 
calculated [M+3H]+3 1655.8 and found 1657.5; calculated [M+4H]+4 1242.1 and found 1243.5; 
calculated [M+5H]+5 993.88 and found 994.5. Purity ≥ 92%. 
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Appendix 15. Flow Cytometry Concentration Selection 
 
Appendix 15. Concentration (µM) selection using flow cytometry at 0.5 µM and 0.05 µM for the 
Vaccine Constructs (A) CD11c+ and (B) F4/80+ cells in triplicate. Dextran-FITC (1 mg/ml) was the 
positive control. PBS was the negative control. The study was performed in triplicate and the results 
were analysed with mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 16 
Appendix 16. Mass transfer limitation study on vaccine constructs 15 and 16 
 
Appendix 16. Mass transfer limitation for (A) Peptide 11 and (B) Peptide 12 measured at 50 
µM using different flow rates (5 µl/min, 15 µl/min, 75 µl/min) to determine changes in the level of 
response units using Biacore® 3000.  Human recombinant mannose receptor (MR) immobilized on 
the CM-5 chip was used as the ligand. No change was observed in the response level (RU) between 
each of these runs indicating that mass transfer was not a limiting factor in this study. 
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Appendix 17 
Appendix 17. Rmax, KD and in vitro OT-II relation of vaccine constructs 13-18  
 
Vaccine construct KD Rmax OT-II in vitro prolifration count 
13 5.31 15.2 1.12E+01 
14 0.83 425 1.47E+02 
15 22.8 51.3 2.97E+01 
16 2.91 5.31 8.07E+00 
17 0.12 27.5 1.49E+01 
18 128 2.28 4.94E+01 
 
Appendix 17.  Rmax, KD and in vitro OT-II relation of vaccine constructs 13-18 
This table summarises the information presented in Chapter 4, Section 4.2.4.1.3, Figure 4-15 on 
binding measurements by SPR, and also the results provided in Chapter 4, Section 4.2.3, Figure 4-
3 from the average of three repeats of in vitro OT-II proliferation assay results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
